CLDF Title
Home | Contact Us | Bookmark
HEPATITIS
HBV HCV HDV
CIRRHOSIS
HEPATIC ENCEPHALOPATHY (HE) HEPATORENAL SYNDROME (HRS) PRIMARY BILIARY CHOLANGITIS (PBC) THROMBOCYTOPENIA
NASH HCC
About CLDF
Board of Trustees Board of Advisors/Faculty 2019 GI Fellow Board of Advisors CLDF Committees
Centers of Educational Expertise  
Live CME Events Webcasts Slide Library Abstract Library Committee Members Conference Highlights
 
HCV | Abstract Library
Abstract Library
 
The summaries are free for public use. The Chronic Liver Disease Foundation will continue to add and archive summaries of articles deemed relevant to CLDF by the Board of Trustees and its Advisors.
1.Applying a diffusion of innovations framework to the scale-up of direct-acting antiviral therapies for hepatitis C virus infection: Identified challenges for widespread implementation
 

Int J Drug Policy. 2020 Oct 12;86:102964. doi: 10.1016/j.drugpo.2020.102964.Online ahead of print.

Alison D Marshall 1, Max Hopwood 2, Jason Grebely 3, Carla Treloar 2
 
2.Sustained Sobriety: A Qualitative Study of Persons with HIV and Chronic Hepatitis C Coinfection and a History of Problematic Drinking
 

AIDS Behav. 2020 Oct 16. doi: 10.1007/s10461-020-03067-x. Online ahead of print.

Abigail Howell 1, Audrey Lambert 2 3, Megan M Pinkston 4, Claire E Blevins 4, Jumi Hayaki 5, Debra S Herman 4, Ethan Moitra 4, Michael D Stein 3, H Nina Kim 6
 
3.Review of Clinically Relevant Drug Interactions with Next Generation Hepatitis C Direct-acting Antiviral Agents
 

J Clin Transl Hepatol. 2020 Sep 28;8(3):322-335. doi: 10.14218/JCTH.2020.00034.Epub 2020 Jul 30.

Jenny Hong 1, Robert C Wright 1, Nilu Partovi 1 2, Eric M Yoshida 3 4, Trana Hussaini 1 2 3
 
4.Update on Hepatitis C Epidemiology: Unaware and Untreated Infected Population Could Be the Key to Elimination
 

SN Compr Clin Med. 2020 Oct 18;1-8. doi: 10.1007/s42399-020-00588-3.Online ahead of print.

Cristina Stasi 1 2, Caterina Silvestri 1, Fabio Voller 1
 
5.Reduced Independence in Daily Living Is Associated with the Gut Microbiome in People with HIV and HCV
 

mSystems. 2020 Oct 13;5(5):e00528-20. doi: 10.1128/mSystems.00528-20.

Bryn C Taylor # 1, Kelly C Weldon # 2 3, Ronald J Ellis 4 5, Donald Franklin 6, Daniel McDonald 7, Gregory Humphrey 7, MacKenzie Bryant 7, Julia Toronczak 7, Tara Schwartz 7, Jennifer Iudicello 6, Robert Heaton 6, Igor Grant 6, Sara Gianella 8
 
6.Addressing the Syndemic of HIV, Hepatitis C, Overdose, and COVID-19 Among People Who Use Drugs: The Potential Roles for Decriminalization and Safe Supply
 

J Stud Alcohol Drugs. 2020 Sep;81(5):556-560.

Matthew Bonn 1, Adam Palayew 2, Sofia Bartlett 3, Thomas D Brothers 4, Natasha Touesnard 1, Mark Tyndall 5
 
7.Management of Hepatitis C in Children and Adolescents
 

J Pediatric Infect Dis Soc. 2020 Oct 12;piaa114. doi: 10.1093/jpids/piaa114. Online ahead of print.

Victoria A Statler 1, Claudia Espinosa 2
 
8.Supportive Interventions During Treatment of Chronic Hepatitis C: A Review of the Literature
 

Gastroenterol Nurs. Sep/Oct 2020;43(5):E172-E183. doi: 10.1097/SGA.0000000000000488.

Donald E Bailey Jr 1, Donna M Zucker
 
9.The role of social capital in facilitating hepatitis C treatment scale-up within a treatment-as-prevention trial in the male prison setting
 

Addiction. 2020 Oct 2. doi: 10.1111/add.15277. Online ahead of print.

Lise Lafferty 1, Jake Rance 1, Gregory J Dore 2, Andrew R Lloyd 2, Carla Treloar 1
 
10.Exploring Patient-Reported Costs Related to Hepatitis C on the Medical Crowdfunding Page GoFundMe®
 

Pharmacoecon Open. 2020 Sep 30. doi: 10.1007/s41669-020-00232-9. Online ahead of print.

T Joseph Mattingly 2nd 1, Karen Li 2, Arnold Ng 2, Tieu-Long Ton-Nu 2, Jennifer Owens 3
 
11.Escape from planned obsolescence: Hepatitis C, the cirrhotic liver, and clonal expansions
 

J Exp Med. 2020 Mar 2;217(3):e20191070. doi: 10.1084/jem.20191070.

Andrea D Branch 1
 
12.T cell immunity to hepatitis C virus: Lessons for a prophylactic vaccine
 

J Hepatol. 2020 Sep 28;S0168-8278(20)33665-5. doi: 10.1016/j.jhep.2020.09.022.Online ahead of print.

Robert Thimme 1
 
13.Characteristics of Adults With Hepatitis C Virus: Evidence From the National Health and Nutrition Examination Survey 2011-2012
 

Gastroenterol Nurs. Sep/Oct 2020;43(5):363-374. doi: 10.1097/SGA.0000000000000459.

Sheila A Williams 1, Lisa C Lindley
 
14.Misclassification Error-Adjusted Prevalence of Injection Drug Use Among Infective Endocarditis Hospitalizations in the United States: A Serial Cross-Sectional Analysis of the 2007-2016 National Inpatient Sample
 

Am J Epidemiol. 2020 Sep 30;kwaa207. doi: 10.1093/aje/kwaa207. Online ahead of print.

Kaitlin M McGrew 1, Tabitha Garwe 1, S Reza Jafarzadeh 2, Douglas A Drevets 3 4, Yan Daniel Zhao 1, Mary B Williams 1 5, Hélène Carabin 1 6 7 8
 
15.EASL recommendations on treatment of hepatitis C: Final update of the series
 

J Hepatol. 2020 Nov;73(5):1170-1218. doi: 10.1016/j.jhep.2020.08.018.Epub 2020 Sep 15.

European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical Practice Guidelines Panel: Chair:; EASL Governing Board representative:; Panel members:
 
16.In the era of direct-acting antivirals, liver transplant delisting due to clinical improvement for hepatitis C remains infrequent
 

Clin Gastroenterol Hepatol. 2020 Sep 21;S1542-3565(20)31294-5.doi: 10.1016/j.cgh.2020.09.033. Online ahead of print.

Therese Bittermann 1, K Rajender Reddy 2
 
17.Impact Of Direct Acting Antiviral Agents On Liver Function In Patients With Chronic Hepatitis C Virus Infection
 

J Viral Hepat. 2020 Sep 26. doi: 10.1111/jvh.13408. Online ahead of print.

Philip J Johnson 1, Sarah Berhane 1, Alex J Walker 2, Fiona H Gordon 3, Steven D Ryder 4 5, Stuart McPherson 6, Aravamuthan Sreedharan 7, Andrew A Ustianowski 8, Kosh Agarwal 9, David Mutimer 10, Takeshi Kumada 11, Hidenori Toyoda 12, William L Irving 5, HCV Research UK
 
18.Depression in Individuals Coinfected with HIV and HCV Is Associated with Systematic Differences in the Gut Microbiome and Metabolome
 

mSystems. 2020 Sep 29;5(5):e00465-20. doi: 10.1128/mSystems.00465-20.

Bryn C Taylor 1, Kelly C Weldon 2 3, Ronald J Ellis 4 5, Donald Franklin 6, Tobin Groth 7, Emily C Gentry 2, Anupriya Tripathi 2 7 8, Daniel McDonald 8, Gregory Humphrey 8, MacKenzie Bryant 8, Julia Toronczak 8, Tara Schwartz 8, Michelli F Oliveira 9, Robert Heaton 6, Igor Grant 6, Sara Gianella 10, Scott Letendre 9 11, Austin Swafford 3, Pieter C Dorrestein 2 3 8, Rob Knight 12 8 13 14
 
19.Detection of Recurrent Hepatitis C Viremia Using Surveillance Data, New York City
 

J Public Health Manag Pract. 2020 Sep 9. doi: 10.1097/PHH.0000000000001150.Online ahead of print.

Kevin Guerra 1, Angelica Bocour, Miranda S Moore, Ann Winters
 
20.Protocol for a systematic review of treatment adherence for HIV, hepatitis C and tuberculosis among homeless populations
 

Syst Rev. 2020 Sep 13;9(1):211. doi: 10.1186/s13643-020-01470-y.

Luke Johnson 1 2, Dan Lewer 3, Robert W Aldridge 4, Andrew C Hayward 1, Alistair Story 1
 
21.The Economic Value of Improved Productivity from Treatment of Chronic Hepatitis C Virus Infection: A Retrospective Analysis of Earnings, Work Loss, and Health Insurance Data
 

Adv Ther. 2020 Nov;37(11):4709-4719. doi: 10.1007/s12325-020-01492-x. Epub 2020 Sep 14.

Mark Sulkowski 1, Raluca Ionescu-Ittu 2, Dendy Macaulay 3, Yuri Sanchez-Gonzalez 4
 
22.Hepatitis C virus infections among people aged 15-44, United States, 2009-2018
 

Public Health Nurs. 2020 Sep 15. doi: 10.1111/phn.12808. Online ahead of print.

Theresa Watts 1, Diane Lauver 2, Ajay K Sethi 3, Traci Snedden 2, Susan Zahner 2
 
23.Will peer-based interventions improve hepatitis C virus treatment uptake among young people who inject drugs?
 

Can J Public Health. 2020 Sep 16. doi: 10.17269/s41997-020-00413-3. Online ahead of print.

Jessica Jacob 1 2, Lianping Ti 1 2, Rod Knight 3 4
 
24.Emerging Viral and Bacterial Infections: Within an Era of Opioid Epidemic
 

Infect Dis Ther. 2020 Sep 11. doi: 10.1007/s40121-020-00335-0.Online ahead of print.

Jessica F Jones 1, Jamie Legaspi 2, Eric Chen 2, Kelly Lee 3, Jennifer Le 3
 
25.Retreatment of Hepatitis C Infection With Direct-Acting Antivirals
 

Fed Pract. 2020 Jul;37(7):316-319.

Marisel Segarra-Newnham 1, Nathalie See 1, Gail Fox-Seaman 1
 
26.Selecting a theoretical framework to explore the social and cognitive uncertainty that hepatitis C treatment represents for people who inject drugs
 

Appl Nurs Res. 2020 Aug 3;151339. doi: 10.1016/j.apnr.2020.151339. Online ahead of print.

Greg Carlson 1, Tracy E Crane 2, Ruth E Taylor-Piliae 3
 
27.Cholesterol sensing by CD81 is important for hepatitis C virus entry
 

J Biol Chem. 2020 Sep 8;jbc.RA120.014761. doi: 10.1074/jbc.RA120.014761.Online ahead of print.

Machaela Palor 1, Lenka Stejskal 1, Piya Mandal 1, Annasara Lenman 2, Maria Pia Alberione 3, Jared Kirui 4, Rebecca Moeller 4, Stefan Ebner 5, Felix Meissner 5, Gisa Gerold 6, Adrian J Shepherd 7, Joe Grove 1
 
28.Housing Stability and Hepatitis C Infection for Young Adults Who Inject Drugs: Examining the Relationship of Consistent and Intermittent Housing Status on HCV Infection Risk
 

J Urban Health. 2020 Sep 8. doi: 10.1007/s11524-020-00445-7. Online ahead of print.

Meghan D Morris 1, Irene H Yen 2, Steve Shiboski 3, Jennifer L Evans 3, Kimberly Page 4
 
29.Prevalence of Hepatitis C Virus Infection in the Veteran Population Undergoing Total Joint Arthroplasty: An Update
 

J Arthroplasty. 2020 Aug 18;S0883-5403(20)30909-8. doi: 10.1016/j.arth.2020.08.023.Online ahead of print.

Cdr Bennett H Shapiro 1, Ramsey C Cheung 2, Nicholas J Giori 3
 
30.Hepatitis C Virus Incidence in a Cohort in Medication-Assisted Treatment for Opioid Use Disorder in New York City
 

J Infect Dis. 2020 Sep 2;222(Supplement_5):S322-S334. doi: 10.1093/infdis/jiz659.

Ashly E Jordan 1 2 3, Charles M Cleland 2 4, Katarzyna Wyka 1, Bruce R Schackman 5, David C Perlman 2 6, Denis Nash 1
 
31.Health Department Efforts to Increase Hepatitis C RNA Testing Among People Appearing Out of Care: Comparison of Outreach Approaches, New York City, 2017
 

Public Health Rep. 2020 Sep 4;33354920952068. doi: 10.1177/0033354920952068.Online ahead of print.

Rachel Webster 1, Miranda S Moore 1, Angelica Bocour 1, Nirah Johnson 1, Ann Winters 1
 
32.Treatment of Chronic Hepatitis C in Young Children Reduces Adverse Outcomes and Is Cost-Effective Compared to Deferring Treatment to Adulthood
 

J Pediatr. 2020 Sep 2;S0022-3476(20)31124-0. doi: 10.1016/j.jpeds.2020.08.088.Online ahead of print.

Emma Greenaway 1, Alexander Haines 2, Simon C Ling 3, Murray Krahn 4
 
33.Comparing direct acting antivirals for hepatitis C using observational data - Why and how?
 

Pharmacol Res Perspect. 2020 Oct;8(5):e00650. doi: 10.1002/prp2.650.

Jim Young 1 2 3, Stanley Wong 4 5, Naveed Z Janjua 4 5, Marina B Klein 1 2 6
 
34.Insights into the unique characteristics of hepatitis C virus genotype 3 revealed by development of a robust sub-genomic DBN3a replicon
 

J Gen Virol. 2020 Sep 8. doi: 10.1099/jgv.0.001486. Online ahead of print.

Joseph C Ward 1, Sebastian Bowyer 1, Shucheng Chen 1, Guilherme Rodrigues Fernandes Campos 2 1, Santseharay Ramirez 3 4, Jens Bukh 3 4, Mark Harris 1
 
35.Persistent Challenges in the Hepatitis C Virus Care Continuum for Patients in a Central Texas Public Health System
 

Open Forum Infect Dis. 2020 Aug 7;7(8):ofaa322. doi: 10.1093/ofid/ofaa322.eCollection 2020 Aug.

Shane W Reader 1, Hyun-Seok Kim 2, Hashem B El-Serag 2, Aaron P Thrift 1
 
36.Screening Emergency Admissions at Risk of Chronic Hepatitis C (SEARCH) to diagnose or
 

J Viral Hepat. 2020 Sep 1. doi: 10.1111/jvh.13393. Online ahead of print.

David Stephen Prince 1 2, Joseph Louis Pipicella 1 3, Melissa Fraser 1, Frank Alvaro 1 4, Michael Maley 1 2 4, Hong Foo 1 4 5, Paul MacConachie Middleton 1 2 3 6 7, Scott Anthony Davison 1 2, Greg John Dore 8, Geoff William McCaughan 7 9, Miriam Tania Levy 1 2 3
 
37.Hepatitis C Virus
 

Ann Intern Med. 2020 Sep 1;173(5):ITC33-ITC48. doi: 10.7326/AITC202009010.
 
38.Late presenters among minority patients with chronic hepatitis C infection in the USA
 

Int J Public Health. 2020 Sep;65(7):1181-1191. doi: 10.1007/s00038-020-01467-3.Epub 2020 Aug 29.

Calvin Q Pan 1 2, Charles Rabinovich 3, Vijay Gayam 4, Milana Normatov 3, Bazhena Fidman 3, Dan Wang 5
 
39.Rates and Characteristics of SARS-CoV-2 Infection in Persons with Hepatitis C Virus Infection
 

Liver Int. 2020 Oct 2. doi: 10.1111/liv.14681. Online ahead of print.

Adeel A Butt 1 2 3, Peng Yan 1
 
40.Hepatic benefits of HCV cure
 

J Hepatol. 2020 Aug 7;S0168-8278(20)30530-4. doi: 10.1016/j.jhep.2020.08.006.Online ahead of print.

Vincenza Calvaruso 1, Antonio Craxì 2
 
41.Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper
 

J Pediatr Gastroenterol Nutr. 2020 Sep;71(3):407-417. doi: 10.1097/MPG.0000000000002814.

Daniel H Leung 1, James E Squires 2, Ravi Jhaveri 3, Nanda Kerkar 4, Chuan-Hao Lin 5, Parvathi Mohan 6, Karen F Murray 7, Regino P Gonzalez-Peralta 8, Eve A Roberts 9, Shikha S Sundaram 10
 
42.Increased cardiovascular risk and reduced quality of life are highly prevalent among individuals with hepatitis C
 

BMJ Open Gastroenterol. 2020 Aug;7(1):e000470. doi: 10.1136/bmjgast-2020-000470.

Stuart McPherson 1 2, Shion Gosrani 3, Sarah Hogg 3, Preya Patel 3, Aaron Wetten 3, Rachael Welton 3, Kate Hallsworth 3 2, Matthew Campbell 4 5
 
43.Alcohol Use Disorder and Hepatitis C Prevention and Care in People Who Inject Drugs: The State of Play
 

Semin Liver Dis. 2020 Aug 26. doi: 10.1055/s-0040-1716343. Online ahead of print.

Fabienne Marcellin 1, Antoine Jaquet 2 3, Jeffrey V Lazarus 4, Patricia Molina 5, Patrizia Carrieri 1
 
44.Cost-effectiveness of using hepatitis C viremic hearts for transplantation into HCV-negative recipients
 

Am J Transplant. 2020 Aug 10. doi: 10.1111/ajt.16245. Online ahead of print.

Cathy Logan 1, Ily Yumul 2, Javier Cepeda 1, Victor Pretorius 3, Eric Adler 4, Saima Aslam 1, Natasha K Martin 1 5
 
45.Identification of Risk Factors for Testing of Hepatitis C in Non-Birth Cohort Patients: Is Universal Screening Necessary?
 

J Addict Med. 2020 Jul 20. doi: 10.1097/ADM.0000000000000702. Online ahead of print.

Amanda Smart 1, Alexander Geboy, Peter Basch, Whitney Nichols, Alexander Zeymo, Idene Perez, Maria Hafeez, Ilan Fleisher, Stephen Fernandez, Dawn Fishbein
 
46.A Patient Decision Support Tool for Hepatitis C Virus and CKD Treatment
 

Kidney Med. 2019 Jul 11;1(4):200-206. doi: 10.1016/j.xkme.2019.06.003.eCollection Jul-Aug 2019.

Nerissa George 1, AnnMarie Liapakis 2, Kevin M Korenblat 3, Tingting Li 4, David Roth 5, Jerry Yee 6, Kevin J Fowler 7, Lehman Howard 8, Jingxia Liu 1, Mary C Politi 1
 
47.Identifying ED patients with previous abnormal HIV or hepatitis C test results who may require additional services
 

Am J Emerg Med. 2020 May 11;38(9):1831-1833. doi: 10.1016/j.ajem.2020.05.020.Online ahead of print.

Andrew H Ruffner 1, Rachel M Ancona 2, Catherine Hamilton 3, Francisco J Fernandez 4, Kiran A Faryar 5, Bennett H Lane 6, Michael S Lyons 7
 
48.Pharmacology Update for the Treatment of Hepatitis C Virus
 

Nurs Clin North Am. 2020 Sep;55(3):347-359.doi: 10.1016/j.cnur.2020.06.008.Epub 2020 Jul 16.

Leslie Hopkins 1, Travis Dunlap 2, Holly Cline 2
 
49.Impact of routine opt-out HIV/HCV screening on testing uptake at a syringe services program: An interrupted time series analysis
 

Int J Drug Policy. 2020 Jul 27;84:102875. doi: 10.1016/j.drugpo.2020.102875.Online ahead of print.

Tyler S Bartholomew 1, Hansel E Tookes 2, David P Serota 2, Czarina N Behrends 3, David W Forrest 4, Daniel J Feaster 5
 
50.Screening for Hepatitis C Virus: How Universal Is Universal?
 

Clin Ther. 2020 Jul 22;S0149-2918(20)30322-2. doi: 10.1016/j.clinthera.2020.06.012.Online ahead of print.

Ravi Jhaveri 1
 
51.Simplification of Care for Chronic Hepatitis C Virus Infection
 

Semin Liver Dis. 2020 Jul 28.doi: 10.1055/s-0040-1713657. Online ahead of print.

Jean-Michel Pawlotsky 1, Christian B Ramers 2, John F Dillon 3, Jordan J Feld 4, Jeffrey V Lazarus 5
 
52.A model of the economic benefits of global hepatitis C elimination: an investment case
 

Lancet Gastroenterol Hepatol. 2020 Jul 27;S2468-1253(20)30008-X.

doi: 10.1016/S2468-1253(20)30008-X. Online ahead of print.

Nick Scott 1, Christian Kuschel 2, Alisa Pedrana 3, Sophia Schroeder 3, Jessica Howell 4, Alexander Thompson 5, David P Wilson 3, Margaret Hellard 6
 
53.Global hepatitis C elimination: an investment framework
 

Lancet Gastroenterol Hepatoldoi: 10.1016/S2468-1253(20)30010-8. Online ahead of print.

 

Alisa Pedrana 1, Jessica Howell 2, Nick Scott 3, Sophia Schroeder 3, Christian Kuschel 4, Jeffrey V Lazarus 5, Rifat Atun 6, Ricardo Baptista-Leite 7, Ellen 't Hoen 8, Sharon J Hutchinson 9, Lisa Aufegger 10, Raquel Peck 11, Annette H Sohn 12, Tracy Swan 13, Mark Thursz 14, Olufunmilayo Lesi 15, Manik Sharma 16, John Thwaites 17, David P Wilson 3, Margaret Hellard 18
 
54.Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy
 

Int J Drug Policy. 2020 Jul 6;83:102837. doi: 10.1016/j.drugpo.2020.102837.Online ahead of print.

Jenny Iversen 1, Gregory J Dore 2, Mitchell Starr 3, Beth Catlett 4, Philip Cunningham 3, Louise Geddes 2, Lisa Maher 2
 
55.Achieving Hepatitis C Elimination By Using Person-Centered, Nurse-Led Models of Care: A Discussion of Four International Case Studies
 

Gastroenterol Nurs. Jul/Aug 2020;43(4):303-309. doi: 10.1097/SGA.0000000000000458.

Jacqueline A Richmond 1, Lesley Gallagher, Lucy McDonald, Margaret O'Sullivan, Christine Fitzsimmons, Alisa Pedrana
 
56.Low Yield of Hepatitis C Infection in an Outreach Screening Program in Harris County, Texas
 

Open Forum Infect Dis. 2020 Jun 2;7(7):ofaa191. doi: 10.1093/ofid/ofaa191. eCollection 2020 Jul.

Hyun-Seok Kim 1, Rosalia Guerrero 2, Shane W Reader 3, Maria Daheri 4, Maya Balakrishnan 1, Catherine L Troisi 2, Hashem B El-Serag 1, Aaron P Thrift 3 5
 
57.Hepatitis C antibody screening and determinants of initial and duplicate screening in the baby boomer patients of six urban primary care clinics
 

PLoS One. 2020 Jul 9;15(7):e0235778. doi: 10.1371/journal.pone.0235778. eCollection 2020.

Dagan Coppock 1, Edgar Chou 2, Edward Gracely 3, Robert Gross 4, Dong Heun-Lee 1
 
58.Post-transplant survey to assess patient experiences with donor-derived HCV infection
 

Transpl Infect Dis. 2020 Jul 7;e13402. doi: 10.1111/tid.13402. Online ahead of print.

Katya Prakash 1, Claudia Ramirez-Sanchez 1, Sydney I Ramirez 1, Cathy Logan 1, Nancy Law 1, Kristin Mekeel 2, Victor Pretorius 2, Saima Aslam 1
 
59.Chronic Hepatitis C Virus Infection After Kidney Transplantation With or Without Direct-Acting Antivirals in a Real-Life Setting: A French Multicenter Experience
 

Transplant Proc. 2020 Jul 4;S0041-1345(20)32581-1. doi:10.1016/j.transproceed.2020.06.005.Online ahead of print.

Eloi Chevallier 1, Matthias Büchler 2, Sophie Caillard 3, Nicolas Bouvier 4, Charlotte Colosio 5, Joseph Rivalan 6, Johnny Sayegh 7, Dominique Bertrand 8, Yannick Le Meur 9, Antoine Thierry 10, Cyril Garrouste 11, Jean-Philippe Rerolle 12, Lionel Rostaing 13, Philippe Gatault 2
 
60.Fibrosis improvement in patients with HCV treated with direct-acting antivirals
 

Eur J Gastroenterol Hepatol. 2020 Jul 3. doi: 10.1097/MEG.0000000000001821.Online ahead of print.

James McPhail 1, Omar T Sims 2 3 4 5 6, Yuqi Guo 7, David Wooten 1, John S Herndon 1, Omar I Massoud 8
 
61.Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions
 

Liver Int. 2020 Jul 8. doi: 10.1111/liv.14591. Online ahead of print.

Julia Dietz 1, Johannes Vermehren 1, Katrin Matschenz 2, Peter Buggisch 2, Hartwig Klinker 3, Julian Schulze Zur Wiesch 4, Holger Hinrichsen 5, Kai-Henrik Peiffer 1, Christiana Graf 1, Thomas Discher 6, Janina Trauth 6, Jörn M Schattenberg 7, Felix Piecha 4, Stefan Mauss 8, Claus Niederau 9, Tobias Müller 10, Christoph Neumann-Haefelin 11, Christoph P Berg 12, Stefan Zeuzem 1, Christoph Sarrazin 1 13, European HCV Resistance Study Group
 
62.Trends in Indicators of Injection Drug Use, Indian Health Service, 2010-2014 : A Study of Health Care Encounter Data
 

Public Health Rep. Jul/Aug 2020;135(4):461-471. doi: 10.1177/0033354920937284.Epub 2020 Jul 7.

Mary E Evans 1 2 3, Marissa Person 4, Brigg Reilley 5, Jessica Leston 5, Richard Haverkate 6, Jeffrey T McCollum 6, Andria Apostolou 6 7, Michele K Bohm 1, Michelle Van Handel 8, Danae Bixler 9, Andrew J Mitsch 2, Dana L Haberling 4, Sarah M Hatcher 3 5, Thomas Weiser 10, Kim Elmore 2, Eyasu H Teshale 9, Paul J Weidle 2, Philip J Peters 2, Kate Buchacz 2
 
63.The Inflammatory Relationship between Hepatitis C Virus with Coronary and Carotid Atherosclerosis
 

Cardiol Rev. 2020 Jun 18. doi: 10.1097/CRD.0000000000000314. Online ahead of print.

Michael Broker 1, Shalom Z Frager 2, Nayan S Patel 3, Edward Lebovics 2, William H Frishman 1
 
64.Transplanting Livers From "HCV-Positive" Donors To HCV-Negative Recipients: Increased Experience But Many Unanswered Questions
 

Am J Gastroenterol. 2020 Jul;115(7):1022-1023.doi: 10.14309/ajg.0000000000000649.

Nathalie Pena Polanco 1, David Goldberg 1
 
65.Impact of Early Initiation of Direct-Acting Antiviral Therapy in Thoracic Organ Transplantation From Hepatitis C Virus Positive Donors
 

Semin Thorac Cardiovasc Surg. 2020 Jul 2;S1043-0679(20)30236-7.doi: 10.1053/j.semtcvs.2020.06.045. Online ahead of print.

Deane E Smith 1, Stacey Chen 2, Anthony Fargnoli 1, Tyler Lewis 3, Aubrey C Galloway 1, Zachary N Kon 1, Nader Moazami 1
 
66.Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection
 

Clin Gastroenterol Hepatol. 2020 Jul 1;S1542-3565(20)30907-1. doi: 10.1016/j.cgh.2020.06.044.Online ahead of print.

Eli Zuckerman 1, Julio A Gutierrez 2, Douglas E Dylla 3, Victor de Ledinghen 4, Andrew J Muir 5, Michael Gschwantler 6, Massimo Puoti 7, Florin Caruntu 8, Jihad Slim 9, Frederik Nevens 10, Samuel Sigal 11, Stanley Cohen 12, Linda M Fredrick 3, Ana Gabriela Pires Dos Santos 3, Lino Rodrigues Jr 3, John F Dillon 13
 
67.Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals
 

Int J Antimicrob Agents. 2020 Jun 26;106067. doi: 10.1016/j.ijantimicag.2020.106067.Online ahead of print.

M Pisaturo 1, M Starace 1, C Minichini 1, S De Pascalis 2, L Occhiello 1, A Di Fraia 1, V Messina 3, V Sangiovanni 4, E Claar 5, N Coppola 6, CampC Network
 
68.Educating Primary Care Providers and Associate Care Providers About Hepatitis C Screening of Baby Boomers: a Multi-practice Study
 

J Cancer Educ. 2020 Jun 25. doi: 10.1007/s13187-020-01805-2. Online ahead of print.

Bertha E Flores 1, Andrea A Fernandez 1, Chen-Pin Wang 2 3, Raudel Bobadilla 3, Ludivina Hernandez 3, Mamta K Jain 4, Barbara J Turner 5
 
69.Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention
 

Drug Alcohol Depend. 2020 Jun 12;213:108116. doi: 10.1016/j.drugalcdep.2020.108116.Online ahead of print.

Brooke Severe 1, Jeanette M Tetrault 2, Lynn Madden 2, Robert Heimer 3
 
70.Finding undiagnosed patients with hepatitis C infection: an application of artificial intelligence to patient claims data
 

Sci Rep. 2020 Jun 29;10(1):10521. doi: 10.1038/s41598-020-67013-6.

Orla M Doyle 1, Nadejda Leavitt 2, John A Rigg 3
 
71.The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services
 

PLoS One. 2020 Jun 30;15(6):e0235445.doi: 10.1371/journal.pone.0235445. eCollection 2020.

Michael W Traeger 1 2, Alisa E Pedrana 1 2, Daniela K van Santen 1 2, Joseph S Doyle 1 3, Jessica Howell 1 4, Alexander J Thompson 4, Carol El-Hayek 1, Jason Asselin 1, Victoria Polkinghorne 1, Dean Membrey 5, Fran Bramwell 5, Allison Carter 6, Rebecca Guy 6, Mark A Stoové 1 2 7, Margaret E Hellard 1 2 3, EC Victoria Partnership and the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Blood-borne Viruses and Sexually Transmitted Infections (ACCESS)
 
72.Cost-effectiveness analysis of an outreach model of Hepatitis C Virus (HCV) assessment to facilitate HCV treatment in primary care
 

PLoS One. 2020 Jun 17;15(6):e0234577.doi: 10.1371/journal.pone.0234577. eCollection 2020.

David Brain 1 2, Jonathan Mitchell 3 4, James O'Beirne 3 4
 
73.Baseline prevalence and correlates of HIV and HCV infection among people who inject drugs accessing a syringe services program; Miami, FL
 

Harm Reduct J. 2020 Jun 10;17(1):40. doi: 10.1186/s12954-020-00385-0.

Tyler S Bartholomew 1, Jason Onugha 1, Corinne Bullock 1, Carolina Scaramutti 1, Hardik Patel 1, David W Forrest 2, Daniel J Feaster 1, Hansel E Tookes 3
 
74.Hepatitis C cascade of care at an integrated community facility for people who inject drugs
 

J Subst Abuse Treat. 2020 Jul;114:108025. doi: 10.1016/j.jsat.2020.108025. Epub 2020 May 4.

Leith Morris 1, Linda Selvey 2, Owain Williams 2, Charles Gilks 2, Amanda Kvassy 3, Andrew Smirnov 4
 
75.Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study
 

Lancet Gastroenterol Hepatol. 2020 Jun 9;S2468-1253(19)30417-0.doi: 10.1016/S2468-1253(19)30417-0. Online ahead of print.

Eric Lawitz 1, Charles S Landis 2, Steven L Flamm 3, Maurizio Bonacini 4, Grisell Ortiz-Lasanta 5, Jonathan Huang 6, Jie Zhang 7, Brian J Kirby 7, Shampa De-Oertel 7, Robert H Hyland 7, Anu O Osinusi 7, Diana M Brainard 7, Richard Robson 8, Benedict J Maliakkal 6, Stuart C Gordon 9, Edward J Gane 10
 
76.Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review
 

Pharmacoeconomics. 2020 Jun 12. doi: 10.1007/s40273-020-00933-3.Online ahead of print.

T Joseph Mattingly 2nd 1, Bryan L Love 2, Bilal Khokhar 3
 
77.Hepatitis C and Treatment in Patients with Chronic Kidney Disease
 

Dis Mon. 2020 Jun 15;101017. doi: 10.1016/j.disamonth.2020.101017.Online ahead of print.

Abhijay Jalota 1, Brian K Lindner 2, Beje Thomas 3, Edgar V Lerma 4
 
78.Glycemic Control after Initiating Direct-Acting Antiviral Agents in Patients with Hepatitis C Virus and Type 2 Diabetes Mellitus Using the United States Integrated Healthcare System
 

J Res Pharm Pract. 2020 Mar 28;9(1):16-23. doi: 10.4103/jrpp.JRPP_19_110.eCollection Jan-Mar 2020.

Alicia Halim Wong 1, John Sie 1, Angela Chen 1, Basuki Gunawan 2, Joanie Chung 3, Nazia Rashid 4
 
79.Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance
 

Hepatol Commun. 2020 Apr 6;4(6):904-915. doi: 10.1002/hep4.1496. eCollection 2020 Jun.

Mark W Douglas 1 2 3, Enoch S E Tay 1 4, Dao Sen Wang 1, Adrian T L Ong 1 2, Caroline Wilson 1, Amy Phu 1, Jen Kok 4, Dominic E Dwyer 3 4, Rowena A Bull 5, Andrew R Lloyd 5, Tanya L Applegate 5, Gregory J Dore 5, Anita Y Howe 6, Richard Harrigan 7, Jacob George 1 3
 
80.Sustained Virologic Suppression After 4 Weeks of Ledipasvir/Sofosbuvir in Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Co-Infection
 

Am J Case Rep. 2020 Jun 4;21:e923326. doi: 10.12659/AJCR.923326.

Joshua P Havens 1 2, Nichole N Regan 1, Sara H Bares 1
 
81.High prevalence of injection drug use and blood-borne viral infections among patients in an urban emergency department
 

PLoS One. 2020 Jun 4;15(6):e0233927. doi: 10.1371/journal.pone.0233927. eCollection 2020.

Erik S Anderson 1, Carly Russell 1, Kellie Basham 1, Martha Montgomery 1, Helen Lozier 1, Abigail Crocker 1, Marisa Zuluaga 1, Douglas A E White 1
 
82.Hepatitis C Virus Infection and Chemotherapy in Breast Cancer: A Retrospective Chart Analysis
 

Oncologist. 2020 Jun 2. doi: 10.1634/theoncologist.2020-0172. Online ahead of print.

Saptaparni Ghosh 1, Minghua L Chen 2, Janice Weinberg 3, Tsion Fikre 4, Naomi Y Ko 4
 
83.Pretreatment Assessment of Psychosocial Readiness Is Not Associated with Improved Treatment Outcomes in a Safety-Net HCV Treatment Clinic
 

South Med J. 2020 Jun;113(6):261-266.doi: 10.14423/SMJ.0000000000001099.

Zoë Kopp 1, Lesley Miller 1, Sara Turbow 1
 
84.Proportion and Characterization of Co-infections of HIV and Hepatitis C or Hepatitis B among People with HIV in Alabama, 2007-2016
 

South Med J. 2020 Jun;113(6):298-304. doi: 10.14423/SMJ.0000000000001104.

Charlene Siza 1, Danae Bixler 1, Sherri Davidson 1
 
85.How do people in prison feel about opt-out hepatitis C virus testing?
 

J Viral Hepat. 2020 Jun 2.doi: 10.1111/jvh.13338. Online ahead of print.

Kathryn Jack 1, Paul Linsley 2, Brian James Thomson 1, William Lucien Irving 1
 
86.Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction
 

Sci Rep. 2020 Jul 24;10(1):12440. doi: 10.1038/s41598-020-69013-y.

Alexandria Miller 1, Jennifer McNamara 2, Scott L Hummel 2 3, Matthew C Konerman 2, Monica A Tincopa 4
 
87.Comparing Treatment Response Between Older and Younger Patients with Chronic Hepatitis C Virus Infection on Direct-acting Antiviral Agents
 

R I Med J (2013). 2020 Jun 1;103(5):35-40.

Alyssa K Francis 1, Francesca L Beaudoin 2, Safiya S Naidjate 3, Christine Berard-Collins 4, Andrew R Zullo 5
 
88.Novel Models to Identify Census Tracts for Hepatitis C Screening Interventions
 

J Am Board Fam Med. May-Jun 2020;33(3):407-416. doi: 10.3122/jabfm.2020.03.190305.

Thomas Ludden 1, Lindsay Shade 2, Jeremy Thomas 2, Brisa Urquieta de Hernandez 2, Sveta Mohanan 2, Mark W Russo 2, Michael Leonard 2, Philippe J Zamor 2, Charity G Patterson 2, Hazel Tapp 2
 
89.Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a
 

Adv Ther. 2020 Jul;37(7):3299-3310. doi: 10.1007/s12325-020-01389-9. Epub 2020 May 25.

Philip Rosenthal 1, Michael R Narkewicz 2, Betty B Yao 3, Christopher D Jolley 4, Steven J Lobritto 5, Jessica Wen 6, Jean P Molleston 7, Evelyn K Hsu 8, Maureen M Jonas 9, Jiuhong Zha 3, Li Liu 3, Daniel H Leung 10
 
90.Real-world utility of HCV core antigen as an alternative to HCV RNA testing: Implications for viral load and genotype
 

J Viral Hepat. 2020 Jun 1. doi: 10.1111/jvh.13337. Online ahead of print.

Kevin G Pollock 1, Scott A McDonald 2, Rory Gunson 3, Allan McLeod 4, April Went 4, David J Goldberg 3, Sharon J Hutchinson 3, Stephen T Barclay 1 5
 
91.Direct acting antiviral HCV treatment does not influence renal function
 

Matt Driedger 1, Chrissi Galanakis 2, Curtis Cooper 1
 
92.Public Health Clinic-Based Hepatitis C Treatment
 

Am J Prev Med. 2020 May 16;S0749-3797(20)30146-X. doi:10.1016/j.amepre.2020.03.006.Online ahead of print.

Amanda M Rosecrans 1, Aneesha Cheedalla 2, Sarah T Rives 3, Lisa A Scotti 3, Robert E Harris 3, Adena H Greenbaum 4, Risha R Irvin 2, Boatemaa A Ntiri-Reid 5, Holly T Brown 3, Karen E Alston 3, Jaeson A Smith 4, Kathleen R Page 3, Oluwaseun O Falade-Nwulia 2
 
93.Peer outreach point-of-care testing as a bridge to hepatitis C care for people who inject drugs in Toronto, Canada
 

Int J Drug Policy. 2020 Jun;80:102755. doi: 10.1016/j.drugpo.2020.102755. Epub 2020 May 14.

Jennifer Broad 1, Kate Mason 1, Mary Guyton 2, Bernadette Lettner 3, John Matelski 4, Jeff Powis 5
 
94.English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed
 

Kathryn Drysdale 1 2, Yevedzo Ntuli 1 3, Jonathan Bestwick 4, William Gelson 5, Kosh Agarwal 3, Daniel Forton 6, David Mutimer 7, Ahmed M Elsharkawy 7, Ceri Townley 8, Faizel Mahomed 9, Graham R Foster 1 2

Aliment Pharmacol Ther. 2020 Jul;52(1):168-181. doi: 10.1111/apt.15780. Epub 2020 May 22.
 
95.Ethical and Practical Issues Associated with the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine
 

Clin Infect Dis. 2020 May 22;ciaa640. doi: 10.1093/cid/ciaa640. Online ahead of print.

Andrea Cox 1 2, Mark Sulkowski 1, Jeremy Sugarman 1 2 3

Affiliations collapse
 
96.Impact of the Centers for Disease Control and Prevention Recommendation and State Law on Birth Cohort Hepatitis C Screening of New York City Medicaid Recipients
 

Am J Prev Med. 2020 Jun;58(6):832-838. doi: 10.1016/j.amepre.2019.12.024.

Angelica Bocour 1, Miranda S Moore 2, Ann Winters 2
 
97."Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs
 

Int J Drug Policy. 2020 Jul;81:102766. doi: 10.1016/j.drugpo.2020.102766. Epub 2020 May 13.

Trevor Goodyear 1, Lianping Ti 2, Patrizia Carrieri 3, Will Small 4, Rod Knight 5
 
98.Resistance-associated Substitutions in Patients With Chronic Hepatitis C Virus Genotype 4 Infection
 

J Viral Hepat. 2020 May 12. doi: 10.1111/jvh.13322. Online ahead of print.

Julia Dietz 1 2, Olga V Kalinina 3 4, Johannes Vermehren 1 2, Kai-Henrik Peiffer 1 2, Katrin Matschenz 5, Peter Buggisch 5, Claus Niederau 6, Jörn M Schattenberg 7, Beat Müllhaupt 8, Sabine Yerly 9, Marc Ringelhan 10, Roland M Schmid 10, Christoph Antoni 11, Tobias Müller 12, Julian Schulze Zur Wiesch 13 14, Felix Piecha 13, Darius Moradpour 15, Katja Deterding 16 17 18, Heiner Wedemeyer 16 17 18, Christophe Moreno 19, Thomas Berg 20, Christoph P Berg 21, Stefan Zeuzem 1 2, Christoph Welsch 1 2, Christoph Sarrazin 1 2 22, European HCV Resistance Study Group
 
99.Standard Versus Extended Duration Direct-Acting Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment
 

Ann Pharmacother. 2020 May 14;1060028020921166. doi: 10.1177/1060028020921166.Online ahead of print.

Ashley H McKnight 1, Mary L Townsend 1, Mohamed G Hashem 1, Susanna Naggie 1 2 3, Lawrence P Park 1 2 4, Rachel B Britt 1
 
100.HCV DAA Therapy in Persons With HIV-HCV Genotype 1 Coinfection Results in High Rate of Sustained Virologic Response and Heterogeneity in Normalization of Soluble Markers of Immune Activation
 

J Infect Dis. 2020 May 15;jiaa254.doi: 10.1093/infdis/jiaa254. Online ahead of print.

Donald D Anthony 1, Mark S Sulkowski 2, Laura M Smeaton 3, Sofi Damjanovska 1, Carey L Shive 1, Corinne M Kowal 1, Daniel E Cohen 4, Debika Bhattacharya 5, Beverly L Alston-Smith 6, Ashwin Balagopal 2, David L Wyles 7
 
101.High Prevalence of Hepatitis C Infection Among Adult Patients at Four Urban Emergency Departments - Birmingham, Oakland, Baltimore, and Boston, 2015-2017
 

MMWR Morb Mortal Wkly Rep. 2020 May 15;69(19):569-574 doi: 10.15585/mmwr.mm6919a1.

James W Galbraith, Erik S Anderson, Yu-Hsiang Hsieh, Ricardo A Franco, John P Donnelly, Joel B Rodgers, Elissa M Schechter-Perkins, William W Thompson, Noele P Nelson, Richard E Rothman, Douglas A E White

Free PMC article
 
102.Impact of Treatment With Direct Acting Antiviral Drugs on Glycemic Control in Patients With Hepatitis C and Diabetes Mellitus
 

Int J Hepatol. 2020 Jan 13;2020:6438753. doi: 10.1155/2020/6438753. eCollection 2020.

Pradeep Kumar Mada 1 2, Matthew E Malus 3, Arvin Parvathaneni 4, Bing Chen 3, Gabriel Castano 5, Sharon Adley 2, Maureen Moore 2, Michinari Hieda 6, Mohammed J Alam 2, Mark Feldman 1, John William King 2
 
103.Progress Toward Hepatitis C Virus Elimination: Therapy and Implementation
 

Gastroenterol Clin North Am. 2020 Jun;49(2):253-277.doi: 10.1016/j.gtc.2020.01.005. Epub 2020 Mar 29.

Marianne Martinello 1, Sahar Bajis 2, Gregory J Dore 2
 
104.Hepatitis C: How Good Are Real-Life Data and Do Generics Work
 

Gastroenterol Clin North Am. 2020 Jun;49(2):279-299.doi: 10.1016/j.gtc.2020.01.006. Epub 2020 Mar 29.

Ashley N Tran 1, Joseph K Lim 2
 
105.Hepatitis C: Does Successful Treatment Alter the Natural History and Quality of Life?
 

Gastroenterol Clin North Am. 2020 Jun;49(2):301-314.doi: 10.1016/j.gtc.2020.01.007. Epub 2020 Mar 29.

Humberto C Gonzalez 1, Stuart C Gordon 2
 
106.Hepatitis C Screening Rates and Care Cascade in a Large US Insured Population, 2010-2016: Gaps to Elimination
 

Popul Health Manag. 2020 May 11. doi: 10.1089/pop.2019.0237. Online ahead of print.

Josephine Nhu Tran 1, Robert J Wong 2, Janet S Lee 3, Tim Bancroft 1, Ami R Buikema 1, Jie Ting 3, Norah Terrault 4
 
107.Global Epidemiology of Viral Hepatitis
 

Gastroenterol Clin North Am. 2020 Jun;49(2):179-189.doi: 10.1016/j.gtc.2020.01.001.

Homie Razavi 1
 
108.Eliciting Patient Views on the Allocation of Limited Healthcare Resources: A Deliberation on Hepatitis C Treatment in the Veterans Health Administration
 

BMC Health Serv Res. 2020 May 1;20(1):369. doi: 10.1186/s12913-020-05211-8.

Akbar K Waljee 1 2 3, Kerry A Ryan 4, Chris D Krenz 4, George N Ioannou 5 6, Lauren A Beste 6 7, Monica A Tincopa 8, Sameer D Saini 9 8 10, Grace L Su 9 8, Maria E Arasim 9, Patti T Roman 9, Brahmajee K Nallamothu 9 10 11, Raymond De Vries 4
 
109.Bayesian Network Modelling Study to Identify Factors Influencing the Risk of Cardiovascular Disease in Canadian Adults With Hepatitis C Virus Infection
 

MJ Open. 2020 May 5;10(5):e035867. doi: 10.1136/bmjopen-2019-035867.

Alaa Badawi 1 2, Giancarlo Di Giuseppe 3 4, Alind Gupta 5, Abbey Poirier 6, Paul Arora 3
 
110.Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model
 

Open. 2020 May 1;3(5):e204192. doi: 10.1001/jamanetworkopen.2020.4192.

Mawuena Binka 1, Naveed Z Janjua 1 2 3, Jason Grebely 2 4, Chris Estes 5, Dena Schanzer 2, Jisoo A Kwon 4, Naglaa H Shoukry 2 6, Jeffrey C Kwong 2 7, Homie Razavi 5, Jordan J Feld 2 8, Mel Krajden 1 2 3
 
111.Direct-Acting Antivirals Improve Overall Survival in Interventional Oncology Patients With Hepatitis C and Hepatocellular Carcinoma
 

Vasc Interv Radiol. 2020 Jun;31(6):953-960. doi: 10.1016/j.jvir.2019.12.809. Epub 2020 May 4.

William M Kamp 1, Cortlandt M Sellers 1, Stacey Stein 2, Joseph K Lim 3, Hyun S Kim 4
 
112.Impact of a Digital Medicine Programme on Hepatitis C Treatment Adherence and Efficacy in Adults at High Risk for Non-Adherence
 

Aliment Pharmacol Ther. 2020 Jun;51(12):1384-1396. doi: 10.1111/apt.15707. Epub 2020 Apr 30.

Mark Sulkowski 1, Annie F Luetkemeyer 2, David L Wyles 3, Claudia Martorell 4, Andrew Muir 5, Ilan Weisberg 6, Stuart C Gordon 7, Richard McLain 8, Gregory Huhn 3 8
 
113.Japan Society of Hepatology Guidelines for the Management of Hepatitis C Virus Infection: 2019 Update
 

Hepatol Res. 2020 Apr 28. doi: 10.1111/hepr.13503. Online ahead of print.

Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology
 
114.The Prevalence and Impact of Hepatic Steatosis on Response to Direct-Acting Antiviral Therapy in HIV-HCV Coinfection
 

Biology (Basel). 2020 Apr 24;9(4):87. doi: 10.3390/biology9040087.

Leigh P Johnson 1, Richard K Sterling 1 2 3
 
115.Utilization and Effectiveness of elbasvir/grazoprevir and Adoption of Resistance-Associated Substitutions Testing in Real-World Treatment of Hepatitis C Virus Genotype 1A Infection: Results From the German Hepatitis C-Registry
 

Eur J Gastroenterol Hepatol. 2020 May 15. doi: 10.1097/MEG.0000000000001759.Online ahead of print.

Holger Hinrichsen 1, Albrecht Stoehr 2, Markus Cornberg 3, Hartwig Klinker 4, Renate Heyne 5, Christine John 6, Karl-Georg Simon 7, Veronika Guenther 8, Karen Martin 8, Vanessa Witte 8, Stefan Zeuzem 9
 
116.Hepatocellular Carcinoma Mechanisms Associated With Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment
 

J Hepatocell Carcinoma. 2020 Apr 15;7:45-76. doi: 10.2147/JHC.S221187.eCollection 2020.

Srikanta Dash 1 2 3, Yucel Aydin 1, Kyle E Widmer 2, Leela Nayak 2
 
117.Antibody Responses in Hepatitis C Infection
 

Cold Spring Harb Perspect Med. 2020 Apr 27;a036962.doi: 10.1101/cshperspect.a036962.Online ahead of print.

Mansun Law 1
 
118.Hepatitis C Prevalence and Risk Factors in Georgia, 2015: Setting a Baseline for Elimination
 

BMC Public Health. 2019 May 10;19(Suppl 3):480. doi: 10.1186/s12889-019-6784-3.

Liesl M Hagan 1, Ana Kasradze 2, Stephanie J Salyer 3, Amiran Gamkrelidze 2, Maia Alkhazashvili 2, Gvantsa Chanturia 2, Nazibrola Chitadze 2, Roena Sukhiashvili 2, Marina Shakhnazarova 2, Steven Russell 3, Curtis Blanton 3, Giorgi Kuchukhidze 2, Davit Baliashvili 2, Susan Hariri 4, Stephen Ko 4 5, Paata Imnadze 2, Jan Drobeniuc 4, Juliette Morgan 3 6, Francisco Averhoff 4
 
119.An Evaluation of the Hepatitis C Testing, Care and Treatment Program in the Country of Georgia's Corrections System, December 2013 - April 2015
 

BMC Public Health. 2019 May 10;19(Suppl 3):466. doi: 10.1186/s12889-019-6783-4.

Aaron M Harris 1, Otar Chokoshvili 2, Joshua Biddle 3, Kostantine Turashvili 4, Maia Japaridze 5, Irma Burjanadze 6, Tengiz Tsertsvadze 2, Lali Sharvadze 2, Marine Karchava 2, Archil Talakvadze 7, Ketevan Chakhnashvili 4, Tamta Demurishvili 4, Paata Sabelashvili 8, Monique Foster 9 10, Liesl Hagan 9, Maia Butsashvili 11, Juliette Morgan 5 12, Francisco Averhoff 9
 
120.HCV Knowledge, Disclosure Practices, and Risk Perceptions Among Gay and Bisexual Men Who Do and Do Not Engage in Group Sex While Using Drugs
 

AIDS Care. 2020 Apr 26;1-4. doi: 10.1080/09540121.2020.1757023. Online ahead of print.

Loren Brener 1, Dean A Murphy 2, Elena Cama 1, Joel Murray 3, Neil Fraser 4, Jeanne Ellard 5
 
121.Excess Weight Gain After Cure of Hepatitis C Infection With Direct-Acting Antivirals
 

J Gen Intern Med. 2020 Apr 27. doi: 10.1007/s11606-020-05782-6. Online ahead of print.

Albert Do 1, Denise A Esserman 2, Supriya Krishnan 3 4, Joseph K Lim 5 4, Tamar H Taddei 5 4, Ronald G Hauser 3rd 4 6, Janet P Tate 3 4, Vincent Lo Re 3rd 7 8, Amy C Justice 3 4
 
122.Cost-effectiveness of Universal Hepatitis C Screening in Pregnant Women: A Systematic Review
 

J Clin Gastroenterol. 2020 Apr 21. doi: 10.1097/MCG.0000000000001360. Online ahead of print.

Sammy Saab 1 2 3, Ravina Kullar 4, Haydar Khalil 1, Prabhu Gounder 5
 
123.Cost-Effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States
 

Clin Infect Dis. 2020 Apr 13;ciaa362.doi: 10.1093/cid/ciaa362. Online ahead of print.

Antoine Chaillon 1, Adriane Wynn 2, Tatyana Kushner 3, Nancy Reau 4, Natasha K Martin 1 5
 
124.HCC Recurrence in HCV-infected Patients After Liver Transplantation: SiLVER Study Reveals Benefits of Sirolimus in Combination With CNIs - A Post-Hoc Analysis
 

Transpl Int. 2020 Apr 21. doi: 10.1111/tri.13621. Online ahead of print.

Jens M Werner 1, Matthias Hornung 1, Rubertha Krah 1, Markus Götz 1, Andreas A Schnitzbauer 1 2, Hans J Schlitt 1, Edward K Geissler 1 3, International SiLVER study group
 
125.Per-Contact Infectivity of Hepatitis C Virus Acquisition in Association With Receptive Needle Sharing Exposures in a Prospective Cohort of Young Adult People Who Inject Drugs in San Francisco, California
 

Forum Infect Dis. 2020 Mar 16;7(4):ofaa092. doi: 10.1093/ofid/ofaa092.eCollection 2020 Apr.

Yuridia Leyva 1, Kimberly Page 2, Stephen Shiboski 3, Judith A Hahn 4, Jennifer Evans 3, Erik Erhardt 5
 
126.Hepatitis C Virus in Pregnancy: A Systematic Review of the Literature
 

Am J Perinatol. 2020 Apr 22. doi: 10.1055/s-0040-1709672. Online ahead of print.

Alexandra Andes 1, Kerry Ellenberg 1, Amanda Vakos 1, James Collins 1, Kimberly Fryer 2
 
127.Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C-Viremic Donor to Uninfected Recipient Kidney Transplantation
 

Kidney Int Rep. 2020 Jan 13;5(4):459-467.doi: 10.1016/j.ekir.2020.01.001. eCollection 2020 Apr.

Meghan E Sise 1, Ian A Strohbehn 2, Donald F Chute 2, Jenna Gustafson 2, Vivianna M Van Deerlin 3, Jennifer R Smith 3, Caren Gentile 3, David Wojciechowski 4, Winfred W Williams 1, Nahel Elias 5, Raymond T Chung 2
 
128.CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020
 

MMWR Recomm Rep. 2020 Apr 10;69(2):1-17. doi: 10.15585/mmwr.rr6902a1.

Sarah Schillie 1, Carolyn Wester 1, Melissa Osborne 1, Laura Wesolowski 1, A Blythe Ryerson 1
 
129.Assessing the Effectiveness of Strategies in US Birth Cohort Screening for Hepatitis C Infection
 

J Clin Transl Hepatol. 2020 Mar 28;8(1):25-41. doi: 10.14218/JCTH.2019.00059.Epub 2020 Mar 24.

Cynthia J Tsay 1, Joseph K Lim 2
 
130.Maternal Hepatitis B or Hepatitis C Virus Carrier Status and Long-Term Infectious Morbidity of the Offspring: A Population-Based Cohort Study
 

J Viral Hepat. 2020 Apr 9.doi: 10.1111/jvh.13300. Online ahead of print.

Naim Abu Freha 1, Tamar Wainstock 2, Liat Poupko 3, Avni Yonat Shemer 4, Ruslan Sergienko 2, Eyal Sheiner 5
 
131.Viral Eradication Restores Normal Iron Status in Chronic Hepatitis C Patients With Abnormal Iron Studies
 

Ann Hepatol. 2020 Mar 17;S1665-2681(20)30024-7.doi: 10.1016/j.aohep.2020.03.002.Online ahead of print.

Yazan Hasan 1, Kyle Brown 2
 
132.Outcomes of Liver Transplantation by Insurance Types in the United States
 

Am J Manag Care. 2020 Apr 1;26(4):e121-e126. doi: 10.37765/ajmc.2020.42839.

Maria Stepanova, Saleh Al Qahtani, Alita Mishra, Issah Younossi, Chapy Venkatesan, Zobair M Younossi 1
 
133.Outcomes of Liver Transplantation by Insurance Types in the United States
 

Am J Manag Care. 2020 Apr 1;26(4):e121-e126. doi: 10.37765/ajmc.2020.42839.

Maria Stepanova, Saleh Al Qahtani, Alita Mishra, Issah Younossi, Chapy Venkatesan, Zobair M Younossi 1
 
134.KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C
 

Am J Kidney Dis. 2020 May;75(5):665-683. doi: 10.1053/j.ajkd.2019.12.016. Epub 2020 Apr 9.

David Roth 1, Roy D Bloom 2, Miklos Z Molnar 3, Peter P Reese 4, Deirdre Sawinski 5, Meghan E Sise 6, Norah A Terrault 7
 
135.Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients With Chronic Hepatitis C Infection
 

Adv Ther. 2020 May;37(5):2267-2274. doi: 10.1007/s12325-020-01301-5. Epub 2020 Apr 11.

Steven L Flamm 1, Jens Kort 2, Steven E Marx 3, John Strezewski 2, Douglas E Dylla 2, Bruce Bacon 4, Michael P Curry 5, Naoky Tsai 6, Nicole Wick 7
 
136.CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020
 

MMWR Recomm Rep. 2020 Apr 10;69(2):1-17. doi: 10.15585/mmwr.rr6902a1.

Sarah Schillie 1, Carolyn Wester 1, Melissa Osborne 1, Laura Wesolowski 1, A Blythe Ryerson 1
 
137.Vital Signs: Newly Reported Acute and Chronic Hepatitis C Cases - United States, 2009-2018
 

MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):399-404.doi: 10.15585/mmwr.mm6914a2.

A Blythe Ryerson 1, Sarah Schillie 1, Laurie K Barker 1, Benjamin A Kupronis 1, Carolyn Wester 1
 
138.Factors Influencing Treatment Outcome in Hepatitis C Virus Minority Patients at an Inner-City Hospital: A STROBE-complaint Article
 

Zaki A Sherif 1, Mehdi Nouraie 2, Rehana Begum 2 3, Ali Afsari 4 5, Babak Shokrani 5, Edward Lee 5 6, Adeyinka O Laiyemo 2 3, Hassan Brim 4 6, Hassan Ashktorab 2 4
 
139.Simeprevir, Daclatasvir, and Sofosbuvir for Hepatitis C Virus-Infected Patients: Long-term Follow-Up Results From the Open-Label, Phase II IMPACT Study
 

Health Sci Rep. 2020 Feb 22;3(2):e145. doi: 10.1002/hsr2.145. eCollection 2020 Jun.

Eric Lawitz 1, Fred Poordad 1, Julio A Gutierrez 2, Maria Beumont 3, Greet Beets 3, Ann Vandevoorde 3, Pieter Van Remoortere 4, Donghan Luo 4, Leen Vijgen 3, Veerle Van Eygen 3, Mohamed Gamil 3
 
140.Elbasvir and Grazoprevir for Hepatitis C Virus Genotype 1 Infection in People With Recent Injecting Drug Use (DARLO-C): An Open-Label, Single-Arm, Phase 4, Multicentre Trial
 

Health Sci Rep. 2020 Mar 15;3(2):e151. doi: 10.1002/hsr2.151. eCollection 2020 Jun.

Jason Grebely 1, Phillip Read 2, Evan B Cunningham 1, Martin Weltman 3, Gail V Matthews 1 4, Adrian Dunlop 5, Mark Montebello 6, Marianne Martinello 1 4, Rosie Gilliver 2, Philippa Marks 1, Tanya L Applegate 1, Gregory J Dore 1 4, DARLO-C Study Group
 
141.Infective Endocarditis Among Persons Aged 18-64 Years With HIV, Hepatitis C Infection, or Opioid Use Disorder - United States, 2007-2017
 

Clin Infect Dis. 2020 Apr 9;ciaa372. doi: 10.1093/cid/ciaa372. Online ahead of print.

Cecillia Y Wong 1, Weiming Zhu 2, Gerard P Aurigemma 1, Nathan Furukawa 2, Eyasu H Teshale 3, Ya-Lin A Huang 2, Philip J Peters 2, Karen W Hoover 2
 
142.The Emergency Department as a Setting-Specific Opportunity for Population-Based Hepatitis C Screening: An Economic Evaluation
 

Liv Int. 2020 Apr 8. doi: 10.1111/liv.14458. Online ahead of print.

Andrew B Mendlowitz 1 2, David Naimark 3, William W L Wong 4, Camelia Capraru 5, Jordan J Feld 5, Wanrudee Isaranuwatchai 2 6, Murray Krahn 1 7
 
143.Ombitasvir/paritaprevir/ritonavir & Dasabuvir ± Ribavirin Following Protease Inhibitors Failure - A Prospective Multi-Centre Trial
 

BMC Infect Dis. 2020 Apr 3;20(1):264. doi: 10.1186/s12879-020-4921-3.

Liat Deutsch 1 2, Inbal Houri 1 2, Ziv Ben-Ari 2 3, Amir Shlomai 2 4, Ella Veitsman 2 3, Oranit Cohen-Ezra 2 3, Assaf Issachar 2 4, Orna Mor 5 6, Yael Gozlan 5, Rafael Bruck 1 2, Yoram Menachem 1 2, Shira Zelber-Sagi 1 7, Helena Katchman 1 2, Oren Shibolet 8 9
 
144.How to Think With Models and Targets: Hepatitis C Elimination as a Numbering Performance
 

Int J Drug Policy. 2020 Mar 31;102694. doi: 10.1016/j.drugpo.2020.102694. Online ahead of print.

Tim Rhodes 1, Kari Lancaster 2
 
145.Is Alzheimer's Disease a Liver Disease of the Brain?
 

Alzheimers Dis. 2020 Apr 2.doi: 10.3233/JAD-190848. Online ahead of print.

Margaret F Bassendine 1 2, Simon D Taylor-Robinson 2, Michael Fertleman 2 3, Michael Khan 4, Dermot Neely 1 5
 
146.Low Uptake of Direct-acting Antiviral Therapy Among Hepatitis C Patients With Advanced Liver Disease and Access to Care, 2014-2017
 

J Clin Gastroenterol. 2020 Apr 3. doi: 10.1097/MCG.0000000000001344. Online ahead of print.

Philip R Spradling 1, Jian Xing 1, Loralee B Rupp 2, Anne C Moorman 1, Stuart C Gordon 2 3, Mei Lu 2, Eyasu H Teshale 1, Joseph A Boscarino 4, Mark A Schmidt 5, Yihe G Daida 6, Scott D Holmberg 1, Chronic Hepatitis Cohort Study (CHeCS) Investigators
 
147.Use of Electronic Health Records at Federally Qualified Health Centers: A Potent Tool to Increase Viral Hepatitis Screening and Address the Climbing Incidence of Liver Cancer
 

Cancer Educ. 2020 Apr 2. doi: 10.1007/s13187-020-01741-1. Online ahead of print.

Christina Pham 1, Mo-Kyung Sin 2
 
148. Antibody Avidity-Based Approach to Estimate Population-Level Incidence of Hepatitis C
 

Hepatol. 2020 Mar 30;S0168-8278(20)30190-2. doi: 10.1016/j.jhep.2020.03.028.Online ahead of print.

Denali Boon 1, Veronica Bruce 2, Eshan U Patel 3, Jeffery Quinn 3, Aylur K Srikrishnan 4, Saravanan Shanmugam 4, Syed Iqbal 4, Pachamuthu Balakrishnan 4, Matthew Sievers 3, Gregory D Kirk 3, David L Thomas 3, Thomas C Quinn 5, Andrea L Cox 3, Kimberly A Page 2, Sunil S Solomon 6, Shruti H Mehta 3, Oliver Laeyendecker 5
 
149.Association Between Statin Use, Intensity and Acute Liver Injury in Human Immunodeficiency Virus, Hepatitis C Virus, and Uninfected US Veterans
 

 J Cardiovasc Drugs. 2020 Apr 1. doi: 10.1007/s40256-020-00404-2. Online ahead of print.

S S Sutton 1 2, Joseph Magagnoli 3 4, Tammy H Cummings 2, James W Hardin 2 5
 
150.Health of Special Immigrant Visa Holders From Iraq and Afghanistan After Arrival Into the United States Using Domestic Medical Examination Data, 2014-2016: A Cross-Sectional Analysis
 

PLoS Med. 2020 Mar 31;17(3):e1003083. doi: 10.1371/journal.pmed.1003083.eCollection 2020 Mar.

Gayathri S Kumar 1, Clelia Pezzi 1, Simone Wien 1, Blain Mamo 2, Kevin Scott 3, Colleen Payton 3, Kailey Urban 2, Stephen Hughes 4, Lori Kennedy 5, Nuny Cabanting 6, Jessica Montour 7, Melissa Titus 8, Jenny Aguirre 9, Breanna Kawasaki 5, Rebecca Ford 10, Emily S Jentes 1
 
151.Influence of Interferon-free Direct-acting Antiviral Therapy on Primary Hepatocellular Carcinoma Recurrence: A Landmark Time Analysis and Time-dependent Extended Cox Proportional Hazards Model Analysis
 

Intern Me. 2020;59(7):901-907. doi: 10.2169/internalmedicine.3382-19. Epub 2020 Apr 1.

Satoshi Miuma 1, Junya Miyamoto 2, Naota Taura 1, Masanori Fukushima 1, Ryu Sasaki 1, Masafumi Haraguchi 1, Hidetaka Shibata 1, Shuntaro Sato 2, Hisamitsu Miyaaki 1, Kazuhiko Nakao 1
 
152. Prescription Opioid Injection Among Young People Who Inject Drugs in New York City: A Mixed-Methods Description and Associations With Hepatitis C Virus Infection and Overdose
 

Harm Reduct J. 2020 Mar 30;17(1):22. doi: 10.1186/s12954-020-00367-2.

Pedro Mateu-Gelabert 1, Honoria Guarino 2, Jon E Zibbell 3, Jennifer Teubl 4, Chunki Fong 2, Elizabeth Goodbody 2, Brian Edlin 5, Carli Salvati 2, Samuel R Friedman 6
 
153.Measuring Hepatitis C Virus Elimination as a Public Health Threat: Beyond Global Targets
 

J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13294. Online ahead of print.

Daniela K van Santen 1 2 3, Rachel Sacks-Davis 1 3, Joseph S Doyle 1 4, Nick Scott 1 3, Maria Prins 2 5, Margaret Hellard 1 4 6
 
154.The Impact of SVR From Direct-Acting Antiviral- And Interferon-Based Treatments for HCV on Hepatocellular Carcinoma Risk
 

J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13295. Online ahead of print.

Naveed Z Janjua 1 2, Stanley Wong 1, Maryam Darvishian 1 2 3, Zahid A Butt 1 2, Amanda Yu 1, Mawuena Binka 1, Maria Alvarez 1, Ryan Woods 3, Eric M Yoshida 4, Alnoor Ramji 4, Jordan Feld 5, Mel Krajden 1 6
 
155.Hepatitis C: Looking Into the Future
 

Expert Rev Gastroenterol Hepatol. 2020 Mar 27;1-8.

 doi: 10.1080/17474124.2020.1746641.Online ahead of print.

Omar Massoud 1
 
156.Comparison of Recommendations for Treatment of Chronic Hepatitis C Virus Infection in Children and Adolescents: A Position Paper of the Global Federation of International Societies of International Societies of Pediatric Gastroenterology, Hepatology and Nutrition (FISPGHAN)
 

J Pediatr Gastroenterol Nutr. 2020 Mar 20.

 doi: 10.1097/MPG.0000000000002710.Online ahead of print.

Giuseppe Indolfi 1, Björn Fischler 2, Regino P Gonzalez-Peralta 3, Mirta Ciocca 4, Gilda Porta 5, Mohan Neelam 6, Mohammed El-Guindi 7, Deirdre Kelly 8, Yen-Hsuan Ni 9, Anupan Sibal 10, Daniel H Leung 11, Mei Hwei Chang 12, Hepatitis Expert Team of the Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition (FISPGHAN)
 
157.Population Impact of Direct-Acting Antiviral Treatment on New Presentations of Hepatitis C-related Decompensated Cirrhosis: A National Record-Linkage Study
 

Gut. 2020 Mar 26;gutjnl-2019-320007. doi: 10.1136/gutjnl-2019-320007. Online ahead of print.

Sharon J Hutchinson 1 2, Heather Valerio 3 2, Scott A McDonald 3 2, Alan Yeung 3 2, Kevin Pollock 3 2, Shanley Smith 3 2, Stephen Barclay 3 4, John F Dillon 5, Raymond Fox 6, Peter Bramley 7, Andrew Fraser 8 9, Nicholas Kennedy 10, Rory N Gunson 11, Kate Templeton 12, Hamish Innes 3 2, Allan McLeod 2, Amanda Weir 2, Peter C Hayes 13, David Goldberg 3 2
 
158.New hepatitis C diagnoses in Ontario, Canada are associated with the local prescription patterns of a controlled-release opioid
 

Meyer M1,2,3, Bondy L4, Koivu S5, Koval J2, Scarffe AD3,6, Silverman MS4. J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13292. [Epub ahead of print]
 
159.Hepatitis C: looking into the future
 

Massoud O1. Expert Rev Gastroenterol Hepatol. 2020 Mar 27:1-8. doi: 10.1080/17474124.2020.1746641. [Epub ahead of print]
 
160.Sustained Improvements in Markers of Liver Disease Severity After Hepatitis C Treatment
 

Wong RJ1, Jain MK2,3, Therapondos G4, Shiffman ML5, Kshirsagar O6, Clark C3, Thamer M6. J Clin Exp Hepatol. 2020 Mar-Apr;10(2):114-123. doi: 10.1016/j.jceh.2019.09.001. Epub 2019 Sep 20.
 
161.T-Cell Immunity against the Hepatitis C Virus: A Persistent Research Priority in an Era of Highly Effective Therapy
 

Smith S1,2, Honegger JR1,2, Walker C1,2. Cold Spring Harb Perspect Med. 2020 Mar 23. pii: a036954. doi: 10.1101/cshperspect.a036954. [Epub ahead of print]
 
162.Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population
 

Banga J1, Nizami S1, Slim J2, Nagarakanti S3, Portilla M1, Swaminathan S1. Medicine (Baltimore). 2020 Mar;99(11):e19140. doi: 10.1097/MD.0000000000019140.
 
163.Australia needs to increase testing to achieve hepatitis C elimination
 

Scott N1, Sacks-Davis R1, Wade AJ1, Stoove M1, Pedrana A1, Doyle JS1, Thompson AJ2, Wilson DP1, Hellard ME1. Med J Aust. 2020 Mar 13. doi: 10.5694/mja2.50544. [Epub ahead of print]
 
164.The Urgent Need for Hepatitis C Screening in Pregnant Women: A Call to Action
 

Saab S1, Kullar R, Gounder P. Obstet Gynecol. 2020 Apr;135(4):773-777. doi: 10.1097/AOG.0000000000003704.
 
165.Present and future management of viral hepatitis B and C in children
 

Clemente MG1, Antonucci R2, Sotgiu G2, Dettori M2, Piana A2, Vajro P3. Clin Res Hepatol Gastroenterol. 2020 Mar 12. pii: S2210-7401(20)30043-7. doi: 10.1016/j.clinre.2020.02.010. [Epub ahead of print]
 
166. Hepatitis C Virus Antibody Screening in a Cohort of Pregnant Women: Identifying Seroprevalence and Risk Factors
 

Prasad M1, Saade GR, Sandoval G, Hughes BL, Reddy UM, Mele L, Salazar A, Varner MW, Gyamfi-Bannerman C, Thorp JM Jr, Tita ATN, Swamy GK, Chien EK, Casey BM, Peaceman AM, El-Sayed YY, Iams JD, Gibbs RS, Sibai B, Wiese N, Kamili S, Macones GA; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Obstet Gynecol. 2020 Apr;135(4):778-788. doi: 10.1097/AOG.0000000000003754.
 
167.Reinfection following successful direct-acting antiviral therapy for hepatitis Cinfection among people who inject drugs
 

Cunningham EB1, Hajarizadeh B1, Amin J1,2, Hellard M3,4, Bruneau J5, Feld JJ6, Cooper C7, Powis J8, Litwin AH9, Marks P1, Dalgard O10, Conway B11, Moriggia A12,13, Stedman C14, Read P1,15, Bruggmann P16, Lacombe K17, Dunlop A18, Applegate TL1, Matthews GV1,19, Fraser C20, Dore GJ1,19, Grebely J1. Clin Infect Dis. 2020 Mar 12. pii: ciaa253. doi: 10.1093/cid/ciaa253. [Epub ahead of print]
 
168.Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky
 

Stone J1, Fraser H2, Young AM3, Havens JR4, Vickerman P2. Int J Drug Policy. 2020 Mar 6:102707. doi: 10.1016/j.drugpo.2020.102707. [Epub ahead of print]
 
169.A Phylogenetic Analysis of HCV Transmission, Relapse, and Reinfection Among People Who Inject Drugs Receiving Opioid Agonist Therapy
 

Akiyama MJ1, Lipsey D1, Ganova-Raeva L2, Punkova L2, Agyemang L1, Sue A2, Ramachandran S2, Khudyakov Y2, Litwin AH3. J Infect Dis. 2020 Mar 9. pii: jiaa100. doi: 10.1093/infdis/jiaa100. [Epub ahead of print]
 
170.Transplant Outcomes in Older Patients with Nonalcoholic Steatohepatitis Compared to Alcohol-Related Liver Disease and Hepatitis C
 

Henson JB1, Wilder JM2,3, Kappus MR2, Barbas AS4, Moylan CA2, Niedzwiecki D5, Muir AJ2,3, Berg CL2, Patel YA2. Transplantation. 2020 Mar 6. doi: 10.1097/TP.0000000000003219. [Epub ahead of print]
 
171.Hepatitis C Virus Prevalence in 50 U.S. States and D.C. by Sex, Birth Cohort, and Race: 2013-2016
 

Bradley H1, Hall EW2, Rosenthal EM3, Sullivan PS2, Ryerson AB4, Rosenberg ES3. Hepatol Commun. 2020 Jan 14;4(3):355-370. doi: 10.1002/hep4.1457. eCollection 2020 Mar.
 
172.Are we on the precipice of a new epidemic? Risk for hepatitis C among HIV-negative men-, trans women-, and trans men- who have sex with men in the United States
 

Grov C1,2, Westmoreland DA2, Carrico AW3,4, Nash D1,2. AIDS Care. 2020 Mar 15:1-9. doi: 10.1080/09540121.2020.1739204. [Epub ahead of print]
 
173.Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-Results from the German Hepatitis C-Registry
 

Knop V1, Mauss S2, Goeser T3, Geier A4, Zimmermann T5, Herzer K6, Postel N7, Friedrich-Rust M1, Hofmann WP8; German Hepatitis C-Registry9. J Viral Hepat. 2020 Feb 24. doi: 10.1111/jvh.13280. [Epub ahead of print]
 
174.A vulnerability assessment for the HCV infections associated with injection drug use
 

Sharareh N1, Hess R2, White S3, Dunn A4, Singer PM5, Cochran J6. Prev Med. 2020 Feb 22;134:106040. doi: 10.1016/j.ypmed.2020.106040. [Epub ahead of print]
 
175.Examination of using alcohol to cope, depressive symptoms, and perceived social support in persons with HIV and Hepatitis C
 

Moitra E1, Anderson BJ2, Herman DS1,2, Hayaki J3, Pinkston MM1,4, Kim HN5,6, Stein MD7. AIDS Care. 2020 Feb 25:1-8. doi: 10.1080/09540121.2020.1734177. [Epub ahead of print]
 
176.Cost effectiveness of an intervention to increase uptake of hepatitis C virus testing and treatment (HepCATT): cluster randomised controlled trial in primary care
 

Roberts K1, Macleod J1,2, Metcalfe C1,3, Hollingworth W1, Williams J4,5, Muir P6, Vickerman P1,2, Clement C2, Gordon F7, Irving W8, Waldron CA9, North P6, Moore P6, Simmons R5,10, Miners A4,5, Horwood J1,2, Hickman M11,2. BMJ. 2020 Feb 26;368:m322. doi: 10.1136/bmj.m322.
 
177.Increasing uptake of hepatitis C virus infection case-finding, testing, and treatment in primary care: evaluation of the HepCATT (Hepatitis C Assessment Through to Treatment) trial
 

Horwood J1, Clement C2, Roberts K2, Waldron CA3, Irving WL4, Macleod J5, Hickman M6. Br J Gen Pract. 2020 Feb 24. pii: bjgp20X708785. doi: 10.3399/bjgp20X708785. [Epub ahead of print]Horwood J1, Clement C2, Roberts K2, Waldron CA3, Irving WL4, Macleod J5, Hickman M6. Br J Gen Pract. 2020 Feb 24. pii: bjgp20X708785. doi: 10.3399/bjgp20X708785. [Epub ahead of print]
 
178.Socio-demographic and ecological factors associated with anti-HCV prevalence in people who inject drugs: A systematic review
 

Colledge S1, Leung J2, Grebely J3, Degenhardt L4, Peacock A4, Hickman M5, Vickerman P5, Stone J5, Trickey A5, Larney S4. Drug Alcohol Depend. 2020 Feb 6;209:107899. doi: 10.1016/j.drugalcdep.2020.107899. [Epub ahead of print]
 
179.Minimal Compared With Standard Monitoring During Sofosbuvir-Based Hepatitis CTreatment: A Randomized Controlled Trial
 

Davis JS1,2, Young M1, Marshall C3, Tate-Baker J3, Madison M3, Sharma S3, Silva C1, Jones T1, Davies J2,3. Open Forum Infect Dis. 2020 Jan 19;7(2):ofaa022. doi: 10.1093/ofid/ofaa022. eCollection 2020 Feb.
 
180.Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients
 

Eckman MH1, Woodle ES2, Thakar CV3, Alloway RR3, Sherman KE4. Am J Kidney Dis. 2020 Feb 5. pii: S0272-6386(19)31163-1. doi: 10.1053/j.ajkd.2019.11.005. [Epub ahead of print]
 
181.The association between etiology of hepatocellular carcinoma and race-ethnicity in Florida
 

Pinheiro PS1, Medina HN2, Callahan KE3, Jones PD4, Brown CP5, Altekruse SF6, McGlynn KA7, Kobetz EN8. Liver Int. 2020 Feb 22. doi: 10.1111/liv.14409. [Epub ahead of print]
 
182.Diagnostic Accuracy of Non-Invasive Tests to Detect Advanced Hepatic Fibrosis in Patients With Hepatitis C and End-Stage Renal Disease
 

Schmoyer CJ1, Kumar D2, Gupta G2, Sterling RK3. Clin Gastroenterol Hepatol. 2020 Feb 18. pii: S1542-3565(20)30189-0. doi: 10.1016/j.cgh.2020.02.019. [Epub ahead of print]
 
183.Hepatitis C Virus Vaccine: Challenges and Prospects
 

Duncan JD1,2,3, Urbanowicz RA1,2,3, Tarr AW1,2,3, Ball JK1,2,3. Vaccines (Basel). 2020 Feb 17;8(1). pii: E90. doi: 10.3390/vaccines8010090.
 
184.Micro-elimination of hepatitis C virus
 

Hollande C1, Parlati L1, Pol S1. Liver Int. 2020 Feb;40 Suppl 1:67-71. doi: 10.1111/liv.14363
 
185.Hepatitis C elimination - Macro-elimination
 

Kåberg M1,2, Weiland O1. Liver Int. 2020 Feb;40 Suppl 1:61-66. doi: 10.1111/liv.14352.
 
186.Increased-risk donors and solid organ transplantation: current practices and opportunities for improvement
 

Brown CS1, Wakam GK, Englesbe MJ. Curr Opin Organ Transplant. 2020 Apr;25(2):139-143. doi: 10.1097/MOT.0000000000000735
 
187.Case Management and Capacity Building to Enhance Hepatitis C Treatment Uptake at Community Health Centers in a Large Urban Setting
 

Boodram B1, Kaufmann M, Aronsohn A, Hamlish T, Peregrine Antalis E, Kim K, Wolf J, Rodriguez I, Millman AJ, Johnson D. Fam Community Health. 2020 Apr/Jun;43(2):150-160. doi: 10.1097/FCH.0000000000000253
 
188.HCV infection and non-Hodgkin lymphomas: an evolving story
 

Defrancesco I1, Zerbi C1, Rattotti S2, Merli M3, Bruno R4,5, Paulli M1,6, Arcaini L7,8. Clin Exp Med. 2020 Feb 12. doi: 10.1007/s10238-020-00615-6. [Epub ahead of print]
 
189.Respect women, promote health and reduce stigma: ethical arguments for universal hepatitis C screening in pregnancy
 

Gross MS1, Ruth AR2, Rasmussen SA3,4. J Med Ethics. 2020 Feb 13. pii: medethics-2019-105692. doi: 10.1136/medethics-2019-105692. [Epub ahead of print]
 
190.Discontinuation of new hepatitis C drugs among Medicare patients
 

Jung J1, Du P, Feldman R, Riley T 3rd. Am J Manag Care. 2020 Feb;26(2):84-88. doi: 10.37765/ajmc.2020.42397
 
191.Hepatitis C Testing Among Perinatally Exposed Infants
 

Lopata SM1,2, McNeer E3,4, Dudley JA5, Wester C6, Cooper WO7,3,5, Carlucci JG7,8, Espinosa CM9,10, Dupont W4,5, Patrick SW7,2,3,5. Pediatrics. 2020 Mar;145(3). pii: e20192482. doi: 10.1542/peds.2019-2482. Epub 2020 Feb 14.
 
192.Hepatitis C vaccine: 10 good reasons for continuing
 

Roingeard P1, Beaumont E1. Hepatology. 2020 Feb 15. doi: 10.1002/hep.31182. [Epub ahead of print]
 
193.Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy - data from the German hepatitis C registry (DHC-R)
 

Schmitt A1, Günther R2, Mauss S3, Boeker KHW4, Buggisch P5, Hillenbrand H6, John C7, Klinker H8, Pathil A9,10, Simon KG11, Serfert Y12, Niederau C13, Vermehren J10, Wedemeyer H12,14,15, Sarrazin C1,10. Z Gastroenterol. 2020 Feb 10. doi: 10.1055/a-1068-3056. [Epub ahead of print]
 
194.The Next Frontier: Universal HCV Screening in pregnant women
 

Saab S1, Kullar R2, Amini C3, Gounder P4. Am J Obstet Gynecol. 2020 Feb 7. pii: S0002-9378(20)30133-2. doi: 10.1016/j.ajog.2020.01.058. [Epub ahead of print]
 
195.Network-based recruitment of people who inject drugs for hepatitis C testing and linkage to care
 

Falade-Nwulia O1, Ward KM1, McCormick S1, Mehta SH2, Pitts SR3, Katz S1, Chander G1, Thomas DL1, Sulkowski M1, Latkin CA2. J Viral Hepat. 2020 Feb 11. doi: 10.1111/jvh.13274. [Epub ahead of print]
 
196.A financial incentive program to improve appointment attendance at a safety-net hospital-based primary care hepatitis C treatment program
 

Lee KS1,2, Quintiliani L1,3, Heinz A4, Johnson NL3, Xuan Z3, Truong V2, Lasser KE1,2,3. PLoS One. 2020 Feb 11;15(2):e0228767. doi: 10.1371/journal.pone.0228767. eCollection 2020
 
197.Alcohol Use and Long-Term Outcomes Among U.S. Veterans Who Received Direct-Acting Antivirals for Hepatitis C Treatment
 

Kim NJ1, Pearson M1, Vutien P1, Su F1, Moon AM2, Berry K3, Green PK3, Williams EC3,4, Ioannou GN1,5. Hepatol Commun. 2020 Jan 2;4(2):314-324. doi: 10.1002/hep4.1464. eCollection 2020 Feb.
 
198.HIV and Hepatitis C Virus Infection Testing Among Commercially Insured Persons Who Inject Drugs, United States, 2010-2017
 

Bull-Otterson L1, Huang YA2, Zhu W3, King H4, Edlin BR1, Hoover KW2. J Infect Dis. 2020 Jan 30. pii: jiaa017. doi: 10.1093/infdis/jiaa017. [Epub ahead of print]
 
199.Exploring Awareness of HCV Among Sexual-Minority Black Generation Millennials and Gen Z: a Qualitative Study
 

D'Anna L1, Washington TA2, Cabudol M3, Canjura C3, Owens J3; PPOWER Project Team. J Racial Ethn Health Disparities. 2020 Jan 31. doi: 10.1007/s40615-019-00684-8. [Epub ahead of print]
 
200.Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation
 

Jordan AE1, Perlman DC2, Cleland CM3, Wyka K4, Schackman BR5, Nash D4. J Clin Virol. 2020 Jan 27;124:104285. doi: 10.1016/j.jcv.2020.104285. [Epub ahead of print]
 
201.Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study
 

Adinolfi LE1, Petta S2, Fracanzani AL3, Coppola C4, Narciso V5, Nevola R6, Rinaldi L6, Calvaruso V2, Staiano L4, Di Marco V2, Marrone A6, Pafundi PC6, Solano A5, Lombardi R3, Sasso FC6, Saturnino M4, Rini F2, Guerrera B6, Troina G2, Giordano M6, Craxì A2. Atherosclerosis. 2020 Jan 21;296:40-47. doi: 10.1016/j.atherosclerosis.2020.01.010. [Epub ahead of print]
 
202.Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs
 

Rosenthal ES1,2, Silk R1,2, Mathur P1,2, Gross C1,2, Eyasu R1,2, Nussdorf L2,3, Hill K2,3, Brokus C2,3, D'Amore A2,3, Sidique N2,3, Bijole P4, Jones M4, Kier R4, McCullough D4, Sternberg D4, Stafford K1, Sun J3, Masur H2,3, Kottilil S1,2, Kattakuzhy S1,2. Clin Infect Dis. 2020 Feb 3. pii: ciaa105. doi: 10.1093/cid/ciaa105. [Epub ahead of print]
 
203.Quality improvement in hepatitis C screening and treatment in a primary care resident clinic
 

Doering T1, Williamson S1, Gadalla M1. J Community Hosp Intern Med Perspect. 2019 Dec 14;9(6):471-472. doi: 10.1080/20009666.2019.1698230. eCollection 2019.
 
204.Hepatitis C Diagnosis and Treatment, Impact on Engagement and Behaviour of People Who Inject Drugs, a service evaluation, the Hooked C project
 

Caven M1, Robinson EM1,2, Eriksen AJ3, Fletcher EH1,3, Dillon JF1,2. J Viral Hepat. 2020 Jan 29. doi: 10.1111/jvh.13269. [Epub ahead of print]
 
205.Cost-effectiveness of transplanting lungs and kidneys from donors with potential hepatitis C exposure or infection
 

Scott N1,2, Snell G3, Westall G3, Pilcher D4,5, Raggatt M6,7, Walker RG8,9, Hellard M6,4,7, Peleg AY7,10, Doyle J6,7. Sci Rep. 2020 Jan 29;10(1):1459. doi: 10.1038/s41598-020-58215-z.
 
206.A Co-localized Hepatitis C Virus Clinic in a Primary Care Practice Improves Linkage to Care in a High Prevalence Population
 

Adamson PC1, Miceli J2, Shiferaw B3, Villaneuva MS2, Canterino JE4. Am J Med. 2020 Jan 24. pii: S0002-9343(20)30039-5. doi: 10.1016/j.amjmed.2019.12.028. [Epub ahead of print]
 
207.Success of Direct-Acting, Antiviral-Based Therapy for Chronic Hepatitis C Is Not Affected by Type 2 Diabetes
 

Niccum BA1, Stine JG2, Wynter JA3, Kelly V3, Caldwell SH3, Shah NL3. Clin Diabetes. 2020 Jan;38(1):40-46. doi: 10.2337/cd18-0112.
 
208.Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort
 

Soria A1, Fava M1,2, Bernasconi DP3, Lapadula G1, Colella E1, Valsecchi MG3, Migliorino GM1, D'Ambrosio R4, Landonio S5, Schiavini M5, Spinetti A6, Carriero C6, Degasperi E4, Cologni G7, Gatti F8, Viganò P8, Hasson H9, Uberti-Foppa C10, Pasulo L7, Baiguera C11, Rossotti R11, Vinci M11, Puoti M11, Giorgini A12, Menzaghi B13, Lombardi A14, Pan A15, Aghemo A16, Grossi PA17, Boldizzoni R18, Colombo S18, Viganò M19, Rumi MG19, Del Poggio P20, Valenti L21, Giglio O22, De Bona A12, d'Arminio Monforte A12, Colombo A22, Spinelli O22, Pigozzi MG6, Molteni C23, Bonfanti P23, Terreni N24, Perini P25, Capretti A26, Bella D27, Liani C27, Polo S27, Aimo G27, Pagnucco L14, Bhoori S28, Centenaro R29, Graffeo M30, Ciaccio A31, Dionigi E32, Lazzaroni S33, Carderi I34, Di Marco M35, Rizzardini G5, Noventa F36, Lampertico P4, Fagiuoli S7. Liver Int. 2020 Jan 22. doi: 10.1111/liv.14386. [Epub ahead of print]
 
209.Electronic medical record alert activation increase hepatitis C and HIV screening rates in primary care practices within a large healthcare system
 

Tapp H1, Ludden T1, Shade L1, Thomas J1, Mohanan S1, Leonard M2. Prev Med Rep. 2020 Jan 7;17:101036. doi: 10.1016/j.pmedr.2019.101036. eCollection 2020 Mar.
 
210.Social values for health technology assessment in Canada: a scoping review of hepatitis C screening, diagnosis and treatment
 

O'Keefe-Markman C1, Lea KD2, McCabe C3,4, Hyshka E1,5, Bubela T6. BMC Public Health. 2020 Jan 20;20(1):89. doi: 10.1186/s12889-020-8190-2.
 
211.Effect of Needle Exchange Program on Maternal Hepatitis C Virus Prevalence
 

Rossi RM1,2, Brady MJ1, Hall ES3,4, Warshak CR1,2. Am J Perinatol. 2020 Jan 21. doi: 10.1055/s-0039-3402753. [Epub ahead of print]
 
212.Global prevalence of hepatitis C virus in children in 2018: a modelling study
 

Schmelzer J1, Dugan E1, Blach S1, Coleman S1, Cai Z1, DePaola M1, Estes C1, Gamkrelidze I1, Jerabek K1, Ma S1, Montoya S1, Razavi-Shearer D1, Razavi-Shearer K1, Robbins-Scott S1, Razavi H2, El Sayed MH3. Lancet Gastroenterol Hepatol. 2020 Jan 16. pii: S2468-1253(19)30385-1. doi: 10.1016/S2468-1253(19)30385-1. [Epub ahead of print]
 
213.Long-Term Safety and Efficacy Results in Hepatitis C Virus Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin in the TOPAZ-I and TOPAZ-II Trials
 

Poordad F1, Castro RE2, Asatryan A3, Aguilar H4, Cacoub P5,6, Dieterich D7, Marinho RT8, Carvalho A9, Siddique A10, Hu YB11, Charafeddine M12, Bondin M11, Khan N11, Cohen DE11, Felizarta F13. J Viral Hepat. 2020 Jan 18. doi: 10.1111/jvh.13261. [Epub ahead of print]
 
214.The Growing Problem of Hepatitis C Virus Infection: The Case of West Virginia
 

Phillips M1, Abboud J, Abodunde B, Paul DP 3rd, Coustasse A. Health Care Manag (Frederick). 2020 Jan/Mar;39(1):2-11. doi: 10.1097/HCM.0000000000000278.
 
215.Management of Hepatitis C in the Older Adult
 

Chahine EB, Guirguis EH, Derrick CB. Sr Care Pharm. 2020 Jan 1;35(1):13-28.
 
216.Control of HCV Infection by Natural Killer Cells and Macrophages
 

Rosen HR1,2, Golden-Mason L1,2. Cold Spring Harb Perspect Med. 2019 Dec 23. pii: a037101. doi: 10.1101/cshperspect.a037101. [Epub ahead of print]
 
217.Effects of Sofosbuvir-Based Hepatitis C Treatment Regimens on Calcineurin Inhibitor Dosing in Liver and Kidney Transplant Recipients
 

Laub M1, Harris M, Sanoff S, Berg C, Byrns J. Exp Clin Transplant. 2019 Dec 24. doi: 10.6002/ect.2019.0289. [Epub ahead of print]
 
218.A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment
 

Palmer AY1, Wade AJ2, Draper B3, Howell J4, Doyle JS5, Petrie D6, Thompson AJ7, Wilson DP8, Hellard ME9, Scott N3. nt J Drug Policy. 2019 Dec 20;76:102633. doi: 10.1016/j.drugpo.2019.102633. [Epub ahead of print]
 
219.Dynamic modeling of hepatitis C transmission among people who inject drugs
 

Stocks T1, Martin LJ2, Kühlmann-Berenzon S2, Britton T3. Epidemics. 2019 Dec 11;30:100378. doi: 10.1016/j.epidem.2019.100378. [Epub ahead of print]
 
220.Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population
 

Choi DT1, Puenpatom A2, Yu X1, Erickson KF1, Kanwal F3, El-Serag HB3, Kramer JR4. Antiviral Res. 2019 Dec 17;174:104698. doi: 10.1016/j.antiviral.2019.104698. [Epub ahead of print]
 
221.Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure
 

Chen Q1, Perales C1, Soria ME2, García-Cehic D1, Gregori J3, Rodríguez-Frías F4, Buti M1, Crespo J5, Calleja JL6, Tabernero D4, Vila M7, Lázaro F8, Rando-Segura A7, Nieto-Aponte L7, Llorens-Revull M1, Cortese MF7, Fernandez-Alonso I2, Castellote J9, Niubó J10, Imaz A11, Xiol X9, Castells L1, Riveiro-Barciela M1, Llaneras J1, Navarro J12, Vargas-Blasco V1, Augustin S1, Conde I13, Rubín Á13, Prieto M13, Torras X14, Margall N15, Forns X16, Mariño Z16, Lens S16, Bonacci M17, Pérez-Del-Pulgar S16, Londoño MC16, García-Buey ML18, Sanz-Cameno P18, Morillas R19, Martró E20, Saludes V20, Masnou-Ridaura H19, Salmerón J21, Quíles R21, Carrión JA22, Forné M23, Rosinach M23, Fernández I24, García-Samaniego J25, Madejón A25, Castillo-Grau P26, López-Núñez C27, Ferri MJ28, Durández R29, Sáez-Royuela F30, Diago M31, Gimeno C32, Medina R32, Buenestado J33, Bernet A34, Turnes J35, Trigo-Daporta M36, Hernández-Guerra M37, Delgado-Blanco M38, Cañizares A39, Arenas JI40, Gomez-Alonso MJ6, Rodríguez M41, Deig E42, Olivé G43, Río OD43, Cabezas J5, Quiñones I44, Roget M45, Montoliu S46, García-Costa J47, Force L48, Blanch S49, Miralbés M50, López-de-Goicoechea MJ51, García-Flores A52, Saumoy M11, Casanovas T9, Baliellas C9, Gilabert P9, Martin-Cardona A9, Roca R9, Barenys M53, Villaverde J9, Salord S9, Camps B9, Silvan di Yacovo M9, Ocaña I12, Sauleda S54, Bes M54, Carbonell J2, Vargas-Accarino E2, Ruzo SP2, Guerrero-Murillo M2, Von Massow G2, Costafreda MI55, López RM7, González-Moreno L18, Real Y18, Acero-Fernández D27, Viroles S27, Pamplona X27, Cairó M23, Ocete MD32, Macías-Sánchez JF43, Estébanez A5, Quer JC46, Mena-de-Cea Á38, Otero A38, Castro-Iglesias Á38, Suárez F38, Vázquez Á38, Vieito D38, López-Calvo S38, Vázquez-Rodríguez P38, Martínez-Cerezo FJ56, Rodríguez R47, Macenlle R47, Cachero A57, Mereish G57, Mora-Moruny C58, Fábregas S58, Sacristán B59, Albillos A60, Sánchez-Ruano JJ61, Baluja-Pino R62, Fernández-Fernández J62, González-Portela C62, García-Martin C63, Sánchez-Antolín G64, Andrade RJ65, Simón MA66, Pascasio JM67, Romero-Gómez M68, Antonio Del-Campo J68, Domingo E69, Esteban R1, Esteban JI70, Quer J71. Antiviral Res. 2019 Dec 16;174:104694. doi: 10.1016/j.antiviral.2019.104694. [Epub ahead of print]
 
222.Cost burden of hepatitis C virus treatment in commercially insured patients
 

Lu CY1, Ross-Degnan D, Zhang F, LeCates R, Lupton C, Sherman M, Wagner A. Am J Manag Care. 2019 Dec 1;25(12):e379-e387.
 
223.Expanding the use of hepatitis C positive donors and keeping recipient safety at the forefront
 

Terrault NA1, Sher L2. Am J Transplant. 2019 Dec 15. doi: 10.1111/ajt.15745. [Epub ahead of print]
 
224.Expanding Heart Transplant in the Era of Direct-Acting Antiviral Therapy for Hepatitis C
 

Schlendorf KH1, Zalawadiya S1, Shah AS1, Perri R1, Wigger M1, Brinkley DM1, Danter MR1, Menachem JN1, Punnoose LR1, Balsara K1, Sacks SB1, Ooi H1, Awad JA1, Sandhaus E1, Schwartz C1, O'Dell H1, Carver AB1, Edmonds CL1, Ruzevich-Scholl S1, Lindenfeld J1. JAMA Cardiol. 2019 Dec 18. doi: 10.1001/jamacardio.2019.4748. [Epub ahead of print]
 
225.Unreported alcohol use was common but did not impact hepatitis C cure in HIV-infected persons who use drugs
 

Irvin R1, Chander G1, Ward KM1, Manogue S1, Falade-Nwulia O1, Moon J1, Sutcliffe CG2, Brinkley S1, Haselhuhn T1, Katz S1, Herne K1, Arteaga L1, Thomas DL1, Mehta SH2, Sulkowski MS1. J Viral Hepat. 2019 Dec 18. doi: 10.1111/jvh.13251. [Epub ahead of print]
 
226."Take Charge, Get Cured": Pilot testing a targeted mHealth treatment decision support tool for methadone patients with hepatitis C virus for acceptability and promise of efficacy
 

Jessop AB1, Bass SB2, Brajuha J2, Alhajji M2, Burke M3, Gashat MT3, Wellington C2, Ventriglia N2, Coleman J2, D'Avanzo P2. J Subst Abuse Treat. 2020 Feb;109:23-33. doi: 10.1016/j.jsat.2019.11.001. Epub 2019 Nov 6.
 
227.Associations of Liver Disease with Alcohol Use among People Living with HIV and the Role of Hepatitis C: The New Orleans Alcohol Use in HIV Study
 

Ferguson TF1,2, Rosen E1,2, Carr R3, Brashear M1,4, Simon L1,5, Theall KP1,4, Ronis MJ1,6, Welsh DA1,7, Molina PE1,5. Alcohol Alcohol. 2019 Dec 8. pii: agz089. doi: 10.1093/alcalc/agz089. [Epub ahead of print]
 
228.HCV Eradication: A Duty of the State, an Option for the Individual
 

Craxì L1,2. Adv Exp Med Biol. 2019 Dec 6. doi: 10.1007/5584_2019_452. [Epub ahead of print]
 
229.Securing sustainable funding for viral hepatitis elimination plans
 

Hatzakis A1, Lazarus JV2, Cholongitas E3, Baptista-Leite R4,5, Boucher C6, Busoi CS7, Deuffic-Burban S8,9, Chhatwal J10, Esmat G11,12, Hutchinson S13,14, Malliori MM15, Maticic M16,17, Mozalevskis A18, Negro F19, Papandreou GA20, Papatheodoridis GV21, Peck-Radosavljevic M22, Razavi H23, Reic T24, Schatz E25, Tozun N26, Younossi Z27, Manns MP28. Liver Int. 2019 Dec 5. doi: 10.1111/liv.14282. [Epub ahead of print]
 
230.Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma
 

He S1, Lockart I2,3, Alavi M1, Danta M2,3, Hajarizadeh B1, Dore GJ1,3. Aliment Pharmacol Ther. 2020 Jan;51(1):34-52. doi: 10.1111/apt.15598. Epub 2019 Dec 6.
 
231.Hepatitis C drug prescriptions and Medicaid policies--four states, Indian health care system, USA 2018
 

Reilley B1, Miller M2, Hudson M3, Haverkate R2, Leston J4. Int J Equity Health. 2019 Dec 4;18(1):190. doi: 10.1186/s12939-019-1101-4.
 
232.HCV NAT positive solid organ allografts transplanted into HCV negative recipients: A real-world experience
 

Kapila N1,2, Menon KVN3, Al-Khalloufi K4, Vanatta JM4, Murgas C4, Reino D4, Ebaid S4, Shaw JJ4, Agrawal N4, Rhazouani S4, Navas V4, Sheffield C4, Rahman AU1, Castillo M5, Miller C3, Quintini C3, Zervos XB4. Hepatology. 2019 Oct 28. doi: 10.1002/hep.31011. [Epub ahead of print]
 
233.Hepatitis C Behind and Beyond Bars: Targeting the US Prison Population and Changing North Carolina Prisoner Health Policy
 

Ocal S1, Muir AJ2, Naggie S3. N C Med J. 2019 Nov-Dec;80(6):352-355. doi: 10.18043/ncm.80.6.352.
 
234.Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections
 

Dietz J1, Spengler U2, Müllhaupt B3, Schulze Zur Wiesch J4, Piecha F4, Mauss S5, Seegers B6, Hinrichsen H6, Antoni C7, Wietzke-Braun P8, Peiffer KH1, Berger A9, Matschenz K10, Buggisch P10, Backhus J11, Zizer E11, Boettler T12, Neumann-Haefelin C12, Semela D13, Stauber R14, Berg T15, Berg C16, Zeuzem S1, Vermehren J1, Sarrazin C17; European HCV Resistance Study Group. Clin Gastroenterol Hepatol. 2019 Nov 6. pii: S1542-3565(19)31260-1. doi: 10.1016/j.cgh.2019.10.051. [Epub ahead of print]
 
235.Rates of hepatitis B and C in patients with schizophrenia: A meta-analysis
 

Lluch E1, Miller BJ2. Gen Hosp Psychiatry. 2019 Nov - Dec;61:41-46. doi: 10.1016/j.genhosppsych.2019.10.007. Epub 2019 Oct 23.
 
236.The Elimination of Hepatitis C as a Public Health Threat
 

Hellard M1,2,3,4, Schroeder SE1,2, Pedrana A1,2, Doyle J1,3, Aitken C1,2. Cold Spring Harb Perspect Med. 2019 Nov 11. pii: a036939. doi: 10.1101/cshperspect.a036939. [Epub ahead of print]
 
237.Hepatitis C Virus Screening and Care: Complexity of Implementation in Primary Care Practices Serving Disadvantaged Populations
 

Turner BJ1, Rochat A2, Lill S2, Bobadilla R2, Hernandez L2, Choi A3, Guerrero JA4. Ann Intern Med. 2019 Dec 3. doi: 10.7326/M18-3573. [Epub ahead of print]
 
238.Hepatitis C Virus Infection In Indigenous Populations: A Systematic Review Of The United States And Canada
 

Bruce V1, Eldredge J2, Leyva Y3, Mera J4, English K5, Page K1. Epidemiol Rev. 2019 Nov 29. pii: mxz015. doi: 10.1093/epirev/mxz015. [Epub ahead of print]
 
239.Hepatitis C-Related Mortality Among American Indian/Alaska Native Persons in the Northwestern United States, 2006-2012
 

Hatcher SM1,2, Joshi S2, Robinson BF1, Weiser T2,3. Public Health Rep. 2020 Jan;135(1):66-73. doi: 10.1177/0033354919887748. Epub 2019 Nov 25.
 
240.Improved Hepatitis C Cure Cascade Outcomes Among Urban Baby Boomers in the Direct-Acting Antiviral Era
 

Dupont SC1, Fluker SA2, Quairoli KM3, Body C4, Okosun I5, Lom J2, Miller LS2. Public Health Rep. 2020 Jan;135(1):107-113. doi: 10.1177/0033354919888228. Epub 2019 Nov 22.
 
241.Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis
 

Boyle A1,2, Marra F1,2, Peters E3, Datta S4, Ritchie T5, Priest M6, Heydtmann M7, Barclay ST8,9. J Viral Hepat. 2019 Nov 22. doi: 10.1111/jvh.13239. [Epub ahead of print]
 
242.Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies
 

Darvishian M1,2,3,4, Wong S1, Binka M1, Yu A1, Ramji A2, Yoshida EM5, Wong J1,2, Rossi C1,2, Butt ZA1,2, Bartlett S1,2, Pearce ME1,2, Samji H1,6, Cook D1, Alvarez M1, Chong M1, Tyndall M1,2, Krajden M1,2, Janjua NZ1,2. J Viral Hepat. 2019 Oct 30. doi: 10.1111/jvh.13228. [Epub ahead of print]
 
243.Viral Hepatitis: Etiology, Epidemiology, Transmission, Diagnostics, Treatment, and Prevention
 

Lanini S1, Ustianowski A2, Pisapia R3, Zumla A4, Ippolito G3. Infect Dis Clin North Am. 2019 Dec;33(4):1045-1062. doi: 10.1016/j.idc.2019.08.004.
 
244.Correlates of hepatitis C viral clustering among people who inject drugs in Baltimore
 

Hackman J1, Falade-Nwulia O2, Patel EU3, Mehta SH2, Kirk GD4, Astemborski J2, Ray SC5, Thomas DL4, Laeyendecker O6. Infect Genet Evol. 2019 Oct 24;77:104078. doi: 10.1016/j.meegid.2019.104078. [Epub ahead of print]
 
245.Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis Ctreatment for people who inject drugs: The HERO study
 

Litwin AH1, Jost J2, Wagner K3, Heo M4, Karasz A5, Feinberg J6, Kim AY7, Lum PJ8, Mehta SH9, Taylor LE10, Tsui JI11, Pericot-Valverde I12, Page K3; HERO Study Group. Contemp Clin Trials. 2019 Dec;87:105859. doi: 10.1016/j.cct.2019.105859. Epub 2019 Oct 24.
 
246.A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments
 

Radley A1,2, Robinson E3, Aspinall EJ4, Angus K5, Tan L3, Dillon JF3. BMC Health Serv Res. 2019 Oct 28;19(1):765. doi: 10.1186/s12913-019-4635-7.
 
247.Provision of and Barriers to Integrating Reproductive and Sexual Health Services for Reproductive-age Women in Opioid Treatment Programs
 

Klaman SL1, Lorvick J, Jones HE. J Addict Med. 2019 Nov/Dec;13(6):422-429. doi: 10.1097/ADM.0000000000000519.
 
248.Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study
 

Bajis S1, Grebely J1, Hajarizadeh B1, Applegate T1, Marshall AD1,2, Harrod ME3, Byrne J4, Bath N3, Read P5, Edwards M6, Gorton C7, Hayllar J8, Cock V9, Peterson S10, Thomson C11, Weltman M12, Jefferies M13, Wood W14, Haber P15, Ezard N16,17, Martinello M1, Maher L1,18, Dore GJ1; LiveRLife Study Group. J Viral Hepat. 2019 Nov 7. doi: 10.1111/jvh.13233. [Epub ahead of print]
 
249.Sustained virological response rates with direct-acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trials
 

Struble K1, Chan-Tack K1, Qi K2, Valappil T2, Connelly S1, Mishra P1, Price D2, Murray J1, Birnkrant D1. J Virus Erad. 2019 Sep 18;5(3):138-144.
 
250.Nurse practitioner interventions for smokers with chronic hepatitis C
 

Reid C1, Fenech M2, Jones L3, Salehi N4. J Am Assoc Nurse Pract. 2019 Nov 5. doi: 10.1097/JXX.0000000000000311. [Epub ahead of print]
 
251.Cost-Effectiveness of One-Time Birth Cohort Screening for Hepatitis C as Part of the National Health Service Health Check Program in England
 

Williams J1, Miners A2, Harris R3, Mandal S4, Simmons R4, Ireland G4, Hickman M5, Gore C6, Vickerman P7. Value Health. 2019 Nov;22(11):1248-1256. doi: 10.1016/j.jval.2019.06.006. Epub 2019 Aug 19.
 
252.Liver and Kidney Recipient Selection of HCV-Viremic Donors - Meeting Consensus Report from the 2019 Controversies in Transplantation
 

Burton JR Jr, Terrault NA, Goldberg DS, Bloom RD, Gilroy R, Heimbach JK, Brown RS Jr, Everson GT, Rubin E, Wiesner R, Pomfret EA. Transplantation. 2019 Oct 18. doi: 10.1097/TP.0000000000003014. [Epub ahead of print]
 
253.Motivation to Quit Drinking in Individuals Coinfected with HIV and Hepatitis C
 

Hayaki J1, Anderson BJ2, Herman DS2,3, Moitra E3, Pinkston MM3,4, Kim HN5,6, Stein MD7. AIDS Behav. 2019 Oct 23. doi: 10.1007/s10461-019-02709-z. [Epub ahead of print]
 
254.Efficacy of Direct-Acting Antivirals for Chronic Hepatitis C in a Large Cohort of Older Adults in the United States
 

Pan CQ1,2, Gayam V3, Rabinovich C4, Normatov M4, Fidman B4, Wang D5, Garlapati P3. J Am Geriatr Soc. 2019 Oct 24. doi: 10.1111/jgs.16206. [Epub ahead of print]
 
255.HCV in the Hemodialysis Population: treat now or later?
 

Martin P1, Jadoul M2, Pol S3. J Viral Hepat. 2019 Oct 24. doi: 10.1111/jvh.13224. [Epub ahead of print]
 
256.Project ECHO Revisited: Propensity Score Analysis And HCV Treatment Outcomes
 

Page K1,2, Qeadan F1,2, Qualls C2, Thornton K1, Arora S1. Hepat Med. 2019 Oct 7;11:149-152. doi: 10.2147/HMER.S212855. eCollection 2019.
 
257.The Impact of Hepatitis C Virus Infection on Buprenorphine Dose in Pregnancy
 

McDowell ML1, Tonismae TR1, Slaven JE2, Abernathy MP1, Shanks AL1, Benjamin TD3, Quinney SK1. Am J Perinatol. 2019 Oct 26. doi: 10.1055/s-0039-1698838. [Epub ahead of print]
 
258.Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals
 

Serper M1, Evon DM2, Stewart PW3, Lok AS4, Amador J3, Reeve BB5, Golin CE6, Fried MW7, Reddy KR1, Sterling RK8, Sarkar S9, Di Bisceglie AM10, Lim JK11, Nelson DR12, Reau N13. J Gen Intern Med. 2019 Oct 28. doi: 10.1007/s11606-019-05394-9. [Epub ahead of print]
 
259.Adherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy
 

Cunningham EB1, Hajarizadeh B1, Amin J1,2, Litwin AH3,4,5, Gane E6, Cooper C7, Lacombe K8, Hellard M9,10, Read P1,11, Powis J12, Dalgard O13,14, Bruneau J15, Matthews GV1,16, Feld JJ17, Dillon JF18, Shaw D19, Bruggmann P20, Conway B21, Fraser C22, Marks P1, Dore GJ1,16, Grebely J1. Clin Infect Dis. 2019 Nov 2. pii: ciz1089. doi: 10.1093/cid/ciz1089. [Epub ahead of print]
 
260.Characteristics and current clinical practices of opioid treatment programs in the United States
 

Jones CM1, Byrd DJ2, Clarke TJ3, Campbell TB2, Ohuoha C4, McCance-Katz EF5. Drug Alcohol Depend. 2019 Oct 17;205:107616. doi: 10.1016/j.drugalcdep.2019.107616. [Epub ahead of print]
 
261.Glecaprevir/pibrentasvir for 8?weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial
 

Brown RS Jr1, Buti M2, Rodrigues L3, Chulanov V4, Chuang WL5, Aguilar H6, Horváth G7, Zuckerman E8, Carrion BR9, Rodriguez-Perez F10, Urbánek P11, Abergel A12, Cohen E3, Lovell SS3, Schnell G3, Lin CW3, Zha J3, Wang S3, Trinh R3, Mensa FJ3, Burroughs M3, Felizarta F13. J Hepatol. 2019 Nov 2. pii: S0168-8278(19)30647-6. doi: 10.1016/j.jhep.2019.10.020. [Epub ahead of print]
 
262.The role of stigma and trauma in hepatitis C virus treatment in veterans: Applying the common-sense model
 

Garvey CM1, Jones R1. Public Health Nurs. 2019 Nov;36(6):829-835. doi: 10.1111/phn.12665. Epub 2019 Oct 3.
 
263.Hepatitis C Virus in Children: Trying to Overcome the Domestic and Global Challenges of Cases and Cost
 

Perfect C1, Jhaveri R2,3. J Pediatric Infect Dis Soc. 2019 Oct 16. pii: piz069. doi: 10.1093/jpids/piz069. [Epub ahead of print]
 
264.A Simplified Algorithm for the Management of Hepatitis C Infection
 

Dieterich DT1. Gastroenterol Hepatol (N Y). 2019 May;15(5 Suppl 3):1-12.
 
265.Patients with Alcoholic Liver Disease Have Worse Functional Status at Time of Liver Transplant Registration and Greater Waitlist and Post-transplant Mortality Which Is Compounded by Older Age
 

McCabe P1, Galoosian A2, Wong RJ3. Dig Dis Sci. 2019 Oct 22. doi: 10.1007/s10620-019-05891-1. [Epub ahead of print]
 
266.Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI?=?1 in a Single-Arm, Open-Label, Multicenter Study.
 

Fontana RJ1, Lens S2, McPherson S3, Elkhashab M4, Ankoma-Sey V5, Bondin M6, Dos Santos AGP6, Xue Z6, Trinh R6, Porcalla A6, Zeuzem S7. Adv Ther. 2019 Oct 23. doi: 10.1007/s12325-019-01123-0. [Epub ahead of print]
 
267.Hepatitis C Screening: Barriers to Linkage to Care
 

Saab S1,2, Challita YP1, Najarian LM1, Guo R3, Saggi SS1, Choi G1,2. J Clin Transl Hepatol. 2019 Sep 28;7(3):226-231. doi: 10.14218/JCTH.2018.00063. Epub 2019 Apr 12.
 
268.Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment
 

Daniel KE1,2, Saeian K1, Rizvi S1. J Viral Hepat. 2019 Oct 10. doi: 10.1111/jvh.13218. [Epub ahead of print]
 
269.Electronic Clinical Decision Support Intervention to Increase Hepatitis C Screening and Linkage to Care Among Baby Boomers in Urban Safety Net Health Systems
 

Armstrong H1, Gonzalez-Drigo M1, Norels G1, Taussig D1, Trick W2, Diep L2, Zhang H2, Catrambone JC1, Adeyemi O1. Popul Health Manag. 2019 Oct 8. doi: 10.1089/pop.2019.0105. [Epub ahead of print]
 
270.Medical Burden of Disease Among Individuals in Recovery From Alcohol and Other Drug Problems in the United States: Findings From the National Recovery Survey
 

Eddie D1, Greene MC, White WL, Kelly JF. J Addict Med. 2019 Sep/Oct;13(5):385-395. doi: 10.1097/ADM.0000000000000512.
 
271.Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinoma
 

Singal AK1, Satapathy SK2, Reau N2, Wong R2, Kuo YF2. Dig Liver Dis. 2019 Sep 30. pii: S1590-8658(19)30785-6. doi: 10.1016/j.dld.2019.08.022. [Epub ahead of print]
 
272.Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol)
 

Hickman M1, Dillon JF2, Elliott L3, De Angelis D4, Vickerman P5, Foster G6,7, Donnan P8, Eriksen A9, Flowers P3, Goldberg D3,10, Hollingworth W5, Ijaz S11, Liddell D12, Mandal S11, Martin N13, Beer LJZ14, Drysdale K6,7, Fraser H5, Glass R11, Graham L15, Gunson RN16, Hamilton E17, Harris H11, Harris M18, Harris R11, Heinsbroek E11, Hope V19, Horwood J5, Inglis SK14, Innes H3,10, Lane A5, Meadows J5, McAuley A3,10, Metcalfe C5, Migchelsen S11, Murray A17, Myring G5, Palmateer NE3,10, Presanis A4, Radley A2,20, Ramsay M11, Samartsidis P4, Simmons R11, Sinka K11, Vojt G3, Ward Z5, Whiteley D21, Yeung A3,10, Hutchinson SJ3,10. BMJ Open. 2019 Sep 24;9(9):e029538. doi: 10.1136/bmjopen-2019-029538.
 
273.Prevalence of viremic HCV infection by age, race/ethnicity, birthplace and disease awareness among viremic persons in the U.S., 1999-2016
 

Zou B1, Yeo YH1, Le MH1, Henry L1, Chang ET2,3, Lok AS4, Cheung R1,5, Nguyen MH1. J Infect Dis. 2019 Sep 27. pii: jiz479. doi: 10.1093/infdis/jiz479. [Epub ahead of print]
 
274.Eradicating hepatitis C virus: The APRN
 

Pozza R1, McCoy-Hill C, Hall K, Hefner A, Wilgers K, Tapelband J, Masroor M, Hassanein T. Nurse Pract. 2019 Nov;44(11):16-27. doi: 10.1097/01.NPR.0000586008.23422.2c.
 
275.Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials
 

Brown A1, Welzel TM2, Conway B3, Negro F4, Bräu N5, Grebely J6, Puoti M7, Aghemo A8, Kleine H9, Pugatch D10, Mensa FJ10, Chen YJ10, Lei Y10, Lawitz E11, Asselah T12. Liver Int. 2019 Sep 30. doi: 10.1111/liv.14266. [Epub ahead of print]
 
276.Hepatitis C Virus Epidemiology and the Impact of Interferon-Free Hepatitis C Virus Therapy
 

Lazarus JV1, Roel E1,2, Elsharkawy AM3. Cold Spring Harb Perspect Med. 2019 Sep 30. pii: a036913. doi: 10.1101/cshperspect.a036913. [Epub ahead of print]
 
277.Challenges and Promise of a Hepatitis C Virus Vaccine
 

Cox AL1. Cold Spring Harb Perspect Med. 2019 Sep 23. pii: a036947. doi: 10.1101/cshperspect.a036947. [Epub ahead of print]
 
278."That Can't Be!": Perceptions of HIV and Hepatitis C Screening during Admission to an Acute Care Surgery Service
 

Privette AR1, Ferguson PL1, Olsen J1, Gay S1, Richey LE2. J Emerg Trauma Shock. 2019 Jul-Sep;12(3):185-191. doi: 10.4103/JETS.JETS_103_18.
 
279.Missed opportunities for prevention and treatment of hepatitis C among persons with HIV/HCV coinfection
 

Millman AJ1, Luo Q2, Nelson NP1, Vellozzi C1, Weiser J3. AIDS Care. 2019 Sep 23:1-9. doi: 10.1080/09540121.2019.1668533. [Epub ahead of print]
 
280.Glecaprevir/Pibrentasvir: The First 8-Week, Pangenotypic HCV Treatment Regimen for Patients 12 Years of Age and Older
 

Huff J1, Andersen R1. Ann Pharmacother. 2019 Sep 19:1060028019877128. doi: 10.1177/1060028019877128. [Epub ahead of print]
 
281.Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline
 

Gordon CE1, Berenguer MC2, Doss W3, Fabrizi F4, Izopet J5, Jha V6, Kamar N7, Kasiske BL8, Lai CL9, Morales JM10, Patel PR11, Pol S12, Silva MO13, Balk EM14, Earley A15, Di M16, Cheung M15, Jadoul M17, Martin P18. Ann Intern Med. 2019 Sep 24. doi: 10.7326/M19-1539. [Epub ahead of print]
 
282.The case for a universal hepatitis C vaccine to achieve hepatitis C elimination
 

Scott N1,2, Wilson DP3,4, Thompson AJ5,6, Barnes E7,8, El-Sayed M9, Benzaken AS10, Drummer HE3,11,12, Hellard ME3,4,12,13. BMC Med. 2019 Sep 18;17(1):175. doi: 10.1186/s12916-019-1411-9.
 
283.Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis
 

Graf C1, Mücke MM1, Dultz G1, Peiffer KH1, Kubesch A1, Ingiliz P2, Zeuzem S1, Herrmann E3, Vermehren J1. Clin Infect Dis. 2019 Sep 12. pii: ciz696. doi: 10.1093/cid/ciz696. [Epub ahead of print]
 
284.Hepatitis C Virus Infection in the Dallas County Jail: Implications for Screening, Prevention, and Linkage to Care
 

Abe CM1, Aguwa M2, Zhao M2, Sullivan J3, Porsa E3, Nijhawan AE4. Public Health Rep. 2019 Sep 17:33354919874081. doi: 10.1177/0033354919874081. [Epub ahead of print]
 
285.Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
 

Cotter TG1, Jensen DM2. Drug Des Devel Ther. 2019 Jul 29;13:2565-2577. doi: 10.2147/DDDT.S172512. eCollection 2019.
 
286.Hepatitis C Treatment Cascade in a Federally Qualified Health Center
 

Hachey DM1, Holmes JT2, Aubuchon-Endsley NL3. J Community Health. 2019 Sep 11. doi: 10.1007/s10900-019-00736-4. [Epub ahead of print]
 
287.Metabolic Changes in Chronic Hepatitis C Patients who Carry IFNL4-?G and Achieve Sustained Virologic Response with Direct-Acting Antiviral Therapy
 

Emmanuel B1, El-Kamary SS2, Magder LS2, Stafford KA1,2, Charurat ME3, Chairez C4, McLaughlin M4, Hadigan C4, Prokunina-Olsson L5, O'Brien TR5, Masur H6, Kottilil S1. J Infect Dis. 2019 Aug 26. pii: jiz435. doi: 10.1093/infdis/jiz435. [Epub ahead of print]
 
288.Defining the hepatitis C cure cascade in an Urban health system using the electronic health record
 

Miller LS1, Millman AJ2, Lom J1, Osinubi A2, Ahmed F3, Dupont S1, Rein D3, Vellozzi C2, Harris AM2. J Viral Hepat. 2019 Sep 10. doi: 10.1111/jvh.13199. [Epub ahead of print]
 
289.Defining the hepatitis C cure cascade in an Urban health system using the electronic health record
 

Miller LS1, Millman AJ2, Lom J1, Osinubi A2, Ahmed F3, Dupont S1, Rein D3, Vellozzi C2, Harris AM2. J Viral Hepat. 2019 Sep 10. doi: 10.1111/jvh.13199. [Epub ahead of print]

 
 
290.Hepatitis C Virus: 30 Years after Its Discovery
 

Houghton M1. Cold Spring Harb Perspect Med. 2019 Sep 9. pii: a037069. doi: 10.1101/cshperspect.a037069. [Epub ahead of print]
 
291.HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study
 

Cooper CL1,2,3, Galanakis C4, Donelle J5, Kwong J5,6,7, Boyd R8, Boucher L9, Kendall CE4,5,9,10,11. BMC Infect Dis. 2019 Aug 23;19(1):712. doi: 10.1186/s12879-019-4315-6.
 
292.Community Perceptions of Comprehensive Harm Reduction Programs and Stigma Towards People Who Inject Drugs in Rural Virginia
 

Baker LS1, Smith W2, Gulley T3, Tomann MM2. J Community Health. 2019 Sep 9. doi: 10.1007/s10900-019-00732-8. [Epub ahead of print]
 
293.Cascade of Care for Alaska Native People with Chronic Hepatitis C Virus Infection: Statewide Program with High Linkage to Care
 

McMahon BJ1,2, Townshend-Bulson L1, Homan C1, Gounder P2, Barbour Y1, Hewitt A1, Bruden D2, Espera H1, Plotnik J1, Gove J1, Stevenson TJ1, Luna SV1, Simons BC1,2. Clin Infect Dis. 2019 Aug 28. pii: ciz832. doi: 10.1093/cid/ciz832. [Epub ahead of print]
 
294.Hepatitis C Virus: 30 Years after Its Discovery
 

Houghton M1. Cold Spring Harb Perspect Med. 2019 Sep 9. pii: a037069. doi: 10.1101/cshperspect.a037069. [Epub ahead of print]
 
295.Hepatitis C Virus Structure: Defined by What It Is Not
 

Dearborn AD1,2, Marcotrigiano J1. Cold Spring Harb Perspect Med. 2019 Sep 9. pii: a036822. doi: 10.1101/cshperspect.a036822. [Epub ahead of print]
 
296.Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake among People Living with HIV
 

Saeed S1,2, Strumpf E1,3, Moodie EEM1, Wong L2, Cox J1,2, Walmsley S4,5, Tyndall M6, Cooper C5,7, Conway B8, Hull M5,9, Martel-Laferriere V10, Gill J11, Wong A12, Vachon ML13, Klein MB2,5; Canadian Co-Infection Cohort Study Investigators. Clin Infect Dis. 2019 Aug 28. pii: ciz833. doi: 10.1093/cid/ciz833. [Epub ahead of print]
 
297.Screening for Chronic Hepatitis C Virus: Occupational Health Nurses Interpreting the Titers
 

Cadet MJ1. Workplace Health Saf. 2019 Sep;67(9):495-496. doi: 10.1177/2165079919865560.
 
298.Impact of Direct Acting Antiviral Agent Therapy upon Extrahepatic Manifestations of Hepatitis C Virus Infection
 

Mohanty A1, Salameh S2, Butt AA3,4,5,6. Curr HIV/AIDS Rep. 2019 Sep 4. doi: 10.1007/s11904-019-00466-1. [Epub ahead of print]
 
299.Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C?
 

Ferrari SM1, Fallahi P2, Ruffilli I1, Elia G1, Ragusa F1, Paparo SR1, Patrizio A1, Mazzi V1, Colaci M3, Giuggioli D4, Ferri C4, Antonelli A1. J Immunol Res. 2019 Aug 8;2019:5878960. doi: 10.1155/2019/5878960. eCollection 2019.
 
300.Hepatitis C Core-Antigen Testing from Dried Blood Spots
 

Biondi MJ1,2,3, van Tilborg M4,5, Smookler D6,7, Heymann G8, Aquino A9, Perusini S10, Mandel E11,12, Kozak RA13, Cherepanov V14, Kowgier M15, Hansen B16,17, Goneau LW18, Janssen HLA19,20, Mazzulli T21,22, Cloherty G23, de Knegt RJ24, Feld JJ25,26,27. Viruses. 2019 Sep 6;11(9). pii: E830. doi: 10.3390/v11090830.
 
301.The Cost Effectiveness of Birth-Cohort Hepatitis C Screening During Pre-Admission Testing for Elective Procedures at a Single Specialty Orthopedic Hospital
 

Sibley RA, Pham V, Moynihan AM, Hutzler LH, Bosco JA. Bull Hosp Jt Dis (2013). 2019 Sep;77(3):206-210.
 
302.Technology preferences to enhance HIV and HCV care among patients with substance use disorders
 

Tofighi B1,2,3, Hein P1, Carvalho AMS4, Lee JD1,2,3, Leonard NR3,5. J Addict Dis. 2019 Aug 5:1-3. doi: 10.1080/10550887.2019.1640056. [Epub ahead of print]
 
303.Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study
 

Trickey A1,2, Fraser H1, Lim AG1, Walker JG1, Peacock A3, Colledge S3, Leung J3,4,5, Grebely J5,6, Larney S3, Martin NK1,7, Degenhardt L3, Hickman M1,2, May MT1,2,8, Vickerman P1,2. J Viral Hepat. 2019 Aug 7. doi: 10.1111/jvh.13187. [Epub ahead of print]
 
304.Promoting treatment for hepatitis C in people who inject drugs: A review of the barriers and opportunities
 

Pedlar A1, Sandhu PJ1. J Am Assoc Nurse Pract. 2019 Aug 14. doi: 10.1097/JXX.0000000000000269. [Epub ahead of print]
 
305.Late diagnosis of hepatitis C virus infection, 2014-2016: continuing missed intervention opportunities
 

Moorman AC1, Xing J, Rupp LB, Gordon SC, Lu M, Spradling PR, Boscarino JA, Schmidt MA, Daida YG, Teshale EH; CHeCS Investigators. Am J Manag Care. 2019 Aug;25(8):369-374.
 
306.Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study
 

Lee KK1, Stelzle D2, Bing R1, Anwar M1, Strachan F1, Bashir S1, Newby DE1, Shah JS3, Chung MH3, Bloomfield GS4, Longenecker CT5, Bagchi S6, Kottilil S6, Blach S7, Razavi H7, Mills PR8, Mills NL9, McAllister DA10, Shah ASV11. Lancet Gastroenterol Hepatol. 2019 Oct;4(10):794-804. doi: 10.1016/S2468-1253(19)30227-4. Epub 2019 Jul 31.
 
307.We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade
 

Lazarus JV1, Pericàs JM2, Picchio C1, Cernosa J3, Hoekstra M1, Luhmann N4, Maticic M5,6, Read P7, Robinson EM8, Dillon JF8. J Intern Med. 2019 Aug 31. doi: 10.1111/joim.12972. [Epub ahead of print]
 
308.Late diagnosis of hepatitis C virus infection, 2014-2016: continuing missed intervention opportunities
 

Moorman AC1, Xing J, Rupp LB, Gordon SC, Lu M, Spradling PR, Boscarino JA, Schmidt MA, Daida YG, Teshale EH; CHeCS Investigators. Am J Manag Care. 2019 Aug;25(8):369-374.
 
309.No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis
 

Rutledge SM1,2, Zheng H2, Li DK1,2, Chung RT1,2. Hepatoma Res. 2019;5. pii: 31. doi: 10.20517/2394-5079.2019.19. Epub 2019 Aug 7.
 
310.Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis
 

Kwo PY1, Puenpatom A2, Zhang Z3, Hui SL4, Kelley AA5, Muschi D6. PLoS One. 2019 Aug 22;14(8):e0218759. doi: 10.1371/journal.pone.0218759. eCollection 2019.
 
311.Relationships among neurotransmitters, cytokines and cognitive performance for individuals with hepatitis C achieving sustained virologic response: A pilot study
 

Weinstein AA1, Estep JM2, de Avila L2, Curry M3, Golabi P2, Escheik C2, Birerdinc A2, Stepanova M4, Price JK2, Gerber L5, Younossi ZM6. J Neuroimmunol. 2019 Oct 15;335:577022. doi: 10.1016/j.jneuroim.2019.577022. Epub 2019 Aug 14.
 
312.Decreased warfarin sensitivity among patients treated with elbasvir and grazoprevir for hepatitis C infection
 

DeCarolis DD1, Chen YC2, Westanmo AD3, Conley C4, Gravely AA5, Khan FB6. Am J Health Syst Pharm. 2019 Sep 1;76(17):1273-1280. doi: 10.1093/ajhp/zxz127.
 
313.Promoting treatment for hepatitis C in people who inject drugs: A review of the barriers and opportunities
 

Pedlar A1, Sandhu PJ1. J Am Assoc Nurse Pract. 2019 Aug 14. doi: 10.1097/JXX.0000000000000269. [Epub ahead of print]
 
314.Infectious complications of addiction: A call for a new subspecialty within infectious diseases
 

Serota DP1, Barocas JA2,3, Springer SA4. Clin Infect Dis. 2019 Aug 17. pii: ciz804. doi: 10.1093/cid/ciz804. [Epub ahead of print]
 
315.Late diagnosis of hepatitis C virus infection, 2014-2016: continuing missed intervention opportunities
 

Moorman AC1, Xing J, Rupp LB, Gordon SC, Lu M, Spradling PR, Boscarino JA, Schmidt MA, Daida YG, Teshale EH; CHeCS Investigators. Am J Manag Care. 2019 Aug;25(8):369-374.
 
316.Short-Term Outcomes and Lessons Learned From the Federal HIV Health Improvement Affinity Group for State Medicaid/Children
 

Davies C1, Klein PW2, Okoye ID3, Heitgerd J4, Shapatava E4, Ihiasota I4, Browne MNC5, Viall A6, Stockmann D5, Hauck H7. J Acquir Immune Defic Syndr. 2019 Sep 1;82 Suppl 1:S62-S68. doi: 10.1097/QAI.0000000000002021.
 
317.Cost-effectiveness of direct anti-viral agents for hepatitis C virus infection and a combined intervention of syringe access and medication assisted therapy for opioid use disorders in an injection drug use population
 

Stevens ER1,2, Nucifora KA1, Hagan H2,3, Jordan AE3,4, Uyei J1, Khan B5, Dombrowski K5, des Jarlais D2, Braithwaite RS1,3. Clin Infect Dis. 2019 Aug 11. pii: ciz726. doi: 10.1093/cid/ciz726. [Epub ahead of print]
 
318.Estimated Impact of Hepatitis C Positive Lung Donor Utilization on US Donor Lung Supply
 

Mooney JJ1, Purington N2, Mohabir P1, Dhillon GS1. Am J Transplant. 2019 Aug 8. doi: 10.1111/ajt.15558. [Epub ahead of print]
 
319.Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct-Acting Antivirals
 

Ioannou GN1,2, Green PK2, Berry K2, Graf SA3,4. Hepatol Commun. 2019 Jun 11;3(8):1124-1136. doi: 10.1002/hep4.1389. eCollection 2019 Aug.
 
320.Efficacy of Glecaprevir and Pibrentasvir in Patients with Genotype 1 Hepatitis C Virus Infection with Treatment Failure after NS5A Inhibitor Plus Sofosbuvir Therapy
 

Lok AS1, Sulkowski MS2, Kort JJ3, Willner I4, Reddy KR5, Shiffman ML6, Hassan MA7, Pearlman BL8, Hinestrosa F9, Jacobson IM10, Morelli G11, Peter JA12, Vainorius M13, Michael LC14, Fried MW15, Wang GP16, Lu W17, Larsen L18, Nelson DR19. Gastroenterology. 2019 Aug 8. pii: S0016-5085(19)41199-2. doi: 10.1053/j.gastro.2019.08.008. [Epub ahead of print]
 
321.Direct-Acting Antiviral Treatment of Patients with Hepatitis C Resolves Serologic and Histopathologic Features of Autoimmune Hepatitis
 

Simoes CC1, Saldarriaga OA1, Utay NS2, Stueck AE3, Merwat SK4, Merwat SN4, Schiano TD5, Fiel MI6, Stevenson HL1. Hepatol Commun. 2019 Jun 8;3(8):1113-1123. doi: 10.1002/hep4.1388. eCollection 2019 Aug.
 
322.What Matters Most for Treatment Decisions in Hepatitis C: Effectiveness, Costs, and Altruism
 

Mattingly TJ 2nd1, Slejko JF2, Perfetto EM2,3, Kottilil S4, Mullins CD2. Patient. 2019 Jul 26. doi: 10.1007/s40271-019-00378-7. [Epub ahead of print]
 
323.Advancing Public Health in Indian Country for Over 20 Years:S97-S100. doi: 10.1097/PHH.0000000000001061
 

An Evaluation of Hepatitis C Virus Telehealth Services Serving Tribal Communities: Patterns of Usage, Evolving Needs, and Barriers.

Stephens D1, Leston J, Terrault NA, Gailloux K, Mera J, Essex W, Reilley B. J Public Health Manag Pract. 2019 Sep/Oct;25 Suppl 5, Tribal Epidemiology Centers:
 
324.Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all
 

Grebely J1, Hajarizadeh B2, Lazarus JV3, Bruneau J4, Treloar C5; International Network on Hepatitis in Substance Users. Int J Drug Policy. 2019 Jul 23. pii: S0955-3959(19)30194-X. doi: 10.1016/j.drugpo.2019.07.016. [Epub ahead of print]
 
325.Point-of-care Hepatitis C virus testing and linkage to treatment in an Australian inner-city emergency department
 

Hutton J1, Doyle J2, Zordan R3, Weiland T3, Cocco A4, Howell J5, Iser S6, Snell J7, Fry S8, New K8, Sloane R8, Jarman M7, Phan D7, Tran S7, Pedrana A9, Williams B9, Johnson J10, Glasgow S8, Thompson A7. Int J Drug Policy. 2019 Jul 24. pii: S0955-3959(19)30176-8. doi: 10.1016/j.drugpo.2019.06.021. [Epub ahead of print]
 
326.The Consensus Hepatitis C Cascade of Care: standardized reporting to monitor progress toward elimination
 

Safreed-Harmon K1, Blach S2, Aleman S3,4, Boe Kielland K5, Bollerup S6, Cooke G7, Dalgard O8,9, Dillon JF10, Dore GJ11, Duberg AS12, Grebely J11, Midgard H13, Porter K14, Razavi H2, Tyndall M15, Weis N6,16, Lazarus JV1,17. Clin Infect Dis. 2019 Jul 28. pii: ciz714. doi: 10.1093/cid/ciz714. [Epub ahead of print]
 
327.Efficacy of direct-acting antivirals: UK real-world data from a well-characterised predominantly cirrhotic HCV cohort
 

Macken L1,2, Gelson W3, Priest M4, Abouda G5, Barclay S4,6, Fraser A7, Healy B8, Irving W9, Verma S1,2. J Med Virol. 2019 Jul 22. doi: 10.1002/jmv.25552. [Epub ahead of print]
 
328.Patterns and Correlates of Prescription Opioid Receipt Among US Veterans: A National, 18-Year Observational Cohort Study
 

Rentsch CT1,2, Edelman EJ3,4, Justice AC5,3,4, Marshall BDL6, Xu K7, Smith AH7, Crystal S8, Gaither JR9,10, Gordon AJ11, Smith RV12, Kember RL13,14, Polimanti R7, Gelernter J7,15, Fiellin DA3,4, Tate JP5,3, Kranzler HR14,16, Becker WC3,10; VACS Project Team. AIDS Behav. 2019 Jul 17. doi: 10.1007/s10461-019-02608-3. [Epub ahead of print]
 
329.Maternal hepatitis B or C status and the long-term risk of gastrointestinal morbidity for offspring: A population-based cohort study
 

Yoles I1,2, Sheiner E2, Abu-Freha N3, Wainstock T4. Liver Int. 2019 Jul 18. doi: 10.1111/liv.14193. [Epub ahead of print]
 
330.Evidence-making hepatitis C cure: Towards a science that knows more carefully
 

Rhodes T1, Lancaster K2. Int J Drug Policy. 2019 Jul 12. pii: S0955-3959(19)30178-1. doi: 10.1016/j.drugpo.2019.06.023. [Epub ahead of print]
 
331.Sociodemographic and clinical characteristics of persons who experienced spontaneous hepatitis C viral clearance
 

Kimble MM1, Javanbakht M2, Chew KW1, Stafylis C3, He D2, Ramirez S4, Baik Y2, Saab S4, Klausner JD1,2. BMC Infect Dis. 2019 Jul 15;19(1):626. doi: 10.1186/s12879-019-4223-9.
 
332.Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs
 

Barbosa C1, Fraser H2, Hoerger TJ1, Leib A3, Havens JR4, Young A4, Kral A1, Page K5, Evans J6, Zibbell J1, Hariri S7, Vellozzi C8, Nerlander L7, Ward JW7, Vickerman P2. Addiction. 2019 Jul 15. doi: 10.1111/add.14731. [Epub ahead of print]
 
333.Interprofessional team-based approach to patients with chronic hepatitis C and personality disorder: Three case studies
 

Gardenier D1, Woody A2, Amory C3, Weiss JJ4. Arch Psychiatr Nurs. 2019 Aug;33(4):352-357. doi: 10.1016/j.apnu.2019.02.001. Epub 2019 Feb 11.
 
334.Hepatitis C Screening in Mothers and Infants Exposed to Opioids
 

Bell R1, Wolfe I2, Cox D3, Thakarar K3, Lucas L3, Craig A3. Hosp Pediatr. 2019 Aug;9(8):639-642. doi: 10.1542/hpeds.2018-0225. Epub 2019 Jul 10.
 
335.Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes
 

Herr MM1, Schonfeld SJ1, Dores GM1,2, Engels EA3, Tucker MA4, Curtis RE1, Morton LM1. Blood Adv. 2019 Jul 9;3(13):1961-1969. doi: 10.1182/bloodadvances.2019030924.
 
336.The remarkable history of the hepatitis C virus
 

Pol S1, Lagaye S2. Microbes Infect. 2019 Jul 8. pii: S1286-4579(19)30068-1. doi: 10.1016/j.micinf.2019.06.008. [Epub ahead of print]
 
337.The Role of Zinc in Antiviral Immunity
 

Read SA1,2, Obeid S3, Ahlenstiel C3, Ahlenstiel G1,2. Adv Nutr. 2019 Jul 1;10(4):696-710. doi: 10.1093/advances/nmz013.
 
338.Efficacy and safety of interferon-free regimens in patients affected by chronic hepatitis C and psychiatric disorders
 

Boglione L1, Lupia T2, Cariti G2, Di Perri G2. J Infect Chemother. 2019 Jul 10. pii: S1341-321X(19)30173-4. doi: 10.1016/j.jiac.2019.06.004. [Epub ahead of print]
 
339.Early improvement of glycaemic control after virus clearance in patients with chronic hepatitis C and severe liver fibrosis: a cohort study
 

Lanini S1, Bartolini B1, Taibi C1, Agresta A1, Garbuglia AR1, Montaldo C1, Pisapia R1, D'Offizi G1, Scognamiglio P1, Capobianchi MR1, Zumla A2, Ippolito G1. New Microbiol. 2019 Jul 15;42(2). [Epub ahead of print]
 
340.Exploring the emotions of patients undergoing therapy for hepatitis C
 

Montague S1, Agarwal K2, Cannon M3. Br J Nurs. 2019 Jul 11;28(13):824-828. doi: 10.12968/bjon.2019.28.13.824.
 
341.HCV compliance and treatment success rates are higher with DAAs in structured HCV clinics compared to general hepatology clinics
 

Chehl N1, Maheshwari A, Yoo H, Cook C, Zhang T, Brown S, Thuluvath PJ. Medicine (Baltimore). 2019 Jul;98(28):e16242. doi: 10.1097/MD.0000000000016242.
 
342.HCV treatment access among Latinxs who inject drugs: qualitative findings from Boston, Massachusetts, 2016
 

Mittal A1, Kosinski KC2, Stopka TJ3. Harm Reduct J. 2019 Jul 9;16(1):44. doi: 10.1186/s12954-019-0314-6.
 
343.Evaluating peer-supported screening as a hepatitis C case-finding model in prisoners
 

Crowley D1,2, Murtagh R3, Cullen W3, Keevans M4, Laird E5, McHugh T6, McKiernan S7, Miggin SJ7, O'Connor E3,6, O'Reilly D4, Betts-Symonds G8, Tobin C9, Van Hout MC10, Lambert JS3,6. Harm Reduct J. 2019 Jul 5;16(1):42. doi: 10.1186/s12954-019-0313-7.
 
344.HCV screening, linkage to care, and treatment patterns at different sites across one academic medical center
 

Calner P1, Sperring H2, Ruiz-Mercado G3, Miller NS4, Andry C4, Battisti L5, Scrudder K3, Shea F3, Chan A3, Schechter-Perkins EM1. PLoS One. 2019 Jul 10;14(7):e0218388. doi: 10.1371/journal.pone.0218388. eCollection 2019.
 
345.A Decade On: Systematic Review of ClinicalTrials.gov Infectious Disease Trials, 2007-2017
 

Jaffe IS1, Chiswell K2, Tsalik EL1. Open Forum Infect Dis. 2019 Apr 15;6(6):ofz189. doi: 10.1093/ofid/ofz189. eCollection 2019 Jun.
 
346.Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic Hepatitis C in the United States
 

Gordon S1, Lee J2, Smith N3, Dieterich D4. Expert Rev Pharmacoecon Outcomes Res. 2019 Jun 17:1-7. doi: 10.1080/14737167.2019.1629291. [Epub ahead of print]
 
347.Evaluating peer-supported screening as a hepatitis C case-finding model in prisoners
 

Crowley D1,2, Murtagh R3, Cullen W3, Keevans M4, Laird E5, McHugh T6, McKiernan S7, Miggin SJ7, O'Connor E3,6, O'Reilly D4, Betts-Symonds G8, Tobin C9, Van Hout MC10, Lambert JS3,6. Harm Reduct J. 2019 Jul 5;16(1):42. doi: 10.1186/s12954-019-0313-7.
 
348.Risk-Based Prenatal Hepatitis C Testing Practices and Results, Alaska 2013-2016
 

Nolen LD1, Gustin C2, Seeman S1, Murphy N2, Truitt S2, Schillie S3, Bruce MG1, Bruden D1, Tiesinga J4, McMahon B4. Can J Gastroenterol Hepatol. 2019 Jun 2;2019:8654741. doi: 10.1155/2019/8654741. eCollection 2019.
 
349.Overdose Deaths and Acute Hepatitis Infections among American Indians in North Carolina
 

Cox ME1, Dzialowy N2, Armstrong L3, Proescholdbell S4. N C Med J. 2019 Jul-Aug;80(4):197-203. doi: 10.18043/ncm.80.4.197.
 
350.The Massachusetts Hepatitis C Testing Cascade, 2014-2016
 

Vo QT1, Onofrey S1, Church D1, Cranston K1, DeMaria A1, Klevens RM1. Microbiol Insights. 2019 Jun 21;12:1178636119857961. doi: 10.1177/1178636119857961. eCollection 2019.
 
351.Observed Changes in Natural Killer and T cell Phenotypes with Evaluation of Immune Outcome in a Longitudinal Cohort Following Sofosbuvir-Based Therapy for Chronic Hepatitis C Infection
 

Stevenson TJ1, Barbour Y1, McMahon BJ1, Townshend-Bulson L1, Hewitt AM1, Espera HGF1, Homan C1, Holck P1, Luna SV1, Knall C2, Simons BC1,2. Open Forum Infect Dis. 2019 May 17;6(6):ofz223. doi: 10.1093/ofid/ofz223. eCollection 2019 Jun.
 
352.Making sense of 'side effects': Counterpublic health in the era of direct-acting antivirals
 

Bryant J1, Rance J2, Hull P3, Mao L4, Treloar C5. Int J Drug Policy. 2019 Jun 17. pii: S0955-3959(19)30157-4. doi: 10.1016/j.drugpo.2019.06.002. [Epub ahead of print]
 
353.Treatment Adherence and Support for People who Inject Drugs Taking Direct Acting Antiviral Therapy for Hepatitis C Infection
 

Read P1,2, Gilliver R1, Kearley J1, Lothian R1, Cunningham EB2, Chronister KJ1, Dore GJ2. J Viral Hepat. 2019 Jul 12. doi: 10.1111/jvh.13175. [Epub ahead of print]
 
354.Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C
 

Schwarz KB1, Rosenthal P2, Murray KF3, Honegger JR4, Hardikar W5, Hague R6, Mittal N7, Massetto B8, Brainard DM8, Hsueh CH8, Shao J8, Parhy B8, Narkewicz MR9, Rao GS10, Whitworth S11, Bansal S12, Balistreri WF13. Hepatology. 2019 Jun 20. doi: 10.1002/hep.30830. [Epub ahead of print]
 
355.A Success Story: Advances in Treatment and Lower Disease Prevalence of Hepatitis C has a Large Impact on Medical Plan Costs
 

Leung N1, Bernacki SE, Bernacki EJ. J Occup Environ Med. 2019 Jun 13. doi: 10.1097/JOM.0000000000001633. [Epub ahead of print]
 
356.Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid
 

Roebuck MC1, Liberman JN. Am J Manag Care. 2019 Jun;25(8 Suppl):S131-S139.
 
357.Effectiveness and Safety of Sofosbuvir/Velpatasvir/ Voxilaprevir in Patients with Chronic Hepatitis C Previously Treated with DAAs
 

Llaneras J1, Riveiro-Barciela M2, Lens S3, Diago M4, Cachero A5, García-Samaniego J6, Conde I7, Arencibia A8, Arenas J9, Gea F10, Torras X11, Luis Calleja J12, Antonio Carrión J13, Fernández I14, María Morillas R15, Miguel Rosales J16, Carmona I17, Fernández-Rodríguez C18, Hernández-Guerra M19, Llerena S20, Bernal V21, Turnes J22, González-Santiago JM23, Montoliu S24, Figueruela B25, Badia E26, Delgado M27, Fernández-Bermejo M28, Iñarrairaegui M29, Manuel Pascasio J30, Esteban R2, Mariño Z3, Buti M31. J Hepatol. 2019 Jun 13. pii: S0168-8278(19)30345-9. doi: 10.1016/j.jhep.2019.06.002. [Epub ahead of print]
 
358.Influence of social determinants of health and substance use characteristics on persons who use drugs pursuit of care for hepatitis C virus infection
 

Williams N1, Bossert N1, Chen Y2, Jaanimägi U1, Markatou M3, Talal AH4. J Subst Abuse Treat. 2019 Jul;102:33-39. doi: 10.1016/j.jsat.2019.04.009. Epub 2019 May 2.
 
359.Clinical evaluation of a hepatitis C antibody rapid immunoassay on self-collected oral fluid specimens
 

Kimble MM1, Stafylis C2, Treut P1, Saab S3, Klausner JD4. Diagn Microbiol Infect Dis. 2019 May 25. pii: S0732-8893(19)30117-8. doi: 10.1016/j.diagmicrobio.2019.05.010. [Epub ahead of print]
 
360.Hepatitis C Competency and Outreach of Occupational Health Nurses
 

Surjadi M1, Nuchols B2, Souza D, Wolfe L3, Burgel B1. Workplace Health Saf. 2019 Jun 10:2165079919841637. doi: 10.1177/2165079919841637. [Epub ahead of print]
 
361.Heart Transplantation for Hepatitis C Virus Non-Viremic Recipients From Hepatitis C Virus Viremic Donors
 

Frager SZ1, Dhand A2, Gass A3, Levine A3, Spielvogel D4, Nog R2, Wolf DC5, Bodin RI5. Cardiol Rev. 2019 Jul/Aug;27(4):179-181. doi: 10.1097/CRD.0000000000000255.
 
362.Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
 

McGlynn EA1, Adams JL2, Kramer J2, Sahota AK3, Silverberg MJ4, Shenkman E5, Nelson DR6. JAMA Netw Open. 2019 Jun 5;2(6):e194765. doi: 10.1001/jamanetworkopen.2019.4765.
 
363.A Pilot Study of Safety and Efficacy of HCV Retreatment with sofosbuvir/velpatasvir/voxilaprevir in Patients With or Without HIV (RESOLVE STUDY)
 

Wilson E1, Covert E2, Hoffmann J1, Comstock E1, Emmanuel B1, Tang L1, Husson J1, Chua J1, Price A1, Mathur P1, Rosenthal E1, Kattakuzhy S1, Masur H3, Kottilil S1. J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30307-1. doi: 10.1016/j.jhep.2019.05.021. [Epub ahead of print]
 
364.Willingness to participate in hepatitis C vaccine trials among socially marginalized people who use drugs
 

Yakovenko I1, Hyshka E1, Tyrrell L2, Wild TC3. J Subst Abuse Treat. 2019 Jun;101:67-71. doi: 10.1016/j.jsat.2019.03.010. Epub 2019 Mar 27.
 
365.Gaps in HCV Knowledge and Risk Behaviors among Young Suburban People Who Inject Drugs
 

Jost JJ1, Tempalski B2, Vera T3, Akiyama MJ4, Mangalonzo AP5, Litwin AH6,7. Int J Environ Res Public Health. 2019 Jun 2;16(11). pii: E1958. doi: 10.3390/ijerph16111958.
 
366.Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL Study
 

Persico M1, Aglitti A1, Milella M2, Coppola C3, Messina V4, Claar E5, Gentile I6, Sogari F7, Pierri P8, Surace LA9, Morisco F10, Tundo P11, Brancaccio G12, Serviddio G13, Gatti P14, Termite AP15, Di Costanzo GG16, Caroleo B17, Cozzolongo R18, Coppola N19, Longo A20, Fontanella L21, Federico A22, Rosato V1,5, Terrenato I23, Masarone M1. Liver Int. 2019 Jun 7. doi: 10.1111/liv.14170. [Epub ahead of print]
 
367.The opioid epidemic in rural northern New England: An approach to epidemiologic, policy, and legal surveillance
 

Stopka TJ1, Jacque E2, Kelso P3, Guhn-Knight H4, Nolte K5, Hoskinson R Jr4, Jones A3, Harding J6, Drew A7, VanDonsel A3, Friedmann PD4. Prev Med. 2019 May 31:105740. doi: 10.1016/j.ypmed.2019.05.028. [Epub ahead of print]
 
368.Randomized feasibility trial of directly observed versus unobserved hepatitis C treatment with ledipasvir-sofosbuvir among people who inject drugs
 

Coffin PO1,2, Santos GM1,2, Behar E1, Hern J1, Walker J1, Matheson T1, Kinnard EN1,3, Silvis J1, Vittinghoff E2, Fox R2, Page K2. PLoS One. 2019 Jun 3;14(6):e0217471. doi: 10.1371/journal.pone.0217471. eCollection 2019.
 
369.Increasing Prevalence of Chronic Hepatitis C Virus Infection in a Southern Academic Obstetrical Clinic
 

Lazenby GB1, Orr C1, Guille C1, Meissner EG1. South Med J. 2019 Jun;112(6):325-330. doi: 10.14423/SMJ.0000000000000988.
 
370.Scaling-up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States - a Rural and Urban Comparison
 

Fraser H1, Vellozzi C2, Hoerger TJ3, Evans JL4, Kral AH3, Havens J5, Young AM5,6, Stone J1, Handanagic S7, Hariri S8, Barbosa C3, Hickman M1, Leib A9, Martin NK1,10, Nerlander L7, Raymond HF11, Page K12, Zibbell J3, Ward JW8,13, Vickerman P1. Am J Epidemiol. 2019 May 31. pii: kwz097. doi: 10.1093/aje/kwz097. [Epub ahead of print]
 
371.Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study
 

Williams B1, Howell J2, Doyle J3, Thompson AJ4, Draper B5, Layton C6, Latham N7, Bramwell F6, Membrey D6, Mcpherson M8, Roney J9, Stoové M5, Hellard ME10, Pedrana A11. Int J Drug Policy. 2019 May 22. pii: S0955-3959(19)30134-3. doi: 10.1016/j.drugpo.2019.05.012. [Epub ahead of print]
 
372.Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs
 

Latham NH1,2, Doyle JS1,3, Palmer AY1, Vanhommerig JW1, Agius P1,4, Goutzamanis S1,4, Li Z1, Pedrana A1,5, Gottfredsson M6,7,8, Bouscaillou J9, Luhmann N9, Mazhnaya A10,11, Altice FL12,13, Saeed S14, Klein M15, Falade-Nwulia OO16, Aspinall E17,18, Hutchinson S17,18, Hellard ME1,3,5,19, Sacks-Davis R1,4,20. Liver Int. 2019 May 24. doi: 10.1111/liv.14152. [Epub ahead of print]
 
373.Community Screening, Identification, and Referral to Primary Care, for Hepatitis C, B, and HIV Among Homeless Persons in Los Angeles
 

Fuster D1, Gelberg L2,3. J Community Health. 2019 May 24. doi: 10.1007/s10900-019-00679-w. [Epub ahead of print]
 
374.Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project
 

Rojas Rojas T1, Di Beo V1, Delorme J2, Barre T1, Mathurin P3, Protopopescu C1, Bailly F4, Coste M1, Authier N2, Carrieri MP5, Rolland B6, Marcellin F1. Int J Drug Policy. 2019 May 22. pii: S0955-3959(19)30135-5. doi: 10.1016/j.drugpo.2019.05.013. [Epub ahead of print]
 
375.The Swiss Hepatitis Strategy as a model for facing future health policy challenges
 

Blindenbacher R1, Maeschli B2, Bruggmann P3. Health Policy. 2019 May 16. pii: S0168-8510(18)30417-2. doi: 10.1016/j.healthpol.2019.05.010. [Epub ahead of print]
 
376.Cost-effectiveness of HCV Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs
 

Gutkind S1, Schackman BR1, Morgan JR2, Leff JA1, Agyemang L3, Murphy SM1, Akiyama MJ3, Norton BL3, Litwin AH4,5, Linas BP2,6. Clin Infect Dis. 2019 May 16. pii: ciz384. doi: 10.1093/cid/ciz384. [Epub ahead of print]
 
377.Cost-effectiveness and budgetary impact of HCV testing, treatment and linkage to care in U.S. prisons
 

Assoumou SA1,2, Tasillo A1, Vellozzi C3, Yazdi GE1, Wang J1, Nolen S1, Hagan L4, Thompson W4, Randall LM5, Strick L6,7, Salomon JA8, Linas BP1,2,9.
 
378.Telementoring of primary care providers delivering hepatitis C treatment in New York City: Results from Project INSPIRE
 

Teixeira PA1, Bresnahan MP2, Laraque F2, Litwin AH3, Shukla SJ3, Schwartz JM3, Reynoso S3, Perumalswami PV4, Weiss JM4, Wyatt B4, Schackman BR1. Learn Health Syst. 2018 Jul;2(3). pii: e10056. doi: 10.1002/lrh2.10056. Epub 2018 May 10.
 
379.Efficacy and safety of direct-acting antiviral therapy for chronic hepatitis C genotype 6: A meta-analysis
 

Luo A1, Xu P, Wang J, Li Z, Wang S, Jiang X, Ren H, Luo Q. Medicine (Baltimore). 2019 May;98(20):e15626. doi: 10.1097/MD.0000000000015626.
 
380.Utilizing Electronic Laboratory Reporting Data to Assess the Burden of Hepatitis C in Arizona
 

Tsang CA1, Khan MA, Brady SM, Erhart LM, Komatsu KK. J Public Health Manag Pract. 2019 May 14. doi: 10.1097/PHH.0000000000001011. [Epub ahead of print]
 
381.Real-world Australian data reflect very high sustained virologic response at 12 weeks with direct acting antiviral therapy for hepatitis C and suggests highly achievable even in those without an end-of-treatment response
 

Williams J1, Lucarelli N2, Nicoll A1,2, Lubel J1,2. Intern Med J. 2019 May;49(5):666-669. doi: 10.1111/imj.14279.
 
382.Sleep disturbances in HIV-HCV coinfected patients: indications for clinical management in the HCV cure era (ANRS CO13 HEPAVIH cohort)
 

Costa M1,2, Rojas Rojas T1,2, Lacoste D3, Villes V1,2, Aumaitre H4, Protopopescu C1,2, Yaya I1,2, Wittkop L5,6, Krause J7, Salmon-Céron D8,9, Marcellin F1,2, Sogni P8,10,11, Carrieri MP1,2; ANRS CO13 HEPAVIH Study Group. Eur J Gastroenterol Hepatol. 2019 May 14. doi: 10.1097/MEG.0000000000001441. [Epub ahead of print]
 
383.The Global State of Harm Reduction in Prisons
 

Sander G1, Shirley-Beavan S1, Stone K1. J Correct Health Care. 2019 Apr;25(2):105-120. doi: 10.1177/1078345819837909.
 
384.Comprehensive nationwide chronic hepatitis C surveillance is necessary for accurate state-level prevalence estimates
 

Moore MS1, Greene SK2, Bocour A3, Brown CM4, Coyle JR5, Kuncio D6, Onofrey S7, Patel MT8, Winters A9. J Viral Hepat. 2019 May 13. doi: 10.1111/jvh.13124. [Epub ahead of print]
 
385.Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors
 

Sise ME1, Strohbehn IA2, Bethea E2, Gustafson JL2, Chung RT2. Curr Opin Organ Transplant. 2019 Jun;24(3):351-357. doi: 10.1097/MOT.0000000000000651.
 
386.Treatment of patients with HIV or hepatitis C by pharmacist clinicians in a patient-centered medical home
 

Ryan KL1, Jakeman B2, Conklin J3, Pineda LJ4, Deming P5, Mercier RC5. Am J Health Syst Pharm. 2019 May 4. pii: zxz059. doi: 10.1093/ajhp/zxz059. [Epub ahead of print]
 
387.Hepatitis C Update and Expanding the Role of Primary Care
 

Simoncini GM1, Koren DE2. J Am Board Fam Med. 2019 May-Jun;32(3):428-430. doi: 10.3122/jabfm.2019.03.180286.
 
388.Integration of Hepatitis C Treatment in a Primary care Federally Qualified Health Center; Philadelphia, Pennsylvania, 2015-2017
 

Bartholomew TS1,2, Grosgebauer K2, Huynh K3, Cos T3,4. Infect Dis (Auckl). 2019 Apr 28;12:1178633719841381. doi: 10.1177/1178633719841381. eCollection 2019.
 
389.Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection
 

Pearlman B1, Perrys M2, Hinds A3. Am J Gastroenterol. 2019 May 8. doi: 10.14309/ajg.0000000000000248. [Epub ahead of print]
 
390.Epidemiologic features of a large hepatitis C cohort evaluated in a major health system in the western United States
 

Mukhtar NA1, Ness EM1, Jhaveri M1, Fix OK1, Hart M1, Dale C1, Pratt C2, Kowdley KV3. Ann Hepatol. 2019 Mar - Apr;18(2):360-365. doi: 10.1016/j.aohep.2018.12.003. Epub 2019 Apr 17.
 
391.Role of HCV Viremia in Corroborated HCV Transmission Events Within Young Adult Injecting Partnerships
 

Hahn JA1, Tully DC2, Evans JL3, Morris MD3, Briceno A3, Bean DJ4, Allen TM4, Page K5. Open Forum Infect Dis. 2019 Apr 25;6(4):ofz125. doi: 10.1093/ofid/ofz125. eCollection 2019 Apr.
 
392.The Costs of Hepatitis C by Liver Disease Stage: Estimates from the Veterans Health Administration
 

Gidwani-Marszowski R1,2,3, Owens DK4,5, Lo J6, Goldhaber-Fiebert JD5, Asch SM4,7, Barnett PG6,4,5. Appl Health Econ Health Policy. 2019 Apr 27. doi: 10.1007/s40258-019-00468-5. [Epub ahead of print]
 
393.Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures
 

Pawlotsky JM1,2. Semin Liver Dis. 2019 Apr 30. doi: 10.1055/s-0039-1687823. [Epub ahead of print]
 
394.High versus low mean arterial pressures in hepatorenal syndrome: A randomized controlled pilot trial
 

Varajic B1, Cavallazzi R2, Mann J2, Furmanek S3, Guardiola J2, Saad M2. J Crit Care. 2019 Apr 15;52:186-192. doi: 10.1016/j.jcrc.2019.04.006. [Epub ahead of print]
 
395.Content Validity and Reliability of a Self-Report Measure of Medication Nonadherence in Hepatitis C Treatment
 

Voils CI1,2, King HA3,4,5, Thorpe CT6,7, Blalock DV3,8, Kronish IM9, Reeve BB4, Boatright C3, Gellad ZF3,10. Dig Dis Sci. 2019 Apr 29. doi: 10.1007/s10620-019-05621-7. [Epub ahead of print]
 
396.The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study
 

Trickey A1, Fraser H2, Lim AG2, Peacock A3, Colledge S3, Walker JG2, Leung J4, Grebely J5, Larney S3, Martin NK6, Hickman M7, Degenhardt L3, May MT8, Vickerman P7. Lancet Gastroenterol Hepatol. 2019 Apr 10. pii: S2468-1253(19)30085-8. doi: 10.1016/S2468-1253(19)30085-8. [Epub ahead of print]
 
397.Life projects: the transformative potential of direct-acting antiviral treatment for hepatitis C among people who inject drugs
 

E Williams B1, Nelons D2, Seaman A3, Witkowska M4, Ronan W5, Wheelock H5, Zaman A3, Garcia J2. Int J Drug Policy. 2019 Apr 15. pii: S0955-3959(19)30074-X. doi: 10.1016/j.drugpo.2019.03.015. [Epub ahead of print]
 
398.Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study
 

Bajis S1, Grebely J1, Cooper L2, Smith J2, Owen G2, Chudleigh A2, Hajarizadeh B1, Martinello M1, Adey S3, Read P4, Gilliver R4, Applegate T1, Treloar C5, Maher L1, Dore GJ1. J Viral Hepat. 2019 Apr 13. doi: 10.1111/jvh.13112. [Epub ahead of print]
 
399.Quantitative evaluation of an integrated nurse model of care providing hepatitis Ctreatment to people attending homeless services in Melbourne, Australia
 

Harney BL1, Whitton B2, Lim C3, Paige E2, McDonald B4, Nolan S5, Pemberton D5, Hellard ME6, Doyle JS6. Int J Drug Policy. 2019 Apr 10. pii: S0955-3959(19)30077-5. doi: 10.1016/j.drugpo.2019.02.012. [Epub ahead of print]
 
400.Liver Fibrosis Determination
 

Lai M1, Afdhal NH2. Gastroenterol Clin North Am. 2019 Jun;48(2):281-289. doi: 10.1016/j.gtc.2019.02.002. Epub 2019 Apr 1.
 
401.Direct-Acting Oral Anticoagulants (DOACs) in Cirrhosis and Cirrhosis-Associated Portal Vein Thrombosis
 

Weinberg EM1, Palecki J1, Reddy KR1. Semin Liver Dis. 2019 May;39(2):195-208. doi: 10.1055/s-0039-1679934. Epub 2019 Apr 12.
 
402.Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection and Psychiatric Disorders: An Integrated Analysis
 

Back D1, Belperio P2, Bondin M3, Negro F4, Talal AH5, Park C3, Zhang Z3, Pinsky B3, Crown E3, Mensa FJ3, Marra F1. J Viral Hepat. 2019 Apr 12. doi: 10.1111/jvh.13110. [Epub ahead of print]
 
403.Drug-Drug Interaction Studies of Methadone and Antiviral Drugs: Lessons Learned
 

Younis IR1,2, Lakota EA1,3, Volpe DA1, Patel V1, Xu Y1, Sahajwalla CG1. J Clin Pharmacol. 2019 Apr 11. doi: 10.1002/jcph.1405. [Epub ahead of print]
 
404.Hepatitis C Virus Treatment with Directly Acting Agents Reduces the Risk of Incident Diabetes - Results from ERCHIVES
 

Butt AA1,2,3, Yan P1, Aslam S1, Shaikh OS1, Abou-Samra AB2,3. Clin Infect Dis. 2019 Apr 12. pii: ciz304. doi: 10.1093/cid/ciz304. [Epub ahead of print]
 
405.Hepatitis C in pregnant American Indian and Alaska native women; 2003-2015
 

Nolen LD1, O'Malley JC2, Seeman SS1, Bruden DJT1, Apostolou A3,4, McMahon BJ5, Bruce MG1. Int J Circumpolar Health. 2019 Dec;78(1):1608139. doi: 10.1080/22423982.2019.1608139.
 
406.HIV and HCV screening among trauma patients
 

Simoncini GM1, Oyola-Jimenez J1, Singleton D1, Volgraf J2, Ramsey FV3, Goldberg A4. Int J STD AIDS. 2019 Apr 8:956462419829590. doi: 10.1177/0956462419829590. [Epub ahead of print]
 
407.Longitudinal assessment of the association between implementation strategy use and the uptake of hepatitis C treatment: Year 2
 

Rogal SS1,2,3, Yakovchenko V4, Waltz TJ5,6, Powell BJ7, Gonzalez R8, Park A9, Chartier M10, Ross D10, Morgan TR8, Kirchner JE11, Proctor EK12, Chinman MJ13,14. Implement Sci. 2019 Apr 8;14(1):36. doi: 10.1186/s13012-019-0881-7.
 
408.Health implications of sex trading characteristics in Long Beach, California, USA
 

Clingan SE1, Fisher DG2,3, Hardan-Khalil K4, Reynolds GL3,5, Huckabay L4, Costa C4, Pedersen WC2, Johnson ME6. Int J STD AIDS. 2019 Apr 8:956462419828138. doi: 10.1177/0956462419828138. [Epub ahead of print]
 
409.Outcomes of a nurse-led model of care for hepatitis C assessment and treatment with direct-acting antivirals in the custodial setting
 

Overton K1, Clegg J2, Pekin F2, Wood J2, McGrath C2, Lloyd A3, Post JJ4. Int J Drug Policy. 2019 Apr 6. pii: S0955-3959(19)30078-7. doi: 10.1016/j.drugpo.2019.02.013. [Epub ahead of print]
 
410.Hepatitis C treatment outcomes among homeless-experienced individuals at a community health centre in Boston
 

Beiser ME1, Smith K2, Ingemi M3, Mulligan E4, Baggett TP5. Int J Drug Policy. 2019 Apr 5. pii: S0955-3959(19)30079-9. doi: 10.1016/j.drugpo.2019.03.017. [Epub ahead of print]
 
411.Hepatitis C virus screening trends: A 2016 update of the National Health Interview Survey
 

Kasting ML1, Giuliano AR2, Reich RR3, Roetzheim RG4, Duong LM5, Thomas E6, Nelson DR7, Shenkman E8, Vadaparampil ST9. Cancer Epidemiol. 2019 Apr 3;60:112-120. doi: 10.1016/j.canep.2019.03.007. [Epub ahead of print]
 
412.Identifying Areas with Disproportionate Local Health Department Services Relative to Opioid Overdose, HIV and Hepatitis C Diagnosis Rates: A Study of Rural Illinois
 

McLuckie C1,2, Pho MT3,4, Ellis K5, Navon L6,7, Walblay K8, Jenkins WD9, Rodriguez C10, Kolak MA11, Chen YT12, Schneider JA13, Zahnd WE14,15. Int J Environ Res Public Health. 2019 Mar 19;16(6). pii: E989. doi: 10.3390/ijerph16060989.
 
413.Causes of death among persons diagnosed with hepatitis C infection in the pre and post DAA era in England: a record linkage study
 

Simmons R1,2, Ireland G1,2, Ijaz S3,2, Ramsay M1, Mandal S1,2; National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Blood Borne and Sexually Transmitted Infections. J Viral Hepat. 2019 Mar 21. doi: 10.1111/jvh.13096. [Epub ahead of print]
 
414.Quality of Life, Functioning, and Coping in HCV Patients Continuing Versus Ceasing Alcohol Use
 

Sims OT1,2, Oh H3, Pollio DE1, Hong BA4, Pollio EW1, North CS5,6. Health Promot Pract. 2019 Mar 21:1524839919837968. doi: 10.1177/1524839919837968. [Epub ahead of print]
 
415.Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection
 

Casey JL1, Feld JJ2,3, MacParland SA4,5. Cells. 2019 Apr 5;8(4). pii: E317. doi: 10.3390/cells8040317.
 
416.Treatment cascade for hepatitis C virus in young adult people who inject drugs in San Francisco: Low number treated
 

Morris MD1, Mirzazadeh A2, Evans JL3, Briceno A3, Coffin P4, Hahn JA5, Page KA6. Drug Alcohol Depend. 2019 Feb 27;198:133-135. doi: 10.1016/j.drugalcdep.2019.02.008. [Epub ahead of print]
 
417.Age-related Differences in Past or Present HCV Infection among People Who Inject Drugs - National HIV Behavioral Surveillance, Eight U.S Cities, 2015
 

Abara WE1, Trujillo L2, Broz D2, Finlayson T2, Teshale E1, Paz-Bailey G2, Glick S3, Al-Tayyib AA4, Robinson WT5, Masiello-Schuette S6, Sey EK7, Anderson BJ8, Poe J Infect Dis. 2019 Mar 27. pii: jiz142. doi: 10.1093/infdis/jiz142. [Epub ahead of print]

J9, Braunstein S10.
 
418.Preoperative Treatment of Hepatitis C Is Associated With Lower Prosthetic Joint Infection Rates in US Veterans
 

Bendich I1, Takemoto S2, Patterson JT1, Monto A3, Barber TC1, Kuo AC2. J Arthroplasty. 2019 Mar 9. pii: S0883-5403(19)30208-6. doi: 10.1016/j.arth.2019.02.052. [Epub ahead of print]
 
419.Effect of Health Insurance on Hepatitis C Sustained Virologic Response Rates to Sofosbuvir-Based Treatment Regimens in a South Florida Community Hospital
 

Eckardt P1, Niu J2, Savage A1, Griffin T1, Sherman E1,3. J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958219835590. doi: 10.1177/2325958219835590.
 
420.Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia
 

Doyle JS1,2, Scott N2,3, Sacks-Davis R2, Pedrana AE2,3, Thompson AJ4,5, Hellard ME1,2,3; Eliminate Hepatitis C Partnership. Aliment Pharmacol Ther. 2019 Mar 25. doi: 10.1111/apt.15210. [Epub ahead of print]

Collaborators (10)
 
421.Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy
 

Thabut D1, Bureau C2, Layese R3, Bourcier V4, Hammouche M4, Cagnot C5, Marcellin P6, Guyader D6, Pol S7, Larrey D8, De Lédinghen V9, Ouzan D10, Zoulim F11, Roulot D12, Tran A13, Bronowicki JP14, Zarski JP15, Goria O16, Calès P17, Péron JM18, Alric L19, Bourlière M20, Mathurin P21, Blanc JF22, Abergel A23, Serfaty L24, Mallat A3, Grangé JD25, Attali P26, Bacq Y27, Wartelle-Bladou C28, Dao T29, Pilette C30, Silvain C31, Christidis C32, Capron D33, Bernard-Chabert B34, Hillaire S35, Di Martino V36, Sutton A37, Audureau E3, Roudot-Thoraval F3, Nahon P4; ANRS CO12 CirVir group.

Collaborators (38) Gastroenterology. 2019 Feb 13. pii: S0016-5085(18)35303-4. doi: 10.1053/j.gastro.2018.11.053. [Epub ahead of print]
 
422.Comparative effectiveness of pharmacist care delivery models for hepatitis Cclinics
 

Naidjate SS1, Zullo AR2, Dapaah-Afriyie R1, Hersey ML1, Marshall BDL3, Winkler RM1, Berard-Collins C4. Am J Health Syst Pharm. 2019 Mar 15. pii: zxz034. doi: 10.1093/ajhp/zxz034. [Epub ahead of print]
 
423.Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia
 

Younossi ZM1, Henry L1, P Ong J2, Tanaka A3, Eguchi Y4, Mizokami M3, Lim YS5, Dan YY6, Yu ML7, Stepanova M8. Aliment Pharmacol Ther. 2019 Mar;49(6):644-653. doi: 10.1111/apt.15131. Epub 2019 Feb 13.
 
424.The health equity implementation framework: proposal and preliminary study of hepatitis C virus treatment
 

Woodward EN1,2, Matthieu MM3,4, Uchendu US5, Rogal S6,7,8, Kirchner JE3,9,10. Implement Sci. 2019 Mar 12;14(1):26. doi: 10.1186/s13012-019-0861-y.
 
425.Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program
 

Jones EA1, Linas BP2, Truong V3, Burgess JF1, Lasser KE2,3. PLoS One. 2019 Mar 14;14(3):e0213745. doi: 10.1371/journal.pone.0213745. eCollection 2019.
 
426.Increasing access for veterans with hepatitis C by enhancing use of clinical pharmacy specialists
 

Ourth HL, Groppi JA, Morreale AP, Jorgenson T, Himsel AS, Jacob DA. J Am Pharm Assoc (2003). 2019 Mar 7. pii: S1544-3191(19)30028-7. doi: 10.1016/j.japh.2019.01.018. [Epub ahead of print]
 
427.Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy
 

Thabut D1, Bureau C2, Layese R3, Bourcier V4, Hammouche M4, Cagnot C5, Marcellin P6, Guyader D6, Pol S7, Larrey D8, De Lédinghen V9, Ouzan D10, Zoulim F11, Roulot D12, Tran A13, Bronowicki JP14, Zarski JP15, Goria O16, Calès P17, Péron JM18, Alric L19, Bourlière M20, Mathurin P21, Blanc JF22, Abergel A23, Serfaty L24, Mallat A3, Grangé JD25, Attali P26, Bacq Y27, Wartelle-Bladou C28, Dao T29, Pilette C30, Silvain C31, Christidis C32, Capron D33, Bernard-Chabert B34, Hillaire S35, Di Martino V36, Sutton A37, Audureau E3, Roudot-Thoraval F3, Nahon P4; ANRS CO12 CirVir group.

Collaborators (38) Gastroenterology. 2019 Feb 13. pii: S0016-5085(18)35303-4. doi: 10.1053/j.gastro.2018.11.053. [Epub ahead of print]
 
428.Family Practitioner-Directed Hepatitis C Therapy With Direct-Acting Antivirals Achieves High-Sustained Virologic Response in Prison Population
 

Mokkarala S1,2, Johnson C3, Sarkar S3, Rudas RJ4. J Correct Health Care. 2019 Mar 13:1078345819832875. doi: 10.1177/1078345819832875. [Epub ahead of print]
 
429.Hepatitis B and C virus infections transmitted through organ transplantation investigated by CDC, United States, 2014-2017
 

Bixler D1, Annambholta P2, Abara WE1, Collier MG1, Jones J2, Mixson-Hayden T1, Basavaraju SV2, Ramachandran S1, Kamili S1, Moorman A1. Am J Transplant. 2019 Mar 12. doi: 10.1111/ajt.15352. [Epub ahead of print]
 
430.Fibrosis reversal after hepatitis C virus elimination
 

Rockey DC1. Curr Opin Gastroenterol. 2019 Mar 6. doi: 10.1097/MOG.0000000000000524. [Epub ahead of print]
 
431.Screening and Treating Hepatitis C in the VA: Achieving Excellence Using Lean and System Redesign
 

Park A1, Gonzalez R1, Chartier M1, Rogal S1, Yakovchenko V1, Ross D1, Morgan TR1. Fed Pract. 2018 Jul;35(7):24-29.
 
432.Understanding how, why, for whom, and under what circumstances opt-out blood-borne virus testing programmes work to increase test engagement and uptake within prison: a rapid-realist review
 

Francis-Graham S1,2,3, Ekeke NA4, Nelson CA5, Lee TY5, Haj SE4, Rhodes T6, Vindrola C7, Colbourn T8, Rosenberg W9,4,10. BMC Health Serv Res. 2019 Mar 8;19(1):152. doi: 10.1186/s12913-019-3970-z.
 
433.Short-term budget affordability of hepatitis C treatments for state Medicaid programs
 

Chou JW1, Silverstein AR2, Goldman DP2. BMC Health Serv Res. 2019 Feb 28;19(1):140. doi: 10.1186/s12913-019-3956-x.
 
434.Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers
 

Sandmann L1,2, Dörge P1,2, Wranke A1,2, Vermehren J3,2, Welzel TM3,2, Berg CP4,2, Grottenthaler JM4,2, Weiss KH5,2, Langel J5,2, Sterneck M6,2, von Wulffen M6,2, Manns MP1,2, Wedemeyer H1,7,2, Hardtke S1,2, von Hahn T1,2. Eur J Gastroenterol Hepatol. 2019 Feb 21. doi: 10.1097/MEG.0000000000001386. [Epub ahead of print]
 
435.Impact of Sofosbuvir-Based Therapy on Liver Transplant Candidates with Hepatitis C Virus Infection
 

Dellay B1, Sexter A2, Wang JH3, Hess GP4,5, Kim WR6, Israni AK3,7. Pharmacotherapy. 2019 Feb 18. doi: 10.1002/phar.2237. [Epub ahead of print]
 
436.Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study
 

Ide T1, Koga H2, Nakano M1, Hashimoto S3, Yatsuhashi H3, Higuchi N4, Nakamuta M4, Oeda S5, Eguchi Y5, Shakado S6, Sakisaka S6, Yoshimaru Y7, Sasaki Y7, Honma Y8, Harada M8, Seike M9, Maeshiro T10, Miuma S11, Nakao K11, Mawatari S12, Ido A12, Nagata K13, Matsumoto S14, Takami Y15, Sohda T16, Kakuma T17, Torimura T1. Hepatol Int. 2019 Feb 28. doi: 10.1007/s12072-019-09939-2. [Epub ahead of print]
 
437.Safety and Efficacy of Elbasvir/Grazoprevir in Asian Participants with Hepatitis CVirus Genotypes 1 and 4 Infection
 

Wei L1, Kumada H2, Perumalswami PV3, Tanwandee T4, Cheng W5, Heo J6, Cheng PN7, Hwang P8, Mu SM9, Zhao XM9, Asante-Appiah E8, Caro L8, Hanna GJ8, Robertson MN8, Haber BA8, Talwani R8. J Gastroenterol Hepatol. 2019 Feb 19. doi: 10.1111/jgh.14636. [Epub ahead of print]
 
438.Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis CVirus Genotype 1 or 4 Infection and Advanced Kidney Disease
 

Lawitz E1, Gane E2, Cohen E3, Vierling J4, Agarwal K5, Hassanein T6, Mantry PS7, Pockros PJ8, Bennett M9, Kemmer N10, Morelli G11, Zha J3, Wang D3, Shulman NS3, Cohen DE3, Reddy KR12. Kidney Int Rep. 2018 Oct 9;4(2):257-266. doi: 10.1016/j.ekir.2018.10.003. eCollection 2019 Feb.
 
439.Update on the Management of Hepatitis C Virus Infection in the Setting of Chronic Kidney Disease and Kidney Transplantation
 

Latt NL1. Gastroenterol Hepatol (N Y). 2018 Dec;14(12):687-705.
 
440.Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease
 

Bernstein DE1, Tran A2, Martin P3, Kowdley KV4, Bourliere M5, Sulkowski MS6, Pockros PJ7, Renjifo B8, Wang D8, Shuster DL8, Cohen DE8, Jacobson IM9. Kidney Int Rep. 2018 Oct 16;4(2):245-256. doi: 10.1016/j.ekir.2018.10.005. eCollection 2019 Feb.

 
 
441.Screening and Treating Hepatitis C in the VA: Achieving Excellence Using Lean and System Redesign
 

Park A1, Gonzalez R1, Chartier M1, Rogal S1, Yakovchenko V1, Ross D1, Morgan TR1. Fed Pract. 2018 Jul;35(7):24-29.
 
442.Impact of Sofosbuvir-Based Therapy on Liver Transplant Candidates with Hepatitis C Virus Infection
 

Dellay B1, Sexter A2, Wang JH3, Hess GP4,5, Kim WR6, Israni AK3,7. Pharmacotherapy. 2019 Feb 18. doi: 10.1002/phar.2237. [Epub ahead of print]
 
443.Safety and Efficacy of Elbasvir/Grazoprevir in Asian Participants with Hepatitis CVirus Genotypes 1 and 4 Infection
 

Wei L1, Kumada H2, Perumalswami PV3, Tanwandee T4, Cheng W5, Heo J6, Cheng PN7, Hwang P8, Mu SM9, Zhao XM9, Asante-Appiah E8, Caro L8, Hanna GJ8, Robertson MN8, Haber BA8, Talwani R8. J Gastroenterol Hepatol. 2019 Feb 19. doi: 10.1111/jgh.14636. [Epub ahead of print]
 
444.Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis CVirus Genotype 1 or 4 Infection and Advanced Kidney Disease
 

Lawitz E1, Gane E2, Cohen E3, Vierling J4, Agarwal K5, Hassanein T6, Mantry PS7, Pockros PJ8, Bennett M9, Kemmer N10, Morelli G11, Zha J3, Wang D3, Shulman NS3, Cohen DE3, Reddy KR12. Kidney Int Rep. 2018 Oct 9;4(2):257-266. doi: 10.1016/j.ekir.2018.10.003. eCollection 2019 Feb.
 
445.Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease
 

Bernstein DE1, Tran A2, Martin P3, Kowdley KV4, Bourliere M5, Sulkowski MS6, Pockros PJ7, Renjifo B8, Wang D8, Shuster DL8, Cohen DE8, Jacobson IM9. Kidney Int Rep. 2018 Oct 16;4(2):245-256. doi: 10.1016/j.ekir.2018.10.005. eCollection 2019 Feb.
 
446.Vitamin D deficiency and health-related quality of life in chronic hepatitis C
 

Palazzo D1, Biliotti E1, Esvan R1, Volpicelli L1, Franchi C1, Fontanelli Sulekova L1, Spaziante M1, Santori M1, Rugova A1, Rucci P2, Taliani G1. J Viral Hepat. 2019 Feb 9. doi: 10.1111/jvh.13076. [Epub ahead of print]
 
447.Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs
 

Day E1, Broder T2, Bruneau J3, Cruse S1, Dickie M4, Fish S4, Grillon C5, Luhmann N5, Mason K6, McLean E7, Trooskin S8, Treloar C9, Grebely J10. Int J Drug Policy. 2019 Feb 8;66:87-93. doi: 10.1016/j.drugpo.2019.01.012. [Epub ahead of print]
 
448.Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs
 

Childs E1, Assoumou SA2, Biello KB3,4,5, Biancarelli DL1,6, Drainoni ML1,2,6,7, Edeza A3,4, Salhaney P3, Mimiaga MJ3,4,5,8, Bazzi AR9. Harm Reduct J. 2019 Feb 11;16(1):14. doi: 10.1186/s12954-019-0286-6.
 
449.Impact of hepatitis C treatment on pain intensity, prescription opioid use and arthritis
 

Kumthekar A1, Shull S2, Lovejoy TI2,3, Morasco BJ2,3, Chang M2,3, Barton J2,3. Int J Rheum Dis. 2019 Feb 6. doi: 10.1111/1756-185X.13479. [Epub ahead of print]
 
450.Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries
 

Ferenci P1, Bourgeois S2, Buggisch P3, Norris S4, Curescu M5, Larrey D6, Marra F7, Kleine H8, Dorr P9, Charafeddine M9, Crown E9, Bondin M9, Back D7, Flisiak R10. J Viral Hepat. 2019 Feb 10. doi: 10.1111/jvh.13080. [Epub ahead of print]
 
451.Stereotactic body radiation therapy for hepatocellular carcinoma: Practice patterns, dose selection and factors impacting survival
 

Robbins JR1,2, Schmid RK2, Hammad AY3, Gamblin TC3, Erickson BA2. Cancer Med. 2019 Jan 31. doi: 10.1002/cam4.1948. [Epub ahead of print]
 
452.Universal Screening for HIV and Hepatitis C Infection: A Community-Based Pilot Project
 

Kempf MC1, Ott C2, Wise JM2, Footman AP3, Araya BY3, Hardy CM4, Walker C4, Latham C5, Stockett R5, Daniels G5, Alexander M5, Lanzi RG3. Am J Prev Med. 2018 Nov;55(5S1):S112-S121. doi: 10.1016/j.amepre.2018.05.015.
 
453.Efficacy and Safety of Ruzasvir 60 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection
 

Lawitz E1, Poordad F1, Anderson LJ2, Vesay M2, Kelly MM2, Liu H2, Gao W2, Fernsler D2, Asante-Appiah E2, Robertson MN2, Hanna GJ2, Barr E2, Butterton J2, Kowdley KV3, Hassanein T4, Sahota A5, Gordon SC6, Yeh WW2. J Viral Hepat. 2019 Feb 9. doi: 10.1111/jvh.13079. [Epub ahead of print]
 
454.Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy
 

Grebely J1, Dore GJ2, Alami NN3, Conway B4, Dillon JF5, Gschwantler M6, Felizarta F7, Hézode C8, Tomasiewicz K9, Fredrick LM3, Dumas EO3, Mensa FJ3. Int J Drug Policy. 2019 Feb 5;66:73-79. doi: 10.1016/j.drugpo.2019.01.011. [Epub ahead of print]
 
455.Cost Effectiveness of Early Treatment with Direct-Acting Antiviral Therapy in Adolescent Patients with Hepatitis C Virus Infection
 

Nguyen J1, Barritt Iv AS2, Jhaveri R3. J Pediatr. 2019 Feb 6. pii: S0022-3476(18)31729-3. doi: 10.1016/j.jpeds.2018.12.012. [Epub ahead of print]
 
456.Cost-Effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in The United States
 

Chaillon A1, Rand EB2, Reau N3, Martin NK1,4. Clin Infect Dis. 2019 Jan 28. doi: 10.1093/cid/ciz063. [Epub ahead of print]
 
457.A Transitioning Epidemic: How The Opioid Crisis Is Driving The Rise In Hepatitis C
 

Powell D1, Alpert A2, Pacula RL3. Health Aff (Millwood). 2019 Feb;38(2):287-294. doi: 10.1377/hlthaff.2018.05232.
 
458.Hepatitis C Virus: No Longer a Barrier to Oncology Care
 

Laique SN1, Vargas HE1. Am J Gastroenterol. 2019 Feb;114(2):207-208. doi: 10.14309/ajg.0000000000000095.
 
459.JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-infected Patients without Cirrhosis: OMEGA-1
 

Shah ND1, Ventura-Cots M2, Abraldes JG3, Alboraie M4, Alfadhli A5, Argemi J6, Badia-Aranda E7, Soler EA8, Barritt AS 4th1, Bessone F9, Biryukova M10, Carrilho FJ11, Fernández MC8, Guiridi ZD10, El Kassas M12, Eng-Kiong T13, Farias A11, George J14, Gui W15, Thurairajah PH13, Hsiang JC13, Husic-Selimovic A16, Isakov V10, Karoney M17, Kim W18, Kluwe J19, Kochhar R20, Dhaka N20, Costa PM21, Nabeshima MA11, Ono SK11, Reis D21, Rodil A11, Domech CR8, Sáez-Royuela F7, Scheurich C19, Siow W14, Sivac-Burina N16, Dos Santos Traquino ES8, Some F17, Spreckic S16, Tan S22, Vorobioff J9, Wandera A17, Wu P22, Yakoub M12, Yang L15, Yu Y22, Zahiragic N16, Zhang C22, Cortez-Pinto H21, Bataller R23. Clin Gastroenterol Hepatol. 2019 Jan 29. pii: S1542-3565(19)30073-4. doi: 10.1016/j.cgh.2019.01.026. [Epub ahead of print]
 
460.Alcohol-related Liver Disease is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide
 

Shaheen AA1, Nguyen HH1, Congly SE1, Kaplan GG1, Swain MG1. Liver Int. 2019 Jan 28. doi: 10.1111/liv.14054. [Epub ahead of print]
 
461.Impact of Substance Use Disorder on the Rate of Sustained Virological Response in Veterans With Chronic Hepatitis C Treated With Direct-Acting Antivirals
  Ottman AA1, Townsend ML1, Hashem MG1, Britt RB1. Ann Pharmacother. 2019 Jan 17:1060028018824988. doi: 10.1177/1060028018824988. [Epub ahead of print]
 
462.The successful scale-up of direct-acting antiviral hepatitis C treatments will benefit from concerted investments in implementation science
  Knight R1, Ti M2. Can J Public Health. 2019 Jan 8. doi: 10.17269/s41997-018-0164-0. [Epub ahead of print]
 
463.Short-Term Effects and Long-Term Cost-Effectiveness of Universal Hepatitis C Testing in Prenatal Care
  Tasillo A1, Eftekhari Yazdi G, Nolen S, Schillie S, Vellozzi C, Epstein R, Randall L, Salomon JA, Linas BP. Obstet Gynecol. 2019 Feb;133(2):289-300. doi: 10.1097/AOG.0000000000003062.
 
464.Hepatitis C in Pregnancy: A Unique Opportunity to Improve the Hepatitis C Cascade of Care
  Kushner T1, Terrault NA2. Hepatol Commun. 2018 Nov 30;3(1):20-28. doi: 10.1002/hep4.1282. eCollection 2019 Jan.
 
465.The HCV care continuum: linkage to HCV care and treatment among patients at an urban health network, Philadelphia, PA
  Coyle C1,2, Moorman AC3, Bartholomew T2, Klein G4, Kwakwa H5, Mehta SH1, Holtzman D3. Hepatology. 2019 Jan 11. doi: 10.1002/hep.30501. [Epub ahead of print]
 
466.Prevalence of Hepatitis C Virus Infection in US States and the District of Columbia, 2013 to 2016
  Rosenberg ES1, Rosenthal EM1, Hall EW2, Barker L3, Hofmeister MG3, Sullivan PS2, Dietz P4, Mermin J4, Ryerson AB3. JAMA Netw Open. 2018 Dec 7;1(8):e186371. doi: 10.1001/jamanetworkopen.2018.6371.
 
467.Treating HCV Infection: It Doesn't Get Much Better Than This
  Naggie S1. Top Antivir Med. 2019 Jan;26(4):104-108.
 
468.Integrating comprehensive hepatitis C virus care within a residential substance use disorder treatment program
  Burton MJ1, Voluse AC2, Anthony V3. J Subst Abuse Treat. 2019 Mar;98:9-14. doi: 10.1016/j.jsat.2018.11.008. Epub 2018 Nov 20.
 
469.Effect of Hepatitis C Treatment on Renal Function in Liver Transplant Patients
  Shoreibah M1, Romano J2, Sims OT3,4,5, Guo Y6, Jones D7, Venkata K2, Kommineni V2, Orr J8, Fitzmorris P1, Massoud OI1. J Clin Transl Hepatol. 2018 Dec 28;6(4):391-395. doi: 10.14218/JCTH.2018.00026. Epub 2018 Jul 11.
 
470.Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era
  Mathur P1, Kottilil S1, Wilson E1. J Clin Transl Hepatol. 2018 Dec 28;6(4):431-437. doi: 10.14218/JCTH.2018.00007. Epub 2018 Sep 27.
 
471.Machine learning models to predict disease progression among veterans with hepatitis C virus
  Konerman MA1, Beste LA2, Van T3, Liu B4, Zhang X4, Zhu J4, Saini SD1,3, Su GL1,3, Nallamothu BK5,6, Ioannou GN7,8, Waljee AK1,3,6. PLoS One. 2019 Jan 4;14(1):e0208141. doi: 10.1371/journal.pone.0208141. eCollection 2019.
 
472.HCV therapy: no one to let behind
  Bourlière M1, Pietri O2. Int J Antimicrob Agents. 2018 Dec 31. pii: S0924-8579(18)30380-7. doi: 10.1016/j.ijantimicag.2018.12.010. [Epub ahead of print]
 
473.Public Health Considerations among People who Inject Drugs with HIV/HCV Co-Infection: A Review
  Murdock RM1, Brizzi MB1, Perez O1, Badowski ME2. Infect Dis Ther. 2019 Jan 3. doi: 10.1007/s40121-018-0228-8. [Epub ahead of print]
 
474.High resolution evolutionary analysis of within-host hepatitis C virus infection
  Raghwani J1, Wu CH2, Ho CKY3, De Jong M3, Molenkamp R3, Schinkel J3, Pybus OG4, Lythgoe KA1. J Infect Dis. 2019 Jan 2. doi: 10.1093/infdis/jiy747. [Epub ahead of print]
 
475.Heavy Drinking and Treatment among HIV/HCV Co-Infected Patients
  Elliott JC1,2, Shalev N3, Hasin DS1,2,4. J Subst Abus Alcohol. 2018;6(2). pii: 1079. Epub 2018 Jul 26.
 
476.Overview of Direct-Acting Antiviral Drugs and Drug Resistance of Hepatitis C Virus
  Li DK1, Chung RT2. Methods Mol Biol. 2019;1911:3-32. doi: 10.1007/978-1-4939-8976-8_1.
 
477.Hepatitis C and pregnancy outcomes: a systematic review protocol
  Parent S1, Salters K1,2, Awendila L1, Ti L3,4. BMJ Open. 2018 Dec 22;8(12):e024288. doi: 10.1136/bmjopen-2018-024288.
 
478.Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure
  Lim TR1,2, Hazlehurst JM3, Oprescu AI1, Armstrong MJ1,2, Abdullah SF4, Davies NP5, Flintham R5, Balfe P1, Mutimer DJ1,2, McKeating JA6, Tomlinson JW7. Clin Endocrinol (Oxf). 2018 Dec 26. doi: 10.1111/cen.13924. [Epub ahead of print]
 
479.Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older
  Foster GR1, Asselah T2, Kopecky-Bromberg S3, Lei Y3, Asatryan A3, Trinh R3, Zadeikis N3, Mensa FJ3. PLoS One. 2019 Jan 2;14(1):e0208506. doi: 10.1371/journal.pone.0208506. eCollection 2019.
 
480.Use of Hepatitis C AB-Positive Donor Liver in Hepatitis C Nonviremic Liver Transplant Recipients
  Luckett K1, Kaiser T1, Bari K1, Safdar K1, Schoech MR1, Apewokin S1, Diwan T1, Cuffy MC1, Anwar N1, Shah SA2. J Am Coll Surg. 2018 Dec 23. pii: S1072-7515(18)32228-2. doi: 10.1016/j.jamcollsurg.2018.12.004. [Epub ahead of print]
 
481.Sustained virological response does not improve long-term glycemic control in patients with type 2 diabetes and chronic hepatitis C
  Li J1, Gordon SC2, Rupp LB3, Zhang T1, Trudeau S1, Holmberg SD4, Moorman AC4, Spradling PR4, Teshale EH4, Boscarino JA5, Schmidt MA6, Daida YG7, Lu M1; CHeCS Investigators. Liver Int. 2018 Dec 20. doi: 10.1111/liv.14031. [Epub ahead of print]
 
482.Sofosbuvir, Velpatasvir, and Voxilaprevir for Treatment of Recurrent Hepatitis C Virus Infection After Liver Transplantation
  Cardona-Gonzalez MG1, Goldman JD1,2, Narayan L1, Brainard DM3, Kowdley KV1. Hepatol Commun. 2018 Nov 14;2(12):1446-1450. doi: 10.1002/hep4.1280. eCollection 2018 Dec.
 
483.A Bitter Pill to Swallow: Why Medication Safety Is Critical in Hepatitis C Treatment
  Sullivan KM, Spooner LM, Harris E, Lowe K, Abraham GM. P T. 2018 Dec;43(12):764-768.
 
484.Use of Hepatitis C-Positive Liver Grafts in Hepatitis C-Negative Recipients
  Shetty A1, Buch A2, Saab S3,4,5. Dig Dis Sci. 2018 Dec 17. doi: 10.1007/s10620-018-5404-x. [Epub ahead of print]
 
485.Chronic hepatitis C infection - Noninvasive assessment of liver fibrosis in the era of direct acting antivirals
  Trivedi HD1, Patwardhan VR2, Malik R3. Dig Liver Dis. 2018 Nov 28. pii: S1590-8658(18)31235-0. doi: 10.1016/j.dld.2018.11.016. [Epub ahead of print]
 
486.Barriers and facilitators to hepatitis C (HCV) screening and treatment-a description of prisoners' perspective
  Crowley D1,2,3, Van Hout MC4,5, Lambert JS6,7, Kelly E8, Murphy C5,8, Cullen W6. Harm Reduct J. 2018 Dec 11;15(1):62. doi: 10.1186/s12954-018-0269-z.
 
487.Building a Hepatitis C Clinical Program: Strategies to Optimize Outcomes
  Zuckerman A1, Carver A1, Chastain CA2. Curr Treat Options Infect Dis. 2018;10(4):431-446. doi: 10.1007/s40506-018-0177-5. Epub 2018 Oct 18.
 
488.Use of Hepatitis C Positive Organs: Patient Attitudes in Urban Chicago
  Couri T1, Cotter TG2, Chen D3, Hammes M4, Reddy B4, Josephson M4, Yeh H5, Chung RT6, Paul S2. Am J Nephrol. 2018 Dec 14;49(1):32-40. doi: 10.1159/000495263. [Epub ahead of print]
 
489.Management and treatment of the HCV-infected kidney transplant patient
  Wong T1, Bloom RD1. Semin Dial. 2018 Dec 9. doi: 10.1111/sdi.12766. [Epub ahead of print]
 
490.Pharmacokinetics and important drug-drug interactions to remember when treating advanced chronic kidney disease patients with hepatitis C direct acting anti-viral therapy
  Cohen E1, Liapakis A2. Semin Dial. 2018 Dec 17. doi: 10.1111/sdi.12763. [Epub ahead of print]
 
491.Risks, benefits, and ethical questions associated with transplanting kidneys from hepatitis Cvirus-infected donors into hepatitis C virus-negative patients
  Goldberg D1,2, Reese PP2,3. Semin Dial. 2018 Nov 26. doi: 10.1111/sdi.12767. [Epub ahead of print]
 
492.Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C
  D'Ambrosio R1, Pasulo L2, Puoti M3, Vinci M4, Schiavini M5, Lazzaroni S2, Soria A6, Gatti F7, Menzaghi B8, Aghemo A9, Capelli F10, Rumi MG11, Morini L12, Giorgini A13, Pigozzi MG14, Rossini A14, Maggiolo F2, Pan A15, Memoli M16, Spinelli O17, Del Poggio P2, Saladino V18, Spinetti A14, De Bona A13, Capretti A13, Uberti-Foppa C19, Bonfanti P20, Terreni N21, Menozzi F22, Colombo AE17, Giglio O17, Centenaro R23, Borghi M24, Baiguera C3, Picciotto V4, Landonio S5, Gori A25, Magnani C26, Noventa F27, Paolucci S28, Lampertico P24, Fagiuoli S2; NAVIGATORE-Lombardia Study Group. J Hepatol. 2018 Nov 23. pii: S0168-8278(18)32543-1. doi: 10.1016/j.jhep.2018.11.011. [Epub ahead of print]
 
493.Hepatitis C: is eradication possible?
  Lombardi A1,2, Mondelli MU1,2; ESCMID Study Group for Viral Hepatitis (ESGVH). Liver Int. 2018 Nov 25. doi: 10.1111/liv.14011. [Epub ahead of print]
 
494.Treating hepatitis C virus in dialysis patients: How, when, and why?
  Pagan J1, Ladino M1,2, Roth D1. Semin Dial. 2018 Nov 26. doi: 10.1111/sdi.12764. [Epub ahead of print]
 
495.Direct acting anti-viral medications for hepatitis C: Clinical trials in patients with advanced chronic kidney disease
  Bruchfeld A1, Lindahl K2. Semin Dial. 2018 Nov 26. doi: 10.1111/sdi.12762. [Epub ahead of print]
 
496.Influence of comorbid drug use disorder on receipt of evidence-based treatment for alcohol use disorder among VA patients with alcohol use disorder and Hepatitis C and/or HIV
  Frost MC1, Matson TE2, Tsui JI3, Williams EC4. Drug Alcohol Depend. 2018 Oct 30;194:288-295. doi: 10.1016/j.drugalcdep.2018.10.008. [Epub ahead of print]
 
497.The Revolution in Treatment of Hepatitis C
  Mayberry J1, Lee WM2. Med Clin North Am. 2019 Jan;103(1):43-55. doi: 10.1016/j.mcna.2018.08.007.
 
498.Hepatitis C Testing and Patient Characteristics in Washington State's Prisons Between 2012 and 2016
  Assoumou SA1, Wang J2, Tasillo A2, Eftekhari Yazdi G2, Tsui JI3, Strick L4, Linas BP5. Am J Prev Med. 2018 Nov 12. pii: S0749-3797(18)32221-9. doi: 10.1016/j.amepre.2018.08.016. [Epub ahead of print]
 
499.Sexually Acquired Hepatitis C Infection in HIV-uninfected Men Who Have Sex with Men Using Pre-exposure Prophylaxis Against HIV
  Price JC1, McKinney JE1, Crouch PC2, Dillon SM3, Radix A4, Stivala A4, Carollo JR5, Fierer DS5. J Infect Dis. 2018 Nov 20. doi: 10.1093/infdis/jiy670. [Epub ahead of print]
 
500.Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients
  Lybeck C1, Brenndörfer ED2, Sällberg M2, Montgomery SM3,4,5, Aleman S6,7, Duberg AS1. Eur J Gastroenterol Hepatol. 2018 Nov 19. doi: 10.1097/MEG.0000000000001316. [Epub ahead of print]
 
501.Implementation of a Collaborative HIV and Hepatitis C Screening Program in Appalachian Urgent Care Settings
  Burrell CN1, Sharon MJ1, Davis SM1, Wojcik EM1, Martin IBK1. West J Emerg Med. 2018 Nov;19(6):1057-1064. doi: 10.5811/westjem.2018.9.39512. Epub 2018 Oct 9.
 
502.Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis
  Stone J1, Fraser H2, Lim AG2, Walker JG2, Ward Z2, MacGregor L2, Trickey A2, Abbott S2, Strathdee SA3, Abramovitz D3, Maher L4, Iversen J4, Bruneau J5, Zang G6, Garfein RS3, Yen YF7, Azim T8, Mehta SH9, Milloy MJ10, Hellard ME11, Sacks-Davis R12, Dietze PM13, Aitken C13, Aladashvili M14, Tsertsvadze T15, Mrav?ík V16, Alary M17, Roy E18, Smyrnov P19, Sazonova Y19, Young AM20, Havens JR21, Hope VD22, Desai M23, Heinsbroek E23, Hutchinson SJ24, Palmateer NE24, McAuley A25, Platt L26, Martin NK27, Altice FL28, Hickman M2, Vickerman P2. Lancet Infect Dis. 2018 Dec;18(12):1397-1409. doi: 10.1016/S1473-3099(18)30469-9. Epub 2018 Oct 29.
 
503.Identifying barriers to treatment of HCV in the primary care setting
  Johnson S1,2, Aluzaite K3, Taar A3, Schultz M3,4. Hepatol Int. 2018 Oct 30. doi: 10.1007/s12072-018-9902-x. [Epub ahead of print]
 
504.Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials
  Grebely J1, Puoti M2, Wedemeyer H3, Cooper C4, Sulkowski MS5, Foster GR6, Berg T7, Villa E8, Rodriguez-Perez F9, Wyles DL10, Schnell G11, Alami NN11, Zhang Z11, Dumas E11, Dore GJ1. Open Forum Infect Dis. 2018 Sep 27;5(11):ofy248. doi: 10.1093/ofid/ofy248. eCollection 2018 Nov.
 
505.Daclatasvir and sofosbuvir with ribavirin for 24 weeks in chronic hepatitis C genotype-3-infected patients with cirrhosis: a Phase III study (ALLY-3C)
  Poordad F1, Shiffman ML2, Ghesquiere W3, Wong A4, Huhn GD5, Wong F6, Ramji A7, Shafran SD8, McPhee F9, Yang R9, Noviello S10, Linaberry M10; ALLY-3C study team. Antivir Ther. 2018 Nov 1. doi: 10.3851/IMP3278. [Epub ahead of print]
 
506.Patient Reaction to Telemedicine for Clinical Management of Hepatitis C Virus Integrated into an Opioid Treatment Program
  Talal AH1,2, McLeod A2, Andrews P2, Nieves-McGrath H1, Chen Y3, Reynolds A4, Sylvester C2, Dickerson SS5, Markatou M3, Brown LS2. Telemed J E Health. 2018 Oct 16. doi: 10.1089/tmj.2018.0161. [Epub ahead of print]
 
507.Status of Direct-acting Antiviral Therapy for HCV Infection and Remaining Challenges
  Baumert TF1, Berg T2, Lim JK3, Nelson DR4. Gastroenterology. 2018 Oct 17. pii: S0016-5085(18)35155-2. doi: 10.1053/j.gastro.2018.10.024. [Epub ahead of print]
 
508.Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc Analysis of Phase 3 Clinical Trials
  Tran TT1, Mehta D2,3, Mensa F3, Park C3, Bao Y3, Sanchez Gonzalez Y4. Infect Dis Ther. 2018 Dec;7(4):473-484. doi: 10.1007/s40121-018-0218-x. Epub 2018 Oct 27.
 
509.Ledipasvir and Sofosbuvir in the Treatment of Early Hepatitis C Virus Infection in HIV-Infected Men
  Palaniswami PM1, El Sayed A1, Asriel B1, Carollo JR1, Fierer DS1; New York Acute Hepatitis C Surveillance Network.Collaborators (61) Open Forum Infect Dis. 2018 Sep 21;5(10):ofy238. doi: 10.1093/ofid/ofy238. eCollection 2018 Oct.
 
510.Sex-Dependent Outcome of Hepatitis B and C Viruses Infections: Synergy of Sex Hormones and Immune Responses?
  Ruggieri A1, Gagliardi MC1, Anticoli S1. Front Immunol. 2018 Oct 8;9:2302. doi: 10.3389/fimmu.2018.02302. eCollection 2018
 
511.Telementoring for hepatitis C treatment in correctional facilities
  Neuhaus M1, Langbecker D1, Caffery LJ1, Taylor M1, Garner L1, Williams G2, Smith AC1, Macdonald GA3. J Telemed Telecare. 2018 Dec;24(10):690-696. doi: 10.1177/1357633X18795361.
 
512.Care of Incarcerated Patients
  Davis DM1, Bello JK1, Rottnek F1. Am Fam Physician. 2018 Nov 15;98(10):577-583.
 
513.Hepatitis C Virus in Women of Childbearing Age, Pregnant Women, and Children
  Schillie SF1, Canary L2, Koneru A2, Nelson NP2, Tanico W3, Kaufman HW4, Hariri S2, Vellozzi CJ2. Am J Prev Med. 2018 Nov;55(5):633-641. doi: 10.1016/j.amepre.2018.05.029.
 
514.The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease
  Younossi Z1,2, Papatheodoridis G3, Cacoub P4,5, Negro F6, Wedemeyer H7, Henry L8, Hatzakis A9,10. J Viral Hepat. 2018 Nov;25 Suppl 3:6-14. doi: 10.1111/jvh.13005.
 
515.Sex hormone levels by presence and severity of cirrhosis in women with chronic hepatitis Cvirus infection
  Sarkar M1, Lai JC1, Sawinski D2, Zeigler TE3, Cedars M4, Forde KA5,6. J Viral Hepat. 2018 Oct 19. doi: 10.1111/jvh.13027. [Epub ahead of print]
 
516.Improved Liver Transplant Waitlist Mortality and Lower Risk of Disease Progression Among Chronic Hepatitis C Patients Awaiting Liver Transplantation After the Introduction of Direct Acting Antiviral Therapies in the United States
  Young K1, Liu B2, Bhuket T2, Gish RG3,4, Wong RJ2. J Viral Hepat. 2018 Nov 9. doi: 10.1111/jvh.13039. [Epub ahead of print]
 
517.Integrated, Co-located, Telemedicine-based Treatment Approaches for Hepatitis C Virus (HCV) Management in Opioid Use Disorder Patients on Methadone
  Talal AH1,2, Andrews P2, Mcleod A2, Chen Y3, Sylvester C2, Markatou M3, Brown LS2. Clin Infect Dis. 2018 Oct 17. doi: 10.1093/cid/ciy899. [Epub ahead of print]
 
518.National Trends in Liver Transplantation in Older Adults
  Haugen CE1, Holscher CM1, Garonzik-Wang J1, Pozo M1, Warsame F1, McAdams-DeMarco M1,2, Segev DL1,2. J Am Geriatr Soc. 2018 Oct 16. doi: 10.1111/jgs.15583. [Epub ahead of print]
 
519.Glecaprevir/Pibrentasvir in Patients with Chronic HCV Genotype 3 Infection: An Integrated Phase 2/3 Analysis
  Flamm S1, Mutimer D2, Asatryan A3, Wang S3, Rockstroh J4, Horsmans Y5, Kwo PY6, Weiland O7, Villa E8, Heo J9, Gane E10, Ryder SD11, Welzel TM12, Ruane PJ13, Agarwal K14, Ng TI3, Xue Z3, Lovell SS3, Krishnan P3, Kopecky-Bromberg S3, Trinh R3, Mensa FJ3, Wyles DL15. J Viral Hepat. 2018 Nov 12. doi: 10.1111/jvh.13038. [Epub ahead of print]
 
520.The actual management of Hepatitis B and Hepatitis C in children
  Batsis ID1, Wasuwanich P2, Karnsakul WW3. Minerva Pediatr. 2018 Oct 18. doi: 10.23736/S0026-4946.18.05410-5. [Epub ahead of print]
 
521.Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir
  Pearlman BL1,2,3, Hinds AE1. Aliment Pharmacol Ther. 2018 Nov;48(9):914-923. doi: 10.1111/apt.14977. Epub 2018 Oct 4.
 
522.Funding Hepatitis C Treatment in Correctional Facilities by Using a Nominal Pricing Mechanism
  Spaulding AC1,2, Chhatwal J3,4, Adee MG1, Lawrence RT5, Beckwith CG6,7, Oehsen WV8. J Correct Health Care. 2018 Oct 15:1078345818805770. doi: 10.1177/1078345818805770. [Epub ahead of print]
 
523.Increased diagnosis and treatment of hepatitis C in prison by universal offer of testing and use of telemedicine
  Morey S1,2, Hamoodi A3, Jones D4, Young T1, Thompson C4, Dhuny J5, Buchanan E1, Miller C1, Hewett M1, Valappil M1, Hunter E6, McPherson S1,7. J Viral Hepat. 2018 Oct 13. doi: 10.1111/jvh.13017. [Epub ahead of print]
 
524.Economic Comparison of Serologic and Molecular Screening Strategies for Hepatitis C Virus
  Saab S1,2,3,4, Ahn T1,2,3,4, McDaniel T1,2,3,4, Yanny B1,2,3,4, Tong MJ1,2,3,4. Gastroenterol Hepatol (N Y). 2018 Aug;14(8):459-462.
 
525.Impact of all-oral direct-acting antivirals on clinical and economic outcomes in chronic hepatitis C patients in the U.S
  Park H1, Wang W1, Henry L1, Nelson DR2. Hepatology. 2018 Oct 5. doi: 10.1002/hep.30303. [Epub ahead of print]
 
526.Approaches, Progress, and Challenges to Hepatitis C Vaccine Development
  Bailey JR1, Barnes E2, Cox AL1. Gastroenterology. 2018 Sep 26. pii: S0016-5085(18)35035-2. doi: 10.1053/j.gastro.2018.08.060. [Epub ahead of print]
 
527.Differences in Referral Access to Care Between Gastrointestinal Subspecialty Patients: Barriers and Opportunities
  Reddy K1, Patrick C1, Liaquat H1, Rodriquez E1, Stocker A1, Cave B2, Cave MC1, Smart L1, Cutts T3, Abell T1. Health Equity. 2018 Jun 1;2(1):103-108. doi: 10.1089/heq.2018.0001. eCollection 2018.
 
528.Elimination of Hepatitis C in Liver Transplant Recipients
  Saab S1,2, Challita Y1, Chen PH2, Jimenez MA2, Lee AD2, Saab EG2, Ahn T2, Choi G1,2, Durazo FA1,2, El-Kabany MM1,2, Han SB1,2, Grotts J1, Agopian VG2, Busuttil RW2. J Clin Transl Hepatol. 2018 Sep 28;6(3):247-250. doi: 10.14218/JCTH.2017.00079. Epub 2018 Jun 8.
 
529.Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C Virus Treatment With Ledipasvir/Sofosbuvir
  Brown PR1, Sadiq O1, Weick A2, Lenhart A1, Elbatta M2, Fernandez C2, Kutait A2, Pompa R2, Jafri SM2. Hepatol Commun. 2018 Sep 24;2(10):1172-1178. doi: 10.1002/hep4.1243. eCollection 2018 Oct.
 
530.Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN)
  Minutolo R1, Aghemo A2,3, Chirianni A4, Fabrizi F5, Gesualdo L6, Giannini EG7, Maggi P8, Montinaro V6, Paoletti E9, Persico M10, Perticone F11, Petta S12, Puoti M13, Raimondo G14, Rendina M15, Zignego AL16; Italian Society of Nephrology (SIN); Italian Association for the Study of the Liver (AISF); Italian Society of Infectious and Tropical Disease (SIMIT); Italian Society of Internal Medicine (SIMI). Infection. 2018 Sep 25. doi: 10.1007/s15010-018-1209-2. [Epub ahead of print]
 
531.Increased HCV Screening Yields Discordant Gains in Diagnoses Among Urban and Rural Veteran Populations in Texas: Results of a Statewide Quality Improvement Initiative
  Wray D, Coppin JD, Scott D, Jacob DA, Jinadatha C. Jt Comm J Qual Patient Saf. 2018 Sep 25. pii: S1553-7250(18)30089-8. doi: 10.1016/j.jcjq.2018.06.005. [Epub ahead of print]
 
532.Hepatitis C virus prevalence and estimated incidence among new injectors during the opioid epidemic in New York City, 2000-2017: Protective effects of non-injecting drug use
  Des Jarlais DC1, Arasteh K2, Feelemyer J2, McKnight C2, Barnes DM2, Perlman DC2, Uuskula A3, Cooper HLF4, Tross S5. Drug Alcohol Depend. 2018 Sep 12;192:74-79. doi: 10.1016/j.drugalcdep.2018.07.034. [Epub ahead of print]
 
533.Talking About Hepatitis C: FAQs From Young Adults Who Inject Drugs
  Knight LL1, Wagner K1, Leyva Y1, Bruce VR1, White KAM1, Talamantes YS1, Price B1, Page K1, Carvour ML1. Health Promot Pract. 2018 Nov;19(6):815-822. doi: 10.1177/1524839918799455. Epub 2018 Sep 18.
 
534.Evolution of Pretreatment Assessment and Direct Acting Antiviral Regimens in Accordance with Upgrading Guidelines: A Retrospective Study in HIV/HCV Coinfected Patients
  Henry Z1, Gonzales Zamora JA2. Med Sci (Basel). 2018 Sep 20;6(4). pii: E81. doi: 10.3390/medsci6040081.
 
535.Kidney Function Decline in Patients with CKD and Untreated Hepatitis C Infection
  Tartof SY1, Hsu JW2, Wei R2, Rubenstein KB3, Hu H3, Arduino JM4, Horberg M3, Derose SF2, Qian L2, Rodriguez CV3. Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1471-1478. doi: 10.2215/CJN.01530218. Epub 2018 Sep 21.
 
536.Race and Hepatitis C Care Continuum in an Underserved Birth Cohort
  Kim NJ1,2, Locke CJ1,2, Park H1,2, Magee C2, Bacchetti P3, Khalili M4,5,6. J Gen Intern Med. 2018 Sep 20. doi: 10.1007/s11606-018-4649-6. [Epub ahead of print]
 
537.Hepatitis C care cascade among persons born 1945-1965: 3 medical centers
  Brady JE1, Vellozzi C, Hariri S, Kruger DL, Nerenz DR, Brown KA, Federman AD, Krauskopf K, Kil N, Massoud OI, Wise JM, Seay TA, Smith BD, Yartel AK, Rein DB. Am J Manag Care. 2018 Sep;24(9):421-427.
 
538.Liver Disease Monitoring Practices After Hepatitis C Cure in the Underserved Population
  Kim NJ1,2, Magee C2, Cummings C1,2, Park H1,2, Khalili M1,2,3. Hepatol Commun. 2018 Sep 24;2(10):1274-1283. doi: 10.1002/hep4.1246. eCollection 2018 Oct.
 
539.Limited Coverage of Hepatitis C Virus Testing in the United States, 2013-2017
  Patel EU1, Mehta SH2, Boon D2, Quinn TC3, Thomas DL4, Tobian AAR1. Clin Infect Dis. 2018 Sep 15. doi: 10.1093/cid/ciy803. [Epub ahead of print]
 
540.Longitudinal transcriptomic characterization of the immune response to acute hepatitis C virus infection in patients with spontaneous viral clearance
  Rosenberg BR1,2, Depla M3, Freije CA2, Gaucher D3, Mazouz S3,4, Boisvert M3, Bédard N3, Bruneau J3,5, Rice CM6,7, Shoukry NH3,8. PLoS Pathog. 2018 Sep 17;14(9):e1007290. doi: 10.1371/journal.ppat.1007290. eCollection 2018 Sep.
 
541.Impact of Cigarette Smoking Status on Pain Intensity Among Veterans With and Without Hepatitis C
  Lynch SM1, Wilson SM2,3, DeRycke EC4, Driscoll MA4,5, Becker WC4,6, Goulet JL4,7, Kerns RD6, Mattocks KM8,9, Brandt CA4,7, Bathulapalli H4, Skanderson M4, Haskell SG4,6, Bastian LA4,6. Pain Med. 2018 Sep 1;19(suppl_1):S5-S11. doi: 10.1093/pm/pny146.
 
542.New York State announces initiative to eliminate hepatitis C
  Nelson R. Lancet Gastroenterol Hepatol. 2018 Oct;3(10):666. doi: 10.1016/S2468-1253(18)30275-9.
 
543.Why Me? Understanding the HCV Care Continuum Among People With Serious Mental Illness
  Arnold RM1, Machover H1, Wall ME1, Ahmadizadeh I1, Potts W1, Himelhoch S1. Psychiatr Serv. 2018 Sep 17:appips201700542. doi: 10.1176/appi.ps.201700542. [Epub ahead of print]
 
544.The Safety and Antiviral Activity of BZF961 with or without Ritonavir in Patients Infected with Hepatitis C Virus: A Randomized, Multicenter Trial
  Lawitz E1, Bidair M2, Marbury T3, Jones CT4, Barve A5, Magnusson B6, Barkan DT4, Bodendorf U6, Bracken K7, Canino E4, Chen D4, Dabovic K5, Heimbach T5, Ison M4, Jones CL4, Kovacs SJ7, Lakshman JP5, Li B7, Raman P5, Steiner-Swiat R5, Thohan S7, Wong KA4, Zhong W4, Colvin RA8. Clin Ther. 2018 Sep;40(9):1567-1581.e4. doi: 10.1016/j.clinthera.2018.07.019. Epub 2018 Sep 2.
 
545.Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
  Chung RT, Ghany MG, Kim AY, Marks KM, Naggie S, Vargas HE, Aronsohn AI, Bhattacharya D, Broder T, Falade-Nwulia OO, Fontana RJ, Gordon SC, Heller T, Holmberg SD, Jhaveri R, Jonas MM, Kiser JJ, Linas BP, Lo Re V 3rd, Morgan TR, Nahass RG, Peters MG, Reddy KR, Reynolds A, Scott JD, Searson G, Swan T, Terrault NA, Trooskin SB, Wong JB, Workowski KA. Clin Infect Dis. 2018 Sep 12. doi: 10.1093/cid/ciy585. [Epub ahead of print]
 
546.Electronic Reminders Increase Hepatitis C Screening, referral, treatment and cure
  Jones H1, Patel P1, Sears D1. J Viral Hepat. 2018 Aug 23. doi: 10.1111/jvh.12988. [Epub ahead of print]
 
547.Quantifying potentially infectious sharing patterns among people who inject drugs in Baltimore, USA
  Smith MK1, Graham M1, Latkin CA1, Mehta SH1, Cummings DAT2. Epidemiol Infect. 2018 Oct;146(14):1845-1853. doi: 10.1017/S0950268818002042. Epub 2018 Aug 2.
 
548.'Hep C's like the common cold': understanding barriers along the HCV care continuum among young people who inject drugs
  Skeer MR1, Ladin K2, Wilkins LE3, Landy DM4, Stopka TJ5. Drug Alcohol Depend. 2018 Sep 1;190:246-254. doi: 10.1016/j.drugalcdep.2018.06.013. Epub 2018 Jul 20.
 
549.Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort
  Rossi C1, Butt ZA2, Wong S3, Buxton JA2, Islam N4, Yu A3, Darvishian M2, Gilbert M2, Wong J2, Chapinal N3, Binka M1, Alvarez M3, Tyndall MW2, Krajden M1, Janjua NZ5; BC Hepatitis Testers Cohort Team. J Hepatol. 2018 Aug 22. pii: S0168-8278(18)32288-8. doi: 10.1016/j.jhep.2018.07.025. [Epub ahead of print]
 
550.Perinatal Transmission of Hepatitis C Virus: Defining the Cascade of Care
  Epstein RL1, Sabharwal V2, Wachman EM3, Saia KA4, Vellozzi C5, Hariri S5, Linas BP6. J Pediatr. 2018 Aug 28. pii: S0022-3476(18)30899-0. doi: 10.1016/j.jpeds.2018.07.006. [Epub ahead of print]
 
551.A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study
  Evon DM1, Stewart PW2, Amador J2, Serper M3, Lok AS4, Sterling RK5, Sarkar S6, Golin CE7,8, Reeve BB9, Nelson DR10, Reau N11, Lim JK12, Reddy KR3, Di Bisceglie AM13, Fried MW1. PLoS One. 2018 Aug 1;13(8):e0196908. doi: 10.1371/journal.pone.0196908. eCollection 2018.
 
552.Population level outcomes and cost-effectiveness of hepatitis C treatment pre- vs postkidney transplantation
  Shelton BA1, Sawinski D2, Linas BP3, Reese PP2, Mustian M1, Hungerpiller M1, Reed RD1, MacLennan PA1, Locke JE1. Am J Transplant. 2018 Jul 30. doi: 10.1111/ajt.15040. [Epub ahead of print]
 
553.Meeting the Challenge: Hepatitis C Virus and HIV Care Experiences Among HIV Specialty Providers
  Adams LM1, Balderson B2, Packett BJ 2nd3. AIDS Patient Care STDS. 2018 Aug;32(8):314-320. doi: 10.1089/apc.2018.0006.
 
554.A Head CT is Unnecessary in the Initial Evaluation of A Cirrhotic Patient with Recurrent Hepatic Encephalopathy
  Kumar S1, Modi R2, Bhandari BM2, Sass DA1, Rothstein KD. Ann Hepatol. 2018 Aug 24;17(5):810-814. doi: 10.5604/01.3001.0012.3141.
 
555.Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis Cin Children Ages 6-11
  Murray KF1, Balistreri WF2, Bansal S3, Whitworth S4, Evans HM5, Gonzalez-Peralta RP6, Wen J7, Massetto B8, Kersey K8, Shao J8, Garrison KL8, Parhy B8, Brainard DM8, Arnon R9, Gillis LA10, Jonas MM11, Chuan-Hao L12, Narkewicz MR13, Schwarz K14, Rosenthal P15. Hepatology. 2018 Aug 2. doi: 10.1002/hep.30123. [Epub ahead of print]
 
556.Successful Implementation of a Shared Medical Appointment Model for Hepatitis C Treatment at a Community Health Center
  Hodges J1, Reyes J2, Campbell J3, Klein W3, Wurcel A2,4. J Community Health. 2018 Aug 21. doi: 10.1007/s10900-018-0568-z. [Epub ahead of print]
 
557.Cost-effectiveness of Transplanting HCV-Infected Livers into Uninfected Recipients with Preemptive Antiviral Therapy
  Bethea ED1, Samur S2, Kanwal F3, Ayer T4, Hur C1, Roberts MS5, Terrault N6, Chung RT7, Chhatwal J8. Clin Gastroenterol Hepatol. 2018 Aug 20. pii: S1542-3565(18)30880-2. doi: 10.1016/j.cgh.2018.08.042. [Epub ahead of print]
 
558.Evaluating HCV screening, linkage to care, and treatment across insurers
  Mulligan K1, Sullivan J, Yoon L, Chou J, Van Nuys K. Am J Manag Care. 2018 Aug 1;24(8):e257-e264.
 
559.Use of hepatitis C-positive grafts in hepatitis C-negative liver transplant recipients is cost effective
  Saab S1,2, Kardashian A1, Saggi S2, Choi G1,2, Agopian V2, Tong MJ2. Clin Transplant. 2018 Aug 21:e13383. doi: 10.1111/ctr.13383. [Epub ahead of print]
 
560.Lack of Patient Compliance in Real-World Practice Negatively Affects Sustained Viral Response Rates to Direct Acting Agent Therapy for Hepatitis C
  Marshall MC1,2, Herrera JL3. Dig Dis Sci. 2018 Aug 20. doi: 10.1007/s10620-018-5247-5. [Epub ahead of print]
 
561.Using HIV Surveillance Data for Targeted, Community-based Hepatitis C Virus Testing among Baby Boomers in Washington, D.C
  Deerin JF, Mikre M, Castel AD, Young AT, Kuo I. J Health Care Poor Underserved. 2018;29(3):964-974. doi: 10.1353/hpu.2018.0072.
 
562.Hepatitis C virus-associated hepatocellular carcinoma as a second primary malignancy: exposing an overlooked presentation of liver cancer
  Dandachi D1,2, Hassan M3, Kaseb A4, Angelidakis G2, Torres HA2,4. J Hepatocell Carcinoma. 2018 Aug 2;5:81-86. doi: 10.2147/JHC.S164568. eCollection 2018.
 
563.Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse
  Bonsall D1, Black S2, Howe AY2, Chase R2, Ingravallo P2, Pak I2, Brown A1, Smith DA1, Bowden R1, Barnes E1. Infect Drug Resist. 2018 Aug 8;11:1119-1135. doi: 10.2147/IDR.S156581. eCollection 2018.
 
564.Danoprevir: First Global Approval
  Markham A1, Keam SJ2. Drugs. 2018 Aug;78(12):1271-1276. doi: 10.1007/s40265-018-0960-0.
 
565.Hepatitis C infection substantially reduces survival of alcohol-dependent patients
  Muga R1, Sanvisens A1, Jarrin I2, Fuster D1, Bolao F3, Tor J1, Muñoz A4. Clin Epidemiol. 2018 Aug 1;10:897-905. doi: 10.2147/CLEP.S162308. eCollection 2018.
 
566.Impact of Sustained Viral Response With Direct-Acting Agents on Glycemic Control and Renal Function in Hepatitis C Liver Transplant Recipients
  Saab S1, Barnard A, Challita Y, Adeniyi A, Aziz A, Choi G, Durazo FA, El-Kabany MM, Han SB, Busuttil RW. Exp Clin Transplant. 2018 Aug;16(4):419-424.
 
567.Eliminating hepatitis C: The importance of frequent testing of people who inject drugs in high-prevalence settings
  Scott N1,2, Sacks-Davis R1,2, Pedrana A1,2, Doyle J1,3, Thompson A4,5, Hellard M1,2,3. J Viral Hepat. 2018 Jul 26. doi: 10.1111/jvh.12975. [Epub ahead of print]
 
568.A novel mHealth application for improving HIV and Hepatitis C knowledge in individuals with opioid use disorder: A pilot study
  Ochalek TA1, Heil SH2, Higgins ST2, Badger GJ3, Sigmon SC2. Drug Alcohol Depend. 2018 Sep 1;190:224-228. doi: 10.1016/j.drugalcdep.2018.05.032. Epub 2018 Jul 19.
 
569.Take Charge, Get Cured: The development and user testing of a culturally targeted mHealth decision tool on HCV treatment initiation for methadone patients
  Bauerle Bass S1, Jessop A2, Gashat M2, Maurer L3, Alhajji M3, Forry J3. Patient Educ Couns. 2018 Jul 20. pii: S0738-3991(18)30350-1. doi: 10.1016/j.pec.2018.07.007. [Epub ahead of print]
 
570.An innovative approach to increase viral hepatitis diagnoses and linkage to care using opt-out testing and an integrated care pathway in a London Emergency Department
  Evans H1,2, Balasegaram S1,2, Douthwaite S3, Hunter L4, Kulasegaram R5, Wong T6, Querol-Rubiera A3, Nebbia G3. PLoS One. 2018 Jul 25;13(7):e0198520. doi: 10.1371/journal.pone.0198520. eCollection 2018.
 
571.Changes in Practice and Perception of Hepatitis C and Liver Transplantation: Results of a National Survey
  Shaffer AA1,2, Thomas AG1, Bowring MG1, Van Pilsum Rasmussen SE1, Cash A1, Kucirka L1,2, Alqahtani S3, Gurakar A3, Sulkowski M3,4, Cameron AM1, Segev DL1,2, Durand CM4. Transpl Infect Dis. 2018 Aug 24:e12982. doi: 10.1111/tid.12982. [Epub ahead of print]
 
572.Hepatitis C Virus (HCV) RNA Level in Plasma and Kidney Tissue in HCV Antibody Positive Donors: Quantitative Comparison
  Shike H1, Kadry Z2, Imamura-Kawasawa Y3, Greene W1, Riley T4, Nathan HM5, Hasz RD5, Jain A2. Clin Transplant. 2018 Jul 25:e13358. doi: 10.1111/ctr.13358. [Epub ahead of print]
 
573.Development and Validation of an Electronic Medical Record-Based Algorithm to Identify Patient Milestones in the Hepatitis C Virus Care Cascade
  Zucker J1,2, Aaron JG1, Feller DJ3, Slowikowski J4, Evans H5, Scherer ML1, Yin MT1, Gordon P1. Open Forum Infect Dis. 2018 Jul 3;5(7):ofy153. doi: 10.1093/ofid/ofy153. eCollection 2018 Jul.
 
574.Prevalence and risk factors of erectile dysfunction in patients with hepatitis B virus or hepatitis C virus or chronic liver disease: results from a prospective study
  Gentile I, Fusco F, Buonomo AR, Scotto R, Zappulo E, Pinchera B, Persico F, Califano G, Borgia G, Longo N. Sex Health. 2018 Jul 26. doi: 10.1071/SH17168. [Epub ahead of print]
 
575.FDA Breakthrough Therapy Designation: Evaluating the Quality of the Evidence behind the Drug Approvals
  Herink MC1, Irwin AN1, Zumach GM1. Pharmacotherapy. 2018 Jul 24. doi: 10.1002/phar.2167. [Epub ahead of print]
 
576.Association Between Vitamin D Levels and Treatment Response to Direct-Acting Antivirals in Chronic Hepatitis C: A Real-World Study
  Gayam V1, Mandal AK1, Khalid M1, Mukhtar O1, Gill A1, Garlapati P1, Tiongson B1, Sherigar J2, Mansour M1, Mohanty S2. Gastroenterology Res. 2018 Aug;11(4):309-316. doi: 10.14740/gr1072w. Epub 2018 Feb 8.
 
577.Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs
  Grebely J1, Larney S2, Peacock A1, Colledge S1, Leung J3, Hickman M4, Vickerman P4, Blach S5, Cunningham E1, Dumchev K6, Lynskey M7, Stone J4, Trickey A4, Razavi H5, Mattick RP2, Farrell M2, Dore GJ1, Degenhardt L2. Addiction. 2018 Jul 23. doi: 10.1111/add.14393. [Epub ahead of print]
 
578.Treating HCV in a Captive Audience: Eradication Efforts in the Prison Microenvironment
  Redman JS1, Sterling RK2.Author informationAm J Gastroenterol. 2018 Jul 24. doi: 10.1038/s41395-018-0201-x. [Epub ahead of print]
 
579.Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection
  Suda G1, Kurosaki M2, Itakura J2, Izumi N2, Uchida Y3, Mochida S3, Hasebe C4, Abe M4, Haga H5, Ueno Y5, Masakane I6, Abe K7, Takahashi A7, Ohira H7, Furuya K8, Baba M8, Yamamoto Y9, Kobayashi T10, Kawakami A11, Kumagai K12, Terasita K1, Ohara M1, Kawagishi N1, Umemura M1, Nakai M1, Sho T1, Natsuizaka M1, Morikawa K1, Ogawa K1, Sakamoto N13; NORTE Study Group. J Gastroenterol. 2018 Jul 17. doi: 10.1007/s00535-018-1495-6. [Epub ahead of print]
 
580.Disparities in Access to Direct Acting Antiviral Regimens for Hepatitis C Virus (HCV): The Impact of Race and Insurance Status
  Younossi ZM1,2. Am J Gastroenterol. 2018 Jul 18. doi: 10.1038/s41395-018-0200-y. [Epub ahead of print]
 
581.Timing of treatment initiation of direct-acting antivirals for HIV/HCV coinfected and HCV monoinfected patients
  Rice DP1, Ordoveza MA1, Palmer AM1, Wu GY2, Chirch LM2. AIDS Care. 2018 Jul 18:1-5. doi: 10.1080/09540121.2018.1499857. [Epub ahead of print]
 
582.Has Access to HCV Therapy Changed for Patients with Mental Health or Substance Use Disorders in the DAA Period?
  Jain MK1,2, Thamer M3, Therapondos G4, Shiffman ML5, Kshirsagar O3, Clark C2, Wong RJ6. Hepatology. 2018 Jul 17. doi: 10.1002/hep.30171. [Epub ahead of print]
 
583.Prevalence and mapping of hepatitis C infections among men who have sex with men in New York City
  Tieu HV1,2, Laeyendecker O3,4, Nandi V5, Rose R6, Fernandez R4, Lynch B3, Hoover DR7, Frye V8, Koblin BA1. PLoS One. 2018 Jul 18;13(7):e0200269. doi: 10.1371/journal.pone.0200269. eCollection 2018.
 
584.The Burden of Untreated HCV Infection in Hospitalized Inmates: a Hospital Utilization and Cost Analysis
  Wurcel AG1,2, Burke DJ3, Wang JJ4, Engle B5, Noonan K6, Knox TA5, Kim AY7, Linas BP4. J Urban Health. 2018 Jul 19. doi: 10.1007/s11524-018-0277-z. [Epub ahead of print]
 
585.Disparities in hepatitis C virus infection screening among Baby Boomers in the United States
  Nili M1, Luo L1, Feng X1, Chang J2, Tan X3. Am J Infect Control. 2018 Jul 13. pii: S0196-6553(18)30699-0. doi: 10.1016/j.ajic.2018.06.008. [Epub ahead of print]
 
586.Patient awareness, willingness, and barriers to point-of-care hepatitis C screening in community pharmacy
  Brewer A, Hanna C, Eckmann L, Schadler A, Divine H. J Am Pharm Assoc (2003). 2018 Jul - Aug;58(4S):S69-S72.e1. doi: 10.1016/j.japh.2018.04.031.
 
587.Ledipasvir/Sofosbuvir Effectively Treats Hepatitis C Virus Infections in an Underserved Population
  Stewart RA1, MacDonald BR2, Chu TC2, Moore JD3, Fasanmi EO4, Ojha RP5,6. Dig Dis Sci. 2018 Jul 16. doi: 10.1007/s10620-018-5205-2. [Epub ahead of print]
 
588.Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection
  Flamm S1, Reddy KR2, Zadeikis N3, Hassanein T4, Bacon BR5, Maieron A6, Zeuzem S7, Bourliere M8, Calleja JL9, Kosloski MP3, Oberoi RK3, Lin CW3, Yu Y3, Lovell S3, Semizarov D3, Mensa FJ3. Clin Gastroenterol Hepatol. 2018 Jul 13. pii: S1542-3565(18)30702-X. doi: 10.1016/j.cgh.2018.07.003. [Epub ahead of print]
 
589.Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection
  Vermehren J1, Park JS2, Jacobson I2, Zeuzem S3. J Hepatol. 2018 Jul 10. pii: S0168-8278(18)32181-0. doi: 10.1016/j.jhep.2018.07.002. [Epub ahead of print]
 
590.Adverse drug reactions during hepatitis C treatment with direct-acting antivirals: The role of medication errors, their impact on treatment discontinuation and their preventability. New insights from the Campania Region (Italy) spontaneous reporting system
  Sessa M1,2, Bernardi FF1, Vitale A3, Schiavone B3, Gritti G1, Mascolo A1, Bertini M1, Scavone C1, Sportiello L1, Rossi F1, Capuano A1. J Clin Pharm Ther. 2018 Jul 16. doi: 10.1111/jcpt.12744. [Epub ahead of print]
 
591.Modeling of patient virus titers suggests that availability of a vaccine could reduce hepatitis C virus transmission among injecting drug users
  Major M1, Gutfraind A2,3, Shekhtman L2,4, Cui Q5, Kachko A5, Cotler SJ2, Hajarizadeh B6, Sacks-Davis R7,8, Page K9, Boodram B3, Dahari H10. Sci Transl Med. 2018 Jul 11;10(449). pii: eaao4496. doi: 10.1126/scitranslmed.aao4496.
 
592.Hepatitis C Screening in Commercially Insured U.S. Birth-cohort Patients: Factors Associated with Testing and Effect of an EMR-based Screening Alert
  Yeboah-Korang A1, Beig MI1, Khan MQ1, Goldstein JL1, Macapinlac DM1, Maurer D1, Sonnenberg A2, Fimmel CJ1. J Transl Int Med. 2018 Jun 26;6(2):82-89. doi: 10.2478/jtim-2018-0012. eCollection 2018 Jun.
 
593.Hepatitis C Virus Treatment in Patients With Chronic Kidney Disease and in Kidney Transplant Recipients
  Corson M1, Moch A1, Saab S1. Gastroenterol Hepatol (N Y). 2018 May;14(5):280-285.
 
594.Transplanting Hepatitis C Virus-Infected Versus Uninfected Kidneys Into Hepatitis C Virus-Infected Recipients: A Cost-Effectiveness Analysis
  Eckman MH1, Woodle ES1, Thakar CV1, Paterno F1, Sherman KE1. Ann Intern Med. 2018 Jul 10. doi: 10.7326/M17-3088. [Epub ahead of print]
 
595.Novel patient-reported outcomes (PROs) used in a pilot and feasibility study of a Cognitive Behavioral Coping Skills (CBCS) group intervention for patients with chronic hepatitis C
  Evon DM1, Golin CE2,3, Ruffin R4, Ayres S3, Fried MW1. Pilot Feasibility Stud. 2018 Jun 27;4:92. doi: 10.1186/s40814-018-0285-5. eCollection 2018.
 
596.Hepatitis C Management Simplification From Test to Cure: A Framework for Primary Care Providers
  Kapadia SN1, Marks KM2. Clin Ther. 2018 Jul 5. pii: S0149-2918(18)30237-6. doi: 10.1016/j.clinthera.2018.05.010. [Epub ahead of print]
 
597.Adverse Effects of Direct Acting Antivirals in HIV/HCV Coinfected Patients: A 4-Year Experience in Miami, Florida
  Gonzales Zamora JA1. Diseases. 2018 Jun 19;6(2). pii: E51. doi: 10.3390/diseases6020051.
 
598.Efficacy and safety of sofosbuvir-containing regimens in chronic hepatitis C patients with genotype 2 and 3: a comprehensive analysis of 18 randomized controlled trials
  Fan H1, Huang P2, Tian T1, Wu J1, Xia X3, Feng Y3, Wang J4, Yu R1, Zhang Y5, Yue M6. J Gastrointestin Liver Dis. 2018 Jun;27(2):159-168. doi: 10.15403/jgld.2014.1121.272.sof.
 
599.Incidence and prevalence of antibody to hepatitis C virus in FDNY first responders before and after work at the World Trade Center disaster site
  Webber MP1,2, Liu Y2, Cohen HW1, Schwartz T2, Weiden MD2, Kelly K2, Ortiz V2, Zeig-Owens R1,2, Jaber N2, Colbeth HL2, Prezant DJ2,3. Am J Ind Med. 2018 Jun 20. doi: 10.1002/ajim.22871. [Epub ahead of print]
 
600.Treating hepatitis C infection in patients with advanced CKD in the real world: time to refocus on what our real treatment goals should be
  Potluri VS1, Bloom RD2. Kidney Int. 2018 Jul;94(1):18-21. doi: 10.1016/j.kint.2018.03.018.
 
601.Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C
  Younossi ZM1,2, Stepanova M3, Reddy R4, Manns MP5, Bourliere M6, Gordon SC7, Schiff E8, Tran T9, Younossi I3, Racila A3. Liver Int. 2018 Jun 12. doi: 10.1111/liv.13900. [Epub ahead of print]
 
602.State Medicaid Reimbursement for Medications for Chronic Hepatitis C Infection from 2012 through 2015
  Lu CY1, Zhang F2, Golonski N2, Lupton C2, Jeffrey P3, Wagner AK2. Value Health. 2018 Jun;21(6):692-697. doi: 10.1016/j.jval.2017.09.011. Epub 2017 Nov 7.
 
603.SVR 24 Achievement Two Weeks After a Tripled Dose of Daclatasvir in an HCV Genotype 3 Patient
  Lo Menzo S1, Biagi E1, Di Nuzzo M1, Grilli A1, Contini C1. Ann Hepatol. 2018 July - August ,;17(4):661-664. doi: 10.5604/01.3001.0012.0950.
 
604.A Surveillance-Based Hepatitis C Care Cascade, New York City, 2017
  Moore MS1, Bocour A1, Laraque F1, Winters A1. Public Health Rep. 2018 Jul/Aug;133(4):497-501. doi: 10.1177/0033354918776641. Epub 2018 Jun 14.
 
605.Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era
  Zuckerman A1, Douglas A2, Nwosu S3, Choi L3, Chastain C4. PLoS One. 2018 Jun 18;13(6):e0199174. doi: 10.1371/journal.pone.0199174. eCollection 2018.
 
606.Hepatitis C antibody reactivity among high-risk rural women: opportunities for services and treatment in the criminal justice system
  Strickland JC1, Staton M2,3, Leukefeld CG2,3, Oser CB3,4, Webster JM2,3. Int J Prison Health. 2018 Jun 11;14(2):89-100. doi: 10.1108/IJPH-03-2017-0012.
 
607.Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1
  Bourlière M1, Gordon SC2, Schiff ER3, Tran TT4, Ravendhran N5, Landis CS6, Hyland RH7, Stamm LM7, Zhang J7, Dvory-Sobol H7, Subramanian GM7, Brainard DM7, McHutchison JG7, Serfaty L8, Thompson AJ9, Sepe TE10, Curry MP11, Reddy KR12, Manns MP13. Lancet Gastroenterol Hepatol. 2018 May 30. pii: S2468-1253(18)30118-3. doi: 10.1016/S2468-1253(18)30118-3. [Epub ahead of print]
 
608.Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment
  Goel A1, Chen Q2,3,4, Chhatwal J3,4, Aggarwal R1. J Gastroenterol Hepatol. 2018 Jun 4. doi: 10.1111/jgh.14301. [Epub ahead of print]
 
609.Intelligent Network DisRuption Analysis (INDRA): A targeted strategy for efficient interruption of hepatitis C transmissions
  Campo DS1, Khudyakov Y2. Infect Genet Evol. 2018 May 31;63:204-215. doi: 10.1016/j.meegid.2018.05.028. [Epub ahead of print]
 
610.Senescence mirrors the extent of liver fibrosis in chronic hepatitis C virus infection
  Wandrer F1, Han B2, Liebig S1, Schlue J3, Manns MP1,4, Schulze-Osthoff K5,6, Bantel H1,4. Aliment Pharmacol Ther. 2018 Aug;48(3):270-280. doi: 10.1111/apt.14802. Epub 2018 Jun 4.
 
611.Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: a prospective observational study
  Sundberg I1, Lannergård A2, Ramklint M3, Cunningham JL3. BMC Psychiatry. 2018 May 29;18(1):157. doi: 10.1186/s12888-018-1735-6.
 
612.Assessing Disparities in the Rates of HCV Diagnoses Within American Indian or Alaska Native Populations Served by the U.S. Indian Health Service, 2005-2015
  Reilley B1, Leston J2, Doshani M3, Haberling DL4, Persvon M4, Weiser T5, Collier M3, Iralu J6, Mera J7, Haverkate R8. J Community Health. 2018 May 28. doi: 10.1007/s10900-018-0528-7. [Epub ahead of print]
 
613.Direct-Acting Antiviral Therapy for Hepatitis C Infection in a Large Immigrant Community
  Tierney AR1, Huepfel W2, Shaukat AP3, Lake JR2, Boldt M4, Wang Q2, Hassan MA2. J Immigr Minor Health. 2018 May 25. doi: 10.1007/s10903-018-0758-x. [Epub ahead of print]
 
614.Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy
  Abutaleb A1,2, Kottilil S1, Wilson E3. Hepatol Int. 2018 May;12(3):214-222. doi: 10.1007/s12072-018-9873-y. Epub 2018 May 29.
 
615.Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis
  Ascione A1, De Luca M2, Melazzini M3, Montilla S3, Trotta MP3, Petta S4, Puoti M5, Sangiovanni V6, Messina V7, Bruno S8, Izzi A9, Villa E10, Aghemo A11, Zignego AL12, Orlandini A13, Fontvanella L14, Gasbarrini A15, Marzioni M16, Giannini EG17, Craxì A4; ABACUS Study Group. Infection. 2018 May 28. doi: 10.1007/s15010-018-1157-x. [Epub ahead of print]
 
616.Efficacy and Tolerability of Direct-Acting Antivirals for Hepatitis C in Older Adults
  Mazzarelli C1,2, Considine A1, Childs K1, Carey I1, Manini MA1, Suddle A1, Dusheiko G1, Agarwal K1, Cannon MD1. J Am Geriatr Soc. 2018 May 25. doi: 10.1111/jgs.15392. [Epub ahead of print]
 
617.Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study
  Butt AA1,2,3,4, Ren Y1, Puenpatom A5, Arduino JM5, Kumar R5, Abou-Samra AB2,3,4. Aliment Pharmacol Ther. 2018 Jul;48(1):35-43. doi: 10.1111/apt.14799. Epub 2018 May 24.
 
618.Hepatitis C genotype change after transplantation utilizing hepatitis C positive donor organs
  Adekunle R1, Jonchhe S2, Ravichandran B2, Wilson E3, Husson J3. Transpl Infect Dis. 2018 May 24:e12925. doi: 10.1111/tid.12925. [Epub ahead of print]
 
619.The Road to Hepatitis C Virus Cure: Practical Considerations from a Health System's Perspective
  Jonas MC1, Loftus B2, Horberg MA3. Infect Dis Clin North Am. 2018 Jun;32(2):481-493. doi: 10.1016/j.idc.2018.02.007.
 
620.Estimation of Hepatitis C Disease Burden and Budget Impact of Treatment Using Health Economic Modeling
  Chhatwal J1, Chen Q2, Aggarwal R3. Infect Dis Clin North Am. 2018 Jun;32(2):461-480. doi: 10.1016/j.idc.2018.02.008.
 
621.Five Questions Concerning Managing Hepatitis C in the Justice System: Finding Practical Solutions for Hepatitis C Virus Elimination
  Spaulding AC1, Adee MG2, Lawrence RT3, Chhatwal J4, von Oehsen W5. Infect Dis Clin North Am. 2018 Jun;32(2):323-345. doi: 10.1016/j.idc.2018.02.014.
 
622.Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice
  Norton BL1, Akiyama MJ2, Zamor PJ3, Litwin AH2. Infect Dis Clin North Am. 2018 Jun;32(2):347-370. doi: 10.1016/j.idc.2018.02.001.
 
623.Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure
  Clement ME1, Collins LF2, Wilder JM3, Mugavero M4, Barker T5, Naggie S6. Infect Dis Clin North Am. 2018 Jun;32(2):407-423. doi: 10.1016/j.idc.2018.02.005.
 
624.A Guide to the Economics of Hepatitis C Virus Cure in 2017
  Linas BP1, Nolen S2. Infect Dis Clin North Am. 2018 Jun;32(2):447-459. doi: 10.1016/j.idc.2018.02.013.
 
625.Hepatitis C Virus Diagnosis and the Holy Grail
  Applegate TL1, Fajardo E2, Sacks JA3. Infect Dis Clin North Am. 2018 Jun;32(2):425-445. doi: 10.1016/j.idc.2018.02.010.
 
626.Hepatitis C Care in the Department of Veterans Affairs: Building a Foundation for Success
  Belperio PS1, Chartier M2, Gonzalez RI3, Park AM4, Ross DB2, Morgan TR5, Backus LI6. Infect Dis Clin North Am. 2018 Jun;32(2):281-292. doi: 10.1016/j.idc.2018.02.011.
 
627.New Treatments Have Changed the Game: Hepatitis C Treatment in Primary Care
  Facente SN1, Burk K2, Eagen K3, Mara ES4, Smith AA2, Lynch CS5. Infect Dis Clin North Am. 2018 Jun;32(2):313-322. doi: 10.1016/j.idc.2018.02.012.
 
628.Long-Term Liver Disease, Treatment, and Mortality Outcomes Among 17,000 Persons Diagnosed with Chronic Hepatitis C Virus Infection: Current Chronic Hepatitis Cohort Study Status and Review of Findings
  Moorman AC1, Rupp LB2, Gordon SC2, Zhong Y3, Xing J3, Lu M4, Boscarino JA5, Schmidt MA6, Daida YG7, Teshale EH3, Spradling PR3, Holmberg SD3; CHeCS Investigators. Infect Dis Clin North Am. 2018 Jun;32(2):253-268. doi: 10.1016/j.idc.2018.02.002.
 
629.Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings-what is required to achieve the WHO's HCV elimination targets?
  Ward Z1, Platt L2, Sweeney S2, Hope VD3,4, Maher L5, Hutchinson S6,7, Palmateer N6,7, Smith J8, Craine N8, Taylor A9, Martin N10, Ayres R11, Dillon J12, Hickman M1, Vickerman P1. Addiction. 2018 May 17. doi: 10.1111/add.14217. [Epub ahead of print]
 
630.Localized US Efforts to Eliminate Hepatitis C
  Gaudino A1, Gay B1, Garmon C2, Selick M3, Vreeland R4, Burk K5, Huriaux E6, Facente SN7, Luetkemeyer A8, Waters P9, Graham CS10. Infect Dis Clin North Am. 2018 Jun;32(2):293-311. doi: 10.1016/j.idc.2018.02.009.
 
631.The New Direct Antiviral Agents and Hepatitis C in Thoracic Transplantation: Impact on Donors and Recipients
  Gottlieb RL1,2,3, Hall SA1,2,3. Curr Transplant Rep. 2018;5(2):145-152. doi: 10.1007/s40472-018-0192-y. Epub 2018 Apr 10.
 
632.Estimates of state-level chronic hepatitis C virus infection, stratified by race and sex, United States, 2010
  Hall EW1, Rosenberg ES2, Sullivan PS3. BMC Infect Dis. 2018 May 16;18(1):224. doi: 10.1186/s12879-018-3133-6.
 
633.Large Outbreak of Hepatitis C Virus Associated With Drug Diversion by a Healthcare Technician
  Alroy-Preis S1, Daly ER1, Adamski C1, Dionne-Odom J1,2, Talbot EA1,2, Gao F1, Cavallo SJ1, Hansen K1, Mahoney JC1, Metcalf E1, Loring C1, Bean C1, Drobeniuc J3, Xia GL3, Kamili S3, Montero JT1; New Hampshire and Centers for Disease Control and Prevention Investigation Teams. Clin Infect Dis. 2018 May 14. doi: 10.1093/cid/ciy193. [Epub ahead of print]
 
634.Integrated Models of Care for Individuals with Opioid Use Disorder: How Do We Prevent HIV and HCV?
  Rich KM1, Bia J2, Altice FL1,3, Feinberg J4. Curr HIV/AIDS Rep. 2018 May 17. doi: 10.1007/s11904-018-0396-x. [Epub ahead of print]
 
635.Incidence of acute kidney injury in patients co-infected with HIV and hepatitis Cvirus receiving tenofovir disoproxil fumarate and ledipasvir/sofosbuvir in a real-world, urban, Ryan White clinic
  Michal JL1, Rab S2, Patel M3, Kyle A4, Miller L5, Easley KA6, Kalapila A7. AIDS Res Hum Retroviruses. 2018 May 16. doi: 10.1089/AID.2017.0271. [Epub ahead of print]
 
636.Evaluation of a hepatitis C clinical care coordination programme's effect on treatment initiation and cure: A surveillance-based propensity score matching approach
  Deming R1, Ford MM1, Moore MS1, Lim S1, Perumalswami P2, Weiss J3, Wyatt B2, Shukla S4, Litwin A4, Reynoso S4, Laraque F1. J Viral Hepat. 2018 May 14. doi: 10.1111/jvh.12929. [Epub ahead of print]
 
637.Outpatient directly observed therapy for hepatitis C among people who use drugs: a systematic review and meta-analysis
  McDermott CL, Lockhart CM1, Devine B2. J Virus Erad. 2018 Apr 1;4(2):118-122.
 
638.Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of the Road?
  Bunchorntavakul C1, Mitrani R2, Reddy KR2. J Clin Exp Hepatol. 2018 Mar;8(1):81-94. doi: 10.1016/j.jceh.2017.11.012. Epub 2017 Dec 7.
 
639.Autoantibodies in chronic hepatitis C virus infection: impact on clinical outcomes and extrahepatic manifestations
  Gilman AJ1, Le AK2, Zhao C3, Hoang J2, Yasukawa LA4, Weber SC4, Vierling JM5, Nguyen MH2. BMJ Open Gastroenterol. 2018 May 5;5(1):e000203. doi: 10.1136/bmjgast-2018-000203. eCollection 2018.
 
640.Receipt of alcohol-related care among patients with HCV and unhealthy alcohol use
  Owens MD1, Ioannou GN2, Tsui JL2, Edelman EJ3, Greene PA4, Williams EC5. Drug Alcohol Depend. 2018 May 8;188:79-85. doi: 10.1016/j.drugalcdep.2018.03.047. [Epub ahead of print]
 
641.The Drug Overdose Epidemic and Deceased-Donor Transplantation in the United States: A National Registry Study
  Durand CM1, Bowring MG1, Thomas AG1, Kucirka LM1, Massie AB2, Cameron A1, Desai NM1, Sulkowski M1, Segev DL3. Ann Intern Med. 2018 Apr 17. doi: 10.7326/M17-2451. [Epub ahead of print]
 
642.Association Between Hepatitis C Virus and Chronic Kidney Disease: A Systematic Review and Meta-Analysis
  Fabrizi F1, Donato FM2, Messa P3. Ann Hepatol. 2018 Apr 9;17(3):364-391. doi: 10.5604/01.3001.0011.7382.
 
643.Higher risk of hepatocellular carcinoma in Hispanic patients with hepatitis Ccirrhosis and metabolic risk factors
  Wong A1,2, Le A3, Lee MH4, Lin YJ4, Nguyen P3, Trinh S3, Dang H3, Nguyen MH5. Sci Rep. 2018 May 8;8(1):7164. doi: 10.1038/s41598-018-25533-2.
 
644.Treatment for hepatitis C virus-associated mixed cryoglobulinaemia
  Montero N1, Favà A, Rodriguez E, Barrios C, Cruzado JM, Pascual J, Soler MJ. Cochrane Database Syst Rev. 2018 May 7;5:CD011403. doi: 10.1002/14651858.CD011403.pub2. [Epub ahead of print]
 
645.Direct Acting Antivirals Improve HCV Treatment Initiation and Adherence Among Underserved African Americans
  Beck KR1, Kim NJ1, Khalili M2. Ann Hepatol. 2018 Apr 9;17(3):413-418. doi: 10.5604/01.3001.0011.7385.
 
646.Under one roof: identification, evaluation, and treatment of chronic hepatitis C in addiction care
  Martin SA1,2,3, Bosse J4, Wilson A5, Losikoff P6,7, Chiodo L5,4. Addict Sci Clin Pract. 2018 Apr 25;13(1):10. doi: 10.1186/s13722-018-0111-7.
 
647.Hepatitis C in Pregnancy
  Dibba P1, Cholankeril R2, Li AA3, Patel M4, Fayek M5, Dibble C6, Okpara N7, Hines A8, Ahmed A9. Diseases. 2018 Apr 27;6(2). pii: E31. doi: 10.3390/diseases6020031.
 
648.Timing of hepatitis C virus infection treatment in kidney transplant candidates
  Cohen-Bucay A1,2, Francis JM1, Gordon CE1. Hemodial Int. 2018 Apr;22 Suppl 1:S61-S70. doi: 10.1111/hdi.12643.
 
649.Mental and physical health-related quality of life in patients with hepatitis C is related to baseline comorbidities and improves only marginally with hepatitis Ccure
  Thuluvath PJ1,2, Savva Y3. Clin Transl Gastroenterol. 2018 Apr 25;9(4):149. doi: 10.1038/s41424-018-0016-5.
 
650.Bioequivalent pharmacokinetics for generic and originator hepatitis C direct-acting antivirals
  Hill A1, Tahat L2, Mohammed MK3, Tayyem RF3, Khwairakpam G4, Nath S5, Freeman J6, Benbitour I7, Helmy S8. J Virus Erad. 2018 Apr 1;4(2):128-131.
 
651.Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network
  Flamm SL1, Bacon B2, Curry MP3, Milligan S4, Nwankwo CU5, Tsai N6, Younossi Z7, Afdhal N3. Aliment Pharmacol Ther. 2018 Apr 17. doi: 10.1111/apt.14635. [Epub ahead of print]
 
652.Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection
  Cory TJ1, Mu Y1, Gong Y2, Kodidela S2, Kumar S2. Expert Opin Pharmacother. 2018 May;19(7):749-757. doi: 10.1080/14656566.2018.1459567. Epub 2018 Apr 10.
 
653.Results of a Hepatitis C Virus Screening Program of the 1945-1965 Birth Cohort in a Large Emergency Department in New Jersey
  Cornett JK1, Bodiwala V1, Razuk V1, Shukla D1, Narayanan N1,2. Open Forum Infect Dis. 2018 Mar 26;5(4):ofy065. doi: 10.1093/ofid/ofy065. eCollection 2018 Apr.
 
654.Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs; the case of France
  Cousien A1, Tran VC2, Deuffic-Burban S1,2, Jauffret-Roustide M3,4, Mabileau G1, Dhersin JS5, Yazdanpanah Y1,6. J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12919. [Epub ahead of print]
 
655.Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection
  Reau N1, Kwo PY2, Rhee S3, Brown RS Jr.4, Agarwal K5, Angus P6, Gane E7, Kao JH8, Mantry PS9, Mutimer D10, Reddy KR11, Tran TT12, Hu YB3, Gulati A3, Krishnan P3, Dumas EO3, Porcalla A3, Shulman NS3, Liu W3, Samanta S3, Trinh R3, Forns X13. Hepatology. 2018 Apr 19. doi: 10.1002/hep.30046. [Epub ahead of print]
 
656.Aiming for elimination: outcomes of a consultation pathway supporting regional general practitioners to prescribe direct acting antiviral therapy for hepatitis C
  Wade AJ1,2,3, McCormack A4, Roder C4, McDonald K5, Davies M5,6, Scott N2, Wardrop M1, Athan E1,4, Hellard ME2,3. J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12910. [Epub ahead of print]
 
657.Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection
  Martinello M1,2, Bhagani S3, Gane E4, Orkin C5, Cooke G6, Dore GJ1,2, Petoumenos K1, Applegate TL1, Tu E1, Marks P1, Pagani N7, Grebely J1, Nelson M7, Matthews GV1,2. J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12917. [Epub ahead of print]
 
658.Estimated hepatitis C prevalence and key population sizes in San Francisco: A foundation for elimination
  Facente SN1,2, Grebe E3, Burk K4, Morris MD2, Murphy EL2,5, Mirzazadeh A2, Smith AA4, Sanchez MA4, Evans JL2, Nishimura A4, Raymond HF2,6; End Hep C SF. PLoS One. 2018 Apr 11;13(4):e0195575. doi: 10.1371/journal.pone.0195575. eCollection 2018.
 
659.Drug-Drug Interaction Profile of the Fixed-Dose Combination Tablet Regimen Ledipasvir/Sofosbuvir
  German P1, Mathias A2, Brainard DM2, Kearney BP2. Clin Pharmacokinet. 2018 Apr 11. doi: 10.1007/s40262-018-0654-5. [Epub ahead of print]
 
660.Alcohol Consumption and Chronic Liver Disease Mortality in New Mexico and the United States, 1999-2013
  Tomedi LE1, Roeber J1, Landen M1. Public Health Rep. 2018 Jan 1:33354918766890. doi: 10.1177/0033354918766890. [Epub ahead of print]
 
661.Linkage and retention in HCV care for HIV-infected populations: early data from the DAA era
  Sacks-Davis R1,2, Doyle JS1,3, Rauch A4, Beguelin C4, Pedrana AE1,5, Matthews GV6, Prins M7, van der Valk M8, Klein MB9, Saeed S10, Lacombe K11, Chkhartishvili N12, Altice FL13,14,15, Hellard ME1,5. J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25051. doi: 10.1002/jia2.25051.
 
662.Is hepatitis C virus elimination possible among people living with HIV and what will it take to achieve it?
  Martin NK1,2, Boerekamps A3, Hill AM4, Rijnders BJA3,5. J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25062. doi: 10.1002/jia2.25062.
 
663.HIV and viral hepatitis coinfection analysis using surveillance data from 15 US states and two cities
  Bosh KA1, Coyle JR2, Hansen V3, Kim EM3, Speers S4, Comer M5, Maddox LM5, Khuwaja S6, Zhou W6, Jatta A7, Mayer R7, Brantley AD8, Muriithi NW8, Bhattacharjee R9, Flynn C9, Bouton L10, John B10, Keusch J2, Barber CA11, Sweet K11, Ramaswamy C12, Westheimer EF12, VanderBusch L13, Nishimura A14, Vu A14, Hoffman-Arriaga L15, Rowlinson E15, Carter AO16, Yerkes LE16, Li W17, Reuer JR17, Stockman LJ18, Tang T19, Brooks JT1, Teshale EH20, Hall HI1. Epidemiol Infect. 2018 Apr 11:1-11. doi: 10.1017/S0950268818000766. [Epub ahead of print]
 
664.How far are we from viral hepatitis elimination service coverage targets?
  Hutin YJ1, Bulterys M1, Hirnschall GO1. J Int AIDS Soc. 2018 Apr;21 Suppl 2:e25050. doi: 10.1002/jia2.25050.